Alpha4beta7 integrin modulators and uses thereof

Abstract

The present disclosure provides small molecule compounds and pharmaceutical compositions useful for modulating alpha4beta7 integrin, useful for the treatment of inflammatory disorders, such as inflammatory bowel diseases, including ulcerative colitis and Crohn's disease.

Description

[0001] Cross-references

[0002] This application claims the benefit of priority to U.S. Provisional Patent Application No. 63 / 341,993, filed on May 13, 2022, and U.S. Provisional Patent Application No. 63 / 497,634, filed on April 21, 2023, each of which is incorporated herein by reference in its entirety. Background of the Invention

[0004] Alpha 4beta 7 integrin (α4β7), also known as the lymphocyte Peyer's patch adhesion molecule (LPAM), is a potent signaling molecule embedded in the cell membrane of immune cells. α4β7 is responsible for guiding T cells to home to gut-associated lymphoid tissue by binding to the mucosal vascular addressin cell adhesion molecule (MAdCAM) located on the high endothelial venules of mucosal lymphoid organs. α4β7 has been shown to be associated with several immune system disorders, including inflammatory bowel disease (IBD) (including, for example, Crohn's disease (CD) and ulcerative colitis (UC)) and graft-versus-host disease (GVHD).

[0005] α4β7 is a clinically validated IBD target, with ENTYVIO (vedolizumab), an injectable anti-α4β7 mAb, approved for the treatment of UC and CD. However, the accessibility of ENTYVIO is limited by the need for parenteral administration. In addition, ENTYVIO induces a range of side effects (including nausea, vomiting, severe diarrhea, stomach cramps, weight loss, and pain), which may be difficult to control due to ENTYVIO's long half-life. Therefore, there is a need for highly active and / or selective small molecule inhibitors of α4β7 that have oral bioavailability and reduced side effects. Summary of the Invention

[0006] In one aspect, provided herein are compounds having the structure of Formula (I), or a pharmaceutically acceptable salt or solvate thereof:

[0007]

[0008] or a pharmaceutically acceptable salt thereof, wherein:

[0009] A is selected from:

[0010]

[0011] X 1 、X 2 、X 3 and X 4Each independently selected from N and C(R 2 ), where X 1 、X 2 and X 3 At least one of them is C(R 2 );

[0012] represents a single bond or a double bond;

[0013] m is 0, 1, 2, or 3;

[0014] n is 0, 1, or 2;

[0015] p is 0, 1, 2, or 3;

[0016] R 1 Each independently selected from:

[0017] Halogen, -OR 11 、-SR 11 、-N(R 11 )2、-C(O)R 11 、-C(O)OR 11 、-OC(O)R 11 、-OC(O)N(R 11 )2、-C(O)N(R 11 )2、-N(R 11 )C(O)R 11 、-N(R 11 )C(O)OR 11 、-N(R 11 )C(O)N(R 11 )2、-N(R 11 )C(S)N(R 11 )2、-N(R 11 )S(O)2(R 11 ),-S(O)R 11 、-S(O)2R 11 、-S(O)2N(R 11 )2, -NO2 and -CN;

[0018] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl, each of which is optionally substituted by one or more independently selected from halogen, -OR 11 、-SR 11 、-N(R 11 )2, substituted by =O, =S and -CN;

[0019] C 3-6Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-4 Alkyl, C 1-4 Haloalkyl, -OR 11 、-SR 11 、-N(R 11 )2, substituted by =O, =S and -CN;

[0020] R2 are each independently selected from:

[0021] Hydrogen, halogen, -OR 12 、-SR 12 、-N(R 12 )2、-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )2、-C(O)N(R 12 )2、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )2、-N(R 12 )C(S)N(R 12 )2、-N(R 12 )S(O)2(R 12 ),-S(O)R 12 、-S(O)2R 12 、-S(O)2N(R 12 )2, -NO2 and -CN;

[0022] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl, each of which is optionally substituted by one or more independently selected from halogen, -OR 12 、-SR 12 、-N(R 12 )2, =O, =S and -CN substituents; and

[0023] C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from: halogen, C 1-4 Alkyl, C 1-4 Haloalkyl, -OR 12 、-SR 12 、-N(R 12 )2, substituted by =O, =S and -CN;

[0024] R 3 is hydrogen or C 1-6 alkyl;

[0025] R 4a and R 4b Each independently selected from:

[0026] Hydrogen, halogen, -OR 13 、-SR 13 、-N(R 13 )2、-C(O)R 13 , -NO2, -CN and C 1-6 Alkyl, the C 1-6 Alkyl is optionally substituted by one or more independently selected from halogen, -OR 13 、-SR 13 、-N(R 13 )2、-C(O)R 13 , -NO2 and -CN substituents;

[0027] R 5 is hydrogen or C 1-6 alkyl;

[0028] Y is a bond, -O-, -N(R 14 )-or-C(R 14a )(R 14b )-;

[0029] Z is selected from:

[0030] bond, -C(O)-, -C(R 15 )2-、-C(O)C(R 15 )2-、-C(O)[C(R 15 )2] q S-, -C(=N-CN)-, -C(O)O-, -C(O)N(R 16 )-、-C(S)-、-C(S)N(R 16 )-, -S(O)- and -S(O)2-;

[0031] wherein q is selected from 1, 2, and 3;

[0032] B is selected from C 3-12 Carbocyclic and 3- to 12-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0033] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )C(S)N(R 17 )2、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN;

[0034] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 alkynyl, each of which is optionally substituted with one or more substituents independently selected from:

[0035] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )C(S)N(R 17 )2、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN;

[0036] C3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )C(S)N(R 17 )2、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN; and

[0037] C 3-10 carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0038] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )C(S)N(R 17 )2、-N(R 17)S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN;

[0039] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )C(S)N(R 17 )2、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN; and

[0040] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-NO2、=O、=S、=NR 17 , -N3 and -CN substituents;

[0041] C is selected from C 3-12 Carbocyclic and 3- to 12-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0042] Halogen, -OR18 、-OR 18A 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)R 18A 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 、-N(R 18 )C(O)OR 18 、-N(R 18 )C(O)N(R 18 )2、-N(R 18 )C(S)N(R 18 )2、-N(R 18 )S(O)2(R 18 ),-S(O)R 18 、-S(O)2R 18 、-S(O)2N(R 18 )2, -NO2, =O, =S, =NR 18 , -N3 and -CN;

[0043] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 alkynyl, each of which is optionally substituted with one or more substituents independently selected from:

[0044] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 、-N(R 18 )C(O)OR 18 、-N(R 18 )C(O)N(R 18 )2、-N(R 18 )C(S)N(R 18 )2、-N(R 18 )S(O)2(R 18 ),-S(O)R18 、-S(O)2R 18 、-S(O)2N(R 18 )2, -NO2, =O, =S, =NR 18 , -N3 and -CN; and

[0045] C 3-12 carbocyclic and 3 to 12 membered heterocyclic rings, any of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2、-C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-N(R 18A )C(O)OR 18A 、-N(R 18A )C(O)N(R 18A )2、-N(R 18A )C(S)N(R 18A )2、-N(R 18A )S(O)2(R 18A ),-S(O)R 18A 、-S(O)2R 18A 、-S(O)2N(R 18A )2, -NO2, =O, =S, =NR 18A 、-N3、-CN、C 1-10 Alkyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-10 Alkyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2、-C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-N(R 18A )C(O)OR 18A 、-N(R18A )C(O)N(R 18A )2、-N(R 18A )C(S)N(R 18A )2、-N(R 18A )S(O)2(R 18A ),-S(O)R 18A 、-S(O)2R 18A 、-S(O)2N(R 18A )2, -NO2, =O, =S, =NR 18A 、-N3、-CN、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 Carbocyclic ring, -C 3-6 Carbocyclic-(C 1-6 haloalkyl) and a 3- to 6-membered heterocyclic ring; and

[0046] C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-NO2、=O、=S、=NR 18 , -N3, -CN; and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2、-C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-N(R 18A )C(O)OR 18A 、-N(R 18A )C(O)N(R 18A )2、-N(R 18A )C(S)N(R 18A )2、-N(R 18A )S(O)2(R 18A ),-S(O)R 18A 、-S(O)2R 18A 、-S(O)2N(R 18A)2, -NO2, =O, =S, =NR 18A 、-N3、-CN、C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, wherein C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2、-C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-N(R 18A )C(O)OR 18A 、-N(R 18A )C(O)N(R 18A )2、-N(R 18A )C(S)N(R 18A )2、-N(R 18A )S(O)2(R 18A ),-S(O)R 18A 、-S(O)2R 18A 、-S(O)2N(R 18A )2, -NO2, =O, =S, =NR 18A , -N3 and -CN;

[0047] R 11 and R 12 Each occurrence is independently selected from hydrogen and C 1-6 Alkyl, where C 1-6 Alkyl is optionally substituted by one or more independently selected from: halogen, -OH, -NH2, -OC 1-6 Alkyl, -OC 1-6 Substitution with haloalkyl, =O and CN substituents;

[0048] R 14 Selected from hydrogen, C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbocyclic ring is optionally substituted by one or more independently selected from halogen, -OH, -NH2, -OC 1-6 Alkyl, -OC 1-6 Substitution with haloalkyl, =O and -CN substituents;

[0049] R 13independently selected at each occurrence from hydrogen and C 1-6 alkyl;

[0050] R 14a and R 14b Each independently selected from:

[0051] Hydrogen, C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbocyclic ring is optionally substituted by one or more independently selected from halogen, -OH, -NH2, -OC 1-6 Alkyl, -OC 1-6 Substituted with haloalkyl, =O and -CN; or

[0052] R 14a and R 14b Together they form C 3-6 carbocyclic or 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, -OH, -NH2, C 1-6 Alkyl, -C 1-6 Haloalkyl, -OC 1-6 Alkyl, -OC 1-6 Substitution with haloalkyl, =O and -CN substituents;

[0053] R 15 is independently selected at each occurrence from hydrogen, halogen, ═O, —CN, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings; or two R 15 Together they form C 3-6 carbon ring;

[0054] R 16 At each occurrence selected from hydrogen and C 1-6 alkyl;

[0055] R 17 independently selected at each occurrence from:

[0056] hydrogen;

[0057] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 21 、-SR 21 、-N(R 21 )2、-C(O)R 21 、-C(O)OR 21 、-OC(O)R 21 、-OC(O)N(R 21)2、-C(O)N(R 21 )2、-N(R 21 )C(O)R 21 、-NO2、=O、=S、=NR 21 and -CN; and

[0058] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 21 、-SR 21 、-N(R 21 )2、-C(O)R 21 、-C(O)OR 21 、-OC(O)R 21 、-OC(O)N(R 21 )2、-C(O)N(R 21 )2、-N(R 21 )C(O)R 21 、-N(R 21 )C(O)OR 21 、-N(R 21 )C(O)N(R 21 )2、-N(R 21 )C(S)N(R 21 )2、-N(R 21 )S(O)2(R 21 ),-S(O)R 21 、-S(O)2R 21 、-S(O)2N(R 21 )2, -NO2, =O, =S, =NR 17 、-CN、C 3-6 carbocyclic rings and 3- to 6-membered heterocyclic rings; and

[0059] R 18 and R 21 Each occurrence is independently selected from hydrogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl and C 1-6 aminoalkyl; and

[0060] R 18A At each occurrence, select from:

[0061] hydrogen;

[0062] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OC1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, C 1-6 Alkyl, C 1-6 Haloalkyl, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, and -CN; and

[0063] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OH, C 1-6 Alkyl, C 1-6 Haloalkyl, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-6 carbocyclic rings and 3- to 6-membered heterocyclic rings.

[0064] In certain embodiments, the present disclosure provides a pharmaceutical composition comprising a compound or salt of Formula (I), (Ia), (II), or (III), and a pharmaceutically acceptable excipient.

[0065] In certain embodiments, the present disclosure provides methods of modulating α4β7 integrin in a subject in need thereof, comprising administering to the subject a compound or salt of Formula (I), (Ia), (II), or (III), or a pharmaceutical composition thereof.

[0066] In certain embodiments, the present disclosure provides a method for treating an inflammatory disease or condition in a subject in need thereof, comprising administering to the subject a compound or salt of Formula (I), (Ia), (II) or (III), or a pharmaceutical composition thereof. In some embodiments, the inflammatory disease or condition is selected from the group consisting of inflammatory bowel disease, ulcerative colitis, Crohn's disease, graft-versus-host disease, type 1 diabetes, immune-mediated colitis, checkpoint inhibitor-induced colitis, and primary sclerosing cholangitis.

[0067] Incorporated by Reference

[0068] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. BRIEF DESCRIPTION OF THE DRAWINGS

[0070] The novel features of the present invention are set forth with particularity in the appended claims. The features and advantages of the present invention will be better understood by reference to the following detailed description and accompanying drawings, which set forth illustrative embodiments utilizing the principles of the invention, wherein: Detailed Description of the Invention

[0072] Integrin α4β7 is an integrin family adhesion receptor that shares subunits with α4β1 (VLA4) and the E-cadherin receptor αEβ7. α4β7 is essential for directing immune cells to the intestinal mucosa and is induced during T cell activation in Peyer's patches or mesenteric lymph nodes. α4β7 is a clinically validated IBD target, and selective inhibition of α4β7 results in significant anti-inflammatory effects and relief of symptoms. However, off-target binding to α4β1 can lead to significant dose-limiting side effects. For example, TYSABRI (natalizumab) binds to both α4β7 and α4β1, and binding to α4β1 is associated with progressive multifocal leukoencephalopathy, which has led to FDA restrictions on TYSABRI for use in IBD.

[0073] In some aspects, the present disclosure provides orally available α4β7 integrin antagonists designed to mimic the anti-inflammatory effects of ENTYVIO, particularly its high selectivity for α4β7 over α4β1. For example, in some embodiments, the compounds provided herein have greater than 100-fold selectivity for α4β7 over α4β1. In some embodiments, the compounds provided herein have greater than 1,000-fold selectivity for α4β7 over α4β1.

[0074] Ulcerative colitis

[0075] UC is a form of IBD characterized by inflammation and ulcers in the large intestine. Clinical symptoms of UC are diarrhea and blood in the stool. Its clinical course is characterized by flare-ups and remissions, which may occur spontaneously or in response to changes in diet, treatment regimens, other illnesses, or stress.

[0076] UC can be debilitating and can sometimes lead to life-threatening complications. Frequent diarrhea and blood in the stool can lead to weight loss, dehydration, and anemia. Persistent UC is associated with an increased risk of colon cancer. The Centers for Disease Control and Prevention estimates that 3 million people in the United States have IBD, approximately half of whom have UC. A similar number of people are estimated to have UC in Europe.

[0077] UC is typically treated with anti-inflammatory medications, starting with milder, topically delivered agents and progressing to systemic immunosuppressive medications for patients with refractory disease. First-line therapies for patients with mild disease include 5-aminosalicylates, such as mesalamine and sulfasalazine. Patients with more severe disease are treated with systemic corticosteroids, aimed at inducing remission and transitioning patients to better tolerated medications, such as 5-aminosalicylates, for maintenance therapy. Some patients may be treated with systemic immunomodulatory drugs, such as azathioprine, cyclosporine, and XELJANZ (tofacitinib). Anti-inflammatory biologics, such as the TNFα antagonists REMICADE (infliximab), HUMIRA (adalimumab), and SIMPONI (golimumab), and the IL-12 / IL-23 antagonist STELARA (ustekinumab), are effective in inducing remission in patients with moderate to severe UC.

[0078] ENTYVIO (vedolizumab), a monoclonal antibody that selectively targets α4β7, was first approved by the FDA in 2014 for the treatment of ulcerative colitis and CD. In clinical trials, approximately 30% of patients treated with ENTYVIO achieved remission at the end of one year of treatment. ENTYVIO is administered as a 30-minute intravenous infusion at weeks 0, 2, and 6, and every 8 weeks thereafter. Long-term therapy is generally well tolerated by patients, but frequent dose adjustments have been reported to be required to maintain efficacy.

[0079] Crohn's disease background

[0080] CD is a chronic inflammatory disease that most commonly affects the end of the small intestine and the beginning of the large intestine, but can involve any part of the gastrointestinal tract. Both CD and ulcerative colitis are types of IBD, with many overlapping symptoms and demographic characteristics. Besides the potential for CD to develop in other segments of the intestine, CD differs from ulcerative colitis in that normal, healthy tissue may be present between patches of diseased tissue in CD, unlike the continuous inflammation seen in ulcerative colitis. CD can also occur in all layers of the intestinal wall, unlike ulcerative colitis, which is limited to the innermost layer. An estimated 1.5 million people in the United States and 1.1 million in Europe suffer from CD.

[0081] The treatment paradigm for CD is very similar to that for UC, with currently approved therapies focusing on anti-inflammatory agents. Nearly 60% of CD patients require surgery within 20 years of diagnosis to treat complications such as fistulas, or abnormal connections between body parts, life-threatening bleeding, and intestinal obstruction.

[0082] Despite the availability of numerous approved therapies for UC and CD, significant unmet medical needs remain for patients and clinicians to effectively and conveniently manage these chronic conditions, which could be facilitated by effective oral therapies.

[0083] In some aspects, the compounds of the present disclosure are used to treat and / or prevent IBD. In some aspects of the present disclosure, the compounds provided herein are used to treat and / or prevent UC. In some aspects of the present disclosure, the compounds provided herein are used to treat and / or prevent CD.

[0084] definition

[0085] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. All patents and publications cited herein are incorporated herein by reference.

[0086] As used in the specification and claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.

[0087] "Alkyl" refers to a straight or branched hydrocarbon chain monovalent group consisting solely of carbon and hydrogen atoms, containing no unsaturation, preferably having from one to twelve carbon atoms (i.e., C1-C 12 Alkyl). The alkyl group is linked to the rest of the molecule by a single bond. In certain embodiments, the alkyl group contains from one to twelve carbon atoms (i.e., C1-C 12 In certain embodiments, the alkyl group comprises one to eight carbon atoms (i.e., C1-C8 alkyl). In other embodiments, the alkyl group comprises one to five carbon atoms (i.e., C1-C5 alkyl). In other embodiments, the alkyl group comprises one to four carbon atoms (i.e., C1-C4 alkyl). In other embodiments, the alkyl group comprises one to three carbon atoms (i.e., C1-C3 alkyl). In other embodiments, the alkyl group comprises one to two carbon atoms (i.e., C1-C2 alkyl). In other embodiments, the alkyl group comprises one carbon atom (i.e., C1 alkyl). In other embodiments, the alkyl group comprises five to fifteen carbon atoms (i.e., C5-C 15In some embodiments, the alkyl group comprises a 5-8 carbon atom (i.e., a C5-C8 alkyl). In other embodiments, the alkyl group comprises a 2-5 carbon atom (i.e., a C2-C5 alkyl). In other embodiments, the alkyl group comprises a 3-5 carbon atom (i.e., a C3-C5 alkyl). For example, the alkyl group can be connected to the rest of the molecule by a single bond, such as methyl, ethyl, 1-propyl (n-propyl), 1-methylethyl (isopropyl), 1-butyl (n-butyl), 1-methylpropyl (sec-butyl), 2-methylpropyl (isobutyl), 1,1-dimethylethyl (tert-butyl), 1-pentyl (n-pentyl), etc.

[0088] "Alkenyl" refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing at least one carbon-carbon double bond, and preferably having from two to twelve carbon atoms (i.e., C2-C 12 In some embodiments, the alkenyl group comprises two to eight carbon atoms (i.e., C2-C8 alkenyl). In some embodiments, the alkenyl group comprises two to six carbon atoms (i.e., C2-C6 alkenyl). In other embodiments, the alkenyl group comprises two to four carbon atoms (i.e., C2-C4 alkenyl). The alkenyl group is connected to the rest of the molecule by a single bond, for example, vinyl (i.e., ethenyl), prop-1-enyl (i.e., allyl), but-1-enyl, pent-1-enyl, pent-1,4-dienyl, etc.

[0089] "Alkynyl" refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing at least one carbon-carbon triple bond, and preferably having from two to twelve carbon atoms (i.e., C2-C 12 In some embodiments, the alkynyl group comprises two to eight carbon atoms (i.e., C2-C8 alkynyl). In other embodiments, the alkynyl group comprises two to six carbon atoms (i.e., C2-C6 alkynyl). In other embodiments, the alkynyl group comprises two to four carbon atoms (i.e., C2-C4 alkynyl). The alkynyl group is attached to the rest of the molecule by a single bond, for example, ethynyl, propynyl, butynyl, pentynyl, hexynyl, etc.

[0090] "Alkylene" refers to a straight divalent hydrocarbon chain connecting the rest of the molecule to a group, consisting only of carbon and hydrogen, free of unsaturation, preferably having one to twelve carbon atoms, such as methylene, ethylene, propylene, butylene, etc. The alkylene chain is connected to the rest of the molecule by a single bond and to the group by a single bond. The connection points of the alkylene chain to the rest of the molecule and the group are respectively through the terminal carbon. The alkylene chain may be optionally substituted with one or more substituents, such as those described herein. In certain embodiments, the alkylene group comprises one to ten carbon atoms (i.e., C1-C 10In certain embodiments, the alkylene group comprises one to eight carbon atoms (i.e., C1-C8 alkylene). In other embodiments, the alkylene group comprises one to five carbon atoms (i.e., C1-C5 alkylene). In other embodiments, the alkylene group comprises one to four carbon atoms (i.e., C1-C4 alkylene). In other embodiments, the alkylene group comprises one to three carbon atoms (i.e., C1-C3 alkylene). In other embodiments, the alkylene group comprises one to two carbon atoms (i.e., C1-C2 alkylene). In other embodiments, the alkylene group comprises one carbon atom (i.e., C1 alkylene). In other embodiments, the alkylene group comprises five to eight carbon atoms (i.e., C5-C8 alkylene). In other embodiments, the alkylene group comprises two to five carbon atoms (i.e., C2-C5 alkylene). In other embodiments, the alkylene group comprises three to five carbon atoms (i.e., C3-C5 alkylene).

[0091] "Alkenylene" refers to a straight divalent hydrocarbon chain connecting the rest of the molecule to a radical, consisting solely of carbon and hydrogen, containing at least one carbon-carbon double bond, and preferably having two to twelve carbon atoms. The alkenylene chain is connected to the rest of the molecule by a single bond and to the radical by a single bond. The connection points of the alkenylene chain to the rest of the molecule and the radical are respectively through the terminal carbon. The alkenylene chain may optionally be substituted with one or more substituents, such as those described herein. In certain embodiments, the alkenylene group comprises two to ten carbon atoms (i.e., C2-C 10 In certain embodiments, the alkenylene group comprises two to eight carbon atoms (i.e., C2-C8 alkenylene). In other embodiments, the alkenylene group comprises two to five carbon atoms (i.e., C2-C5 alkenylene). In other embodiments, the alkenylene group comprises two to four carbon atoms (i.e., C2-C4 alkenylene). In other embodiments, the alkenylene group comprises two to three carbon atoms (i.e., C2-C3 alkenylene). In other embodiments, the alkenylene group comprises two carbon atoms (i.e., C2 alkenylene). In other embodiments, the alkenylene group comprises five to eight carbon atoms (i.e., C5-C8 alkenylene). In other embodiments, the alkenylene group comprises three to five carbon atoms (i.e., C3-C5 alkenylene).

[0092] "Alkynylidene" refers to a straight divalent hydrocarbon chain connecting the rest of the molecule to a radical, consisting solely of carbon and hydrogen, containing at least one carbon-carbon triple bond, and preferably having two to twelve carbon atoms. The alkynylene chain is connected to the rest of the molecule by a single bond and to the radical by a single bond. The points of attachment of the alkynylene chain to the rest of the molecule and to the radical are respectively through the terminal carbons. The alkynylene chain may be optionally substituted with one or more substituents, such as those described herein. In certain embodiments, the alkynylene group comprises two to ten carbon atoms (i.e., C2-C 10In certain embodiments, the alkynylene group comprises two to eight carbon atoms (i.e., C2-C8 alkynylene). In other embodiments, the alkynylene group comprises two to five carbon atoms (i.e., C2-C5 alkynylene). In other embodiments, the alkynylene group comprises two to four carbon atoms (i.e., C2-C4 alkynylene). In other embodiments, the alkynylene group comprises two to three carbon atoms (i.e., C2-C3 alkynylene). In other embodiments, the alkynylene group comprises two carbon atoms (i.e., C2 alkynylene). In other embodiments, the alkynylene group comprises five to eight carbon atoms (i.e., C5-C8 alkynylene). In other embodiments, the alkynylene group comprises three to five carbon atoms (i.e., C3-C5 alkynylene).

[0093] The term "C x-y " when used in conjunction with a chemical moiety such as an alkyl, alkenyl, or alkynyl group, is intended to include groups containing from x to y carbons in the chain. For example, the term "C 1-6 "Alkyl" refers to a substituted or unsubstituted saturated hydrocarbon group, including straight-chain and branched-chain alkyl groups containing 1 to 6 carbon atoms. The term -C x-y Alkylene- refers to a substituted or unsubstituted alkylene chain containing x to y carbon atoms in the alkylene chain. For example, -C 1-6 Alkylene- may be selected from methylene, ethylene, propylene, butylene, pentylene and hexylene, any of which is optionally substituted.

[0094] The term "C x-y Alkenyl" and "C x-y "Alkynyl" refers to an unsaturated aliphatic group analogous in length and possible substitution to the alkyl groups described above, but containing at least one double or triple bond, respectively. The term -C x-y Alkenylene- refers to a substituted or unsubstituted alkenylene chain containing x to y carbons in the alkenylene chain. For example, -C 2-6 Alkenylene- can be selected from ethenylene, propenylene, butenylene, pentenylene and hexenylene, any of which is optionally substituted. The alkenylene chain can have one double bond or more than one double bond in the alkenylene chain. The term -C x-y Alkyne- refers to a substituted or unsubstituted alkynylene chain containing x to y carbon atoms in the alkynylene chain. For example, -C 2-6 Alkynylene- can be selected from ethynylene, propynylene, butynylene, pentynylene and hexynylene, any of which is optionally substituted. The alkynylene chain can have one triple bond or more than one triple bond in the alkynylene chain.

[0095] As used herein, the term "carbocycle" refers to a saturated, unsaturated, or aromatic ring in which each atom of the ring is carbon. Carbocycles include 3 to 10-membered monocycles and 6 to 12-membered bicyclic rings. Each ring of a bicyclic carbocycle can be selected from a saturated, unsaturated, and aromatic ring. The bicyclic carbocycle can be a fused, bridged, or spirocyclic ring system. In some embodiments, the carbocycle is an aryl group. In some embodiments, the carbocycle is a cycloalkyl group. In some embodiments, the carbocycle is a cycloalkenyl group. In exemplary embodiments, an aromatic ring (e.g., phenyl) can be fused to a saturated or unsaturated ring (e.g., cyclohexane, cyclopentane, or cyclohexene). Any combination of saturated, unsaturated, and aromatic bicyclic rings, as long as valence permits, is included in the definition of carbocycle. Exemplary carbocycles include cyclopentyl, cyclohexyl, cyclohexenyl, adamantyl, phenyl, indanyl, and naphthyl. The carbocycle can optionally be substituted with one or more substituents, such as those described herein.

[0096] "Cycloalkyl" refers to a stable, fully saturated monocyclic or polycyclic hydrocarbon radical consisting solely of carbon and hydrogen atoms, including fused or bridged ring systems, preferably having from three to twelve carbon atoms (i.e., C 3-12 In certain embodiments, a cycloalkyl group contains three to ten carbon atoms (i.e., C 3-10 In other embodiments, the cycloalkyl group contains five to seven carbon atoms (i.e., C 5-7 Cycloalkyl). The cycloalkyl group may be connected to the rest of the molecule by a single bond. Examples of monocyclic cycloalkyl groups include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic cycloalkyl groups include, for example, adamantyl, norbornyl (i.e., bicyclo[2.2.1]heptyl), norbornenyl, decahydronaphthyl, 7,7-dimethyl-bicyclo[2.2.1]heptyl, and the like. The cycloalkyl group may be optionally substituted with one or more substituents, such as those described herein.

[0097] "Cycloalkenyl" refers to a stable, unsaturated, non-aromatic monocyclic or polycyclic hydrocarbon radical consisting solely of carbon and hydrogen atoms, including fused or bridged ring systems, preferably having three to twelve carbon atoms and containing at least one double bond (i.e., C 3-12 In certain embodiments, a cycloalkenyl group contains three to ten carbon atoms (i.e., C 3-10 In other embodiments, the cycloalkenyl group contains five to seven carbon atoms (i.e., C 5-7 Cycloalkenyl). The cycloalkenyl group can be connected to the rest of the molecule by a single bond. Examples of monocyclic cycloalkenyl groups include, for example, cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl. The cycloalkenyl group can be optionally substituted with one or more substituents, such as those described herein.

[0098] "Aryl" refers to a radical derived from an aromatic monocyclic or polycyclic hydrocarbon ring system by removing hydrogen atoms from ring carbon atoms. The aromatic monocyclic or polycyclic hydrocarbon ring system contains only hydrogen and carbon and five to eighteen carbon atoms, wherein at least one ring in the ring system is aromatic, i.e., it contains a cyclic, delocalized (4n+2) π electron system according to the Hückel theory. Ring systems derived from aryl include, but are not limited to, radicals such as benzene, fluorene, indane, indene, tetralin, and naphthalene. Aryl groups may be optionally substituted with one or more substituents, such as those described herein.

[0099] “C x-y "Carbocycle" refers to a group containing x to y carbon atoms in the ring. For example, the term "C 3-6 A "carbocycle" can be a saturated ring system, an unsaturated ring system, or an aromatic ring system containing from 3 to 6 carbon atoms, any of which is optionally substituted as provided herein.

[0100] The term "heterocycle" as used herein refers to a saturated, unsaturated, non-aromatic or aromatic ring containing one or more heteroatoms. Exemplary heteroatoms include N, O, Si, P, B and S atoms. Heterocycle includes 3 to 10-membered monocycles and 6 to 12-membered bicyclic rings. Each ring of the bicyclic heterocycle can be selected from a saturated ring, an unsaturated ring and an aromatic ring. In some embodiments, the heterocycle includes at least one heteroatom selected from oxygen, nitrogen, sulfur or any combination thereof. In some embodiments, the heterocycle includes at least one heteroatom selected from oxygen, nitrogen or any combination thereof. In some embodiments, the heterocycle includes at least one heteroatom selected from oxygen, sulfur or any combination thereof. In some embodiments, the heterocycle includes at least one heteroatom selected from oxygen, sulfur or any combination thereof. In some embodiments, the heterocycle includes at least one heteroatom selected from nitrogen, sulfur or any combination thereof. The heterocycle can be connected to the rest of the molecule, such as a carbon atom or nitrogen atom of the heterocycle, by any atom of the heterocycle (where valence permits). In some embodiments, the heterocycle is a heteroaryl. In some embodiments, the heterocycle is a heterocycloalkyl. Exemplary heterocycles include pyrrolidinyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, piperidinyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, thienyl, oxazolyl, thiazolyl, morpholinyl, indazolyl, indolyl and quinolyl. Heterocycle can be optionally substituted by one or more substituents, such as those described herein. Bicyclic heterocycle can be fused, bridged or spirocyclic system. In exemplary embodiments, heterocycle (e.g., pyridyl) can be fused with saturated or unsaturated ring (e.g., cyclohexane, cyclopentane or cyclohexene). Heterocycle can be optionally substituted by one or more substituents, such as those described herein.

[0101] "Heterocycloalkyl" refers to a stable 3 to 12 membered non-aromatic ring group containing two to twelve carbon atoms and at least one heteroatom, wherein each heteroatom can be selected from N, O, Si, P, B and S atoms. In some embodiments, heterocycloalkyl includes at least one heteroatom selected from oxygen, nitrogen, sulfur or any combination thereof. In some embodiments, heterocycloalkyl includes at least one heteroatom selected from oxygen, nitrogen or any combination thereof. In some embodiments, heterocycloalkyl includes at least one heteroatom selected from oxygen, sulfur or any combination thereof. In some embodiments, heterocycloalkyl includes at least one heteroatom selected from nitrogen, sulfur or any combination thereof. Heterocycloalkyl can be selected from monocyclic or bicyclic and fused or bridged ring systems. The heteroatoms in heterocycloalkyl are optionally oxidized. If one or more nitrogen atoms are present, it is optionally quaternized. Heterocycloalkyl is partially or completely saturated. Heterocycloalkyl is connected to the rest of the molecule through any atom of heterocycloalkyl (e.g., any carbon atom or nitrogen atom of heterocycloalkyl, where valence permits). Examples of heterocycloalkyl include, but are not limited to, dioxolane, thienyl[1,3]dithianyl, decahydroisoquinolinyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuranyl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxothiomorpholinyl, and 1,1-dioxothiomorpholinyl. Heterocycloalkyl may be optionally substituted with one or more substituents, such as those described herein.

[0102] The term "heteroaryl" refers to a group derived from a 3 to 12 membered aromatic ring group comprising one to eleven carbon atoms and at least one heteroatom, wherein each heteroatom may be selected from N, O, and S. In some embodiments, the heteroaryl group comprises at least one heteroatom selected from oxygen, nitrogen, sulfur, or any combination thereof. In some embodiments, the heteroaryl group comprises at least one heteroatom selected from oxygen, nitrogen, or any combination thereof. In some embodiments, the heteroaryl group comprises at least one heteroatom selected from oxygen, sulfur, or any combination thereof. In some embodiments, the heteroaryl group comprises at least one heteroatom selected from oxygen, sulfur, or any combination thereof. In some embodiments, the heteroaryl group comprises at least one heteroatom selected from nitrogen, sulfur, or any combination thereof. As used herein, the heteroaryl ring may be selected from a monocyclic or bicyclic and fused or bridged ring system ring, wherein at least one ring in the ring system is an aromatic ring, i.e., according to Hückel theory, it comprises a cyclic, delocalized (4n+2) π electron system. The (one or more) heteroatoms in the heteroaryl group may be optionally oxidized. If one or more nitrogen atoms are present, it is optionally quaternized. Heteroaryl groups can be connected to the rest of the molecule through any atom of the heteroaryl group (e.g., a carbon atom or nitrogen atom of the heteroaryl group, where valence permits). Heteroaryl groups include aromatic monocyclic ring structures, preferably 5 to 6 membered rings, whose ring structures include at least one heteroatom, preferably one to four heteroatoms, more preferably one or two heteroatoms. Heteroaryl groups include, for example, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyridine, pyrazine, pyridazine, and pyrimidine. Heteroaryl groups can optionally be substituted with one or more substituents, such as those described herein. Heteroaryl groups also include polycyclic ring systems with two or more rings, wherein two or more atoms are shared by two adjacent rings, wherein at least one ring is a heteroaromatic ring, for example, the other rings can be aromatic or non-aromatic carbocyclic or heterocyclic rings. Heteroaryl groups can optionally be substituted with one or more substituents, such as those described herein.

[0103] "X-membered heterocycle" refers to the number of atoms in the ring, that is, the number of X in the ring. For example, a 5-membered heteroaromatic ring or a 5-membered aromatic heterocycle has 5 atoms in the ring, such as triazole, oxazole, thiophene, etc.

[0104] "Alkoxy" refers to a group of formula -O-alkyl bonded through an oxygen atom, wherein alkyl is an alkyl chain as defined above.

[0105] "Halo" or "halogen" refers to a halogen substituent such as bromo, chloro, fluoro, and iodo substituents.

[0106] As used herein, the term "haloalkyl" or "haloalkane" refers to an alkyl group as defined above that is substituted with one or more halogen groups, for example, trifluoromethyl, dichloromethyl, bromomethyl, 2,2,2-trifluoroethyl, 1-fluoromethyl-2-fluoroethyl, etc. In some embodiments, the alkyl portion of the fluoroalkyl group is optionally further substituted. Examples of halogen-substituted alkanes ("haloalkanes") include methyl halides (e.g., methyl chloride, methyl bromide, methyl fluoride, methyl iodide), dihalomethanes and trihalomethanes (e.g., trichloromethane, tribromomethane, trifluoromethane, triiodomethane), 1-haloethane, 2-haloethane, 1,2-dihaloethane, 1-halopropane, 2-halopropane, 3-halopropane, 1,2-dihalopropane, 1,3-dihalopropane, 2,3-dihalopropane, 1,2,3-trihalopropane, and any other suitable combination of an alkane (or substituted alkane) and a halogen (e.g., Cl, Br, F, and I). When an alkyl group is substituted with more than one halogen group, each halogen can be independently selected, for example, 1-chloro-2-fluoroethane.

[0107] The term "substituted" refers to a portion with a substituent that replaces one or more carbon or substitutable hydrogen atoms on a heteroatom, such as the NH or NH2 of a compound. It will be understood that "substituted" or "substituted by..." includes implicit conditions, i.e., such substitutions conform to the valence allowed by the substituted atom and the substituent, and that the substitution produces a stable compound, i.e., a compound that does not spontaneously undergo transformation (e.g., by rearrangement, cyclization, elimination, etc.). In certain embodiments, substituted refers to a portion with a substituent that replaces two hydrogen atoms on the same carbon atom, such as replacing two hydrogen atoms on a single carbon with an oxo, imino, or thio group. As used herein, the term "substituted" is intended to include all permissible substituents of an organic compound. Broadly speaking, permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of an organic compound. For appropriate organic compounds, permissible substituents may be one or more, identical or different substituents.

[0108] In some embodiments, the substituents may include any of the substituents described herein, for example, halogen, hydroxy, oxo (=O), thio (=S), cyano (-CN), nitro (-NO2), imino (=NH), oxime (=N-OH), hydrazine (=N-NH2), -R b -OR a 、-R b -OC(O)-R a 、-R b -OC(O)-OR a 、-R b -OC(O)-N(R a )2. -R b -N(Ra )2. -R b -C(O)R a 、-R b -C(O)OR a 、-R b -C(O)N(R a )2. -R b -OR c -C(O)N(R a )2. -R b -N(R a )C(O)OR a 、-R b -N(R a )C(O)R a 、-R b -N(R a )S(O) t R a (where t is 1 or 2), -R b -S(O) t R a (where t is 1 or 2), -R b -S(O) t OR a (where t is 1 or 2) and -R b -S(O) t N(R a )2 (wherein t is 1 or 2); and alkyl, alkenyl, alkynyl, aryl, aralkyl, aralkenyl, aralkynyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl and heteroarylalkyl, any of which is optionally substituted by alkyl, alkenyl, alkynyl, halogen, haloalkyl, haloalkenyl, haloalkynyl, oxo (=O), thioxo (=S), cyano (-CN), nitro (-NO2), imino (=NH), oxime (=N-OH), hydrazine (=N-NH2), -R b -OR a 、-R b -OC(O)-R a 、-R b -OC(O)-OR a 、-R b -OC(O)-N(R a )2. -R b -N(R a )2. -R b -C(O)R a 、-R b -C(O)OR a 、-R b -C(O)N(R a )2. -Rb -OR c -C(O)N(R a )2. -R b -N(R a )C(O)OR a 、-R b -N(R a )C(O)R a 、-R b -N(R a )S(O) t R a (where t is 1 or 2), -R b -S(O) t R a (where t is 1 or 2), -R b -S(O) t OR a (where t is 1 or 2) and -R b -S(O) t N(R a )2 (where t is 1 or 2); where each R a are independently selected from hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or heteroarylalkyl, wherein each R a (where valence permits) may be optionally substituted with the following groups: alkyl, alkenyl, alkynyl, halogen, haloalkyl, haloalkenyl, haloalkynyl, oxo (=O), thio (=S), cyano (-CN), nitro (-NO2), imino (=NH), oxime (=N-OH), hydrazine (=N-NH2), -R b -OR a 、-R b -OC(O)-R a 、-R b -OC(O)-OR a 、-R b -OC(O)-N(R a )2. -R b -N(R a )2. -R b -C(O)R a 、-R b -C(O)OR a 、-R b -C(O)N(R a )2. -R b -OR c -C(O)N(R a )2. -R b -N(R a )C(O)ORa 、-R b -N(R a )C(O)R a 、-R b -N(R a )S(O) t R a (where t is 1 or 2), -R b -S(O) t R a (where t is 1 or 2), -R b -S(O) t OR a (where t is 1 or 2) and -R b -S(O) t N(R a )2 (where t is 1 or 2); where each R b are independently selected from a direct bond or a straight or branched alkylene, alkenylene or alkynylene chain, and each R c It will be understood by those skilled in the art that the substituents may themselves be substituted, if appropriate.

[0109] The term "salt" or "pharmaceutically acceptable salt" refers to salts derived from various organic and inorganic counterions well known in the art. Pharmaceutically acceptable acid addition salts can be formed with inorganic and organic acids. Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases.

[0110] As used herein, the phrase "pharmaceutically acceptable" refers to those compounds, materials, compositions, and / or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.

[0111] As used herein, the phrase "pharmaceutically acceptable excipient" or "pharmaceutically acceptable carrier" refers to a pharmaceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, solvent, or encapsulating material. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient.

[0112] The terms "subject," "individual," and "patient" are used interchangeably to refer to humans as well as non-human mammals (e.g., non-human primates, canines, equines, felines, porcines, bovines, ungulates, lagomorphs, etc.). In various embodiments, the subject can be a human (e.g., an adult male, adult female, adolescent male, adolescent female, male child, female child) who is receiving care from a physician or other health worker as an outpatient in a hospital or other clinical setting. In certain embodiments, the subject may not be under the care or prescription of a physician or other health worker.

[0113] As used herein, the phrase "a subject in need thereof" refers to a subject having or at risk of having a pathology that requires prophylactic or therapeutic treatment with a compound or salt described herein.

[0114] The terms "administer," "administered," "administrators," and "administering" are defined as providing a composition to a subject by a route known in the art, including but not limited to intravenous, intraarterial, oral, parenteral, buccal, topical, transdermal, rectal, intramuscular, subcutaneous, intraosseous, transmucosal, or intraperitoneal administration. In certain embodiments, the composition can be administered using an oral route. The term "administering" a compound should be understood as providing a compound of the invention or a prodrug of a compound of the invention to an individual in need thereof.

[0115] As used herein, "treatment" or "treating" refers to methods for obtaining beneficial or desired results for a disease, condition, or medical disorder, including but not limited to therapeutic benefits and / or preventive benefits. In certain embodiments, treatment involves administering a compound or composition disclosed herein to a subject. Therapeutic benefits may include eradicating or improving the underlying condition being treated. In addition, therapeutic benefits may be achieved by eradicating or improving one or more physiological symptoms associated with the underlying condition, such as observing improvement in the subject, although the subject may still be suffering from the underlying condition. In certain embodiments, in order to obtain preventive benefits, the composition is administered to a subject at risk of developing a specific disease, or to a subject reporting one or more physiological symptoms of a disease, even if a diagnosis of the disease may not yet be made. Treatment may include, for example, reducing, delaying, or alleviating the severity of one or more symptoms of a disease or disorder, or it may include reducing the frequency of symptoms such as a disease, defect, condition, or adverse condition experienced by the patient. Treatment may be used herein to refer to a method for treating or improving a certain degree of a disease or disorder, and a series of results for this purpose may be expected, including but not limited to preventing the disorder completely.

[0116] In certain embodiments, the terms "prevent" or "preventing" in relation to a disease or condition may refer to a compound that reduces the incidence of the condition or disorder in a treated sample relative to an untreated control sample, or delays the onset of or lessens the severity of one or more symptoms of the condition or disorder relative to an untreated control sample.

[0117] The term "therapeutic effect" as used herein encompasses therapeutic benefits and / or prophylactic benefits as described above. A prophylactic effect includes delaying or eliminating the appearance of a disease or condition, delaying or eliminating the onset of symptoms of a disease or condition, slowing, arresting or reversing the progression of a disease or condition, or any combination thereof.

[0118] Compound

[0119] In one aspect, provided herein are compounds having the structure of Formula (I), or a pharmaceutically acceptable salt or solvate thereof:

[0120]

[0121] or a pharmaceutically acceptable salt thereof, wherein:

[0122] A is selected from:

[0123]

[0124] X 1 、X 2 、X 3 and X 4 Each independently selected from N and C(R 2 ), where X 1 、X 2 and X 3 At least one of them is C(R 2 );

[0125] represents a single bond or a double bond;

[0126] m is 0, 1, 2, or 3;

[0127] n is 0, 1, or 2;

[0128] p is 0, 1, 2, or 3;

[0129] R 1 Each independently selected from:

[0130] Halogen, -OR 11 、-SR 11 、-N(R 11 )2、-C(O)R 11 、-C(O)OR 11、-OC(O)R 11 、-OC(O)N(R 11 )2、-C(O)N(R 11 )2、-N(R 11 )C(O)R 11 、-N(R 11 )C(O)OR 11 、-N(R 11 )C(O)N(R 11 )2、-N(R 11 )C(S)N(R 11 )2、-N(R 11 )S(O)2(R 11 ),-S(O)R 11 、-S(O)2R 11 、-S(O)2N(R 11 )2, -NO2 and -CN;

[0131] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl, each of which is optionally substituted by one or more independently selected from halogen, -OR 11 、-SR 11 、-N(R 11 )2, substituted by =O, =S and -CN;

[0132] C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-4 Alkyl, C 1-4 Haloalkyl, -OR 11 、-SR 11 、-N(R 11 )2, substituted by =O, =S and -CN;

[0133] R2 are each independently selected from:

[0134] Hydrogen, halogen, -OR 12 、-SR 12 、-N(R 12 )2、-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )2、-C(O)N(R 12 )2、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R12 )C(O)N(R 12 )2、-N(R 12 )C(S)N(R 12 )2、-N(R 12 )S(O)2(R 12 ),-S(O)R 12 、-S(O)2R 12 、-S(O)2N(R 12 )2, -NO2 and -CN;

[0135] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl, each of which is optionally substituted by one or more independently selected from halogen, -OR 12 、-SR 12 、-N(R 12 )2, =O, =S and -CN substituents; and

[0136] C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from: halogen, C 1-4 Alkyl, C 1-4 Haloalkyl, -OR 12 、-SR 12 、-N(R 12 )2, substituted by =O, =S and -CN;

[0137] R 3 is hydrogen or C 1-6 alkyl;

[0138] R 4a and R 4b Each independently selected from:

[0139] Hydrogen, halogen, -OR 13 、-SR 13 、-N(R 13 )2、-C(O)R 13 , -NO2, -CN and C 1-6 Alkyl, the C 1-6 Alkyl is optionally substituted by one or more independently selected from halogen, -OR 13 、-SR 13 、-N(R 13 )2、-C(O)R 13 , -NO2 and -CN substituents;

[0140] R 5 is hydrogen or C 1-6 alkyl;

[0141] Y is a bond, -O-, -N(R 14 )-or-C(R 14a )(R 14b )-;

[0142] Z is selected from:

[0143] bond, -C(O)-, -C(R 15 )2-、-C(O)C(R 15 )2-、-C(O)[C(R 15 )2] q S-, -C(=N-CN)-, -C(O)O-, -C(O)N(R 16 )-、-C(S)-、-C(S)N(R 16 )-, -S(O)- and -S(O)2-;

[0144] wherein q is selected from 1, 2, and 3;

[0145] B is selected from C 3-12 Carbocyclic and 3- to 12-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0146] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )C(S)N(R 17 )2、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN;

[0147] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6alkynyl, each of which is optionally substituted with one or more substituents independently selected from:

[0148] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )C(S)N(R 17 )2、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN;

[0149] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )C(S)N(R 17 )2、-N(R 17 )S(O)2(R 17),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN; and

[0150] C 3-10 carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0151] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )C(S)N(R 17 )2、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN;

[0152] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17)C(O)N(R 17 )2、-N(R 17 )C(S)N(R 17 )2、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN; and

[0153] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-NO2、=O、=S、=NR 17 , -N3 and -CN substituents;

[0154] C is selected from C 3-12 Carbocyclic and 3- to 12-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0155] Halogen, -OR 18 、-OR 18A 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)R 18A 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 、-N(R 18 )C(O)OR 18 、-N(R 18 )C(O)N(R 18 )2、-N(R 18 )C(S)N(R 18 )2、-N(R 18 )S(O)2(R 18 ),-S(O)R 18 、-S(O)2R 18 、-S(O)2N(R 18)2, -NO2, =O, =S, =NR 18 , -N3 and -CN;

[0156] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 alkynyl, each of which is optionally substituted with one or more substituents independently selected from:

[0157] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 、-N(R 18 )C(O)OR 18 、-N(R 18 )C(O)N(R 18 )2、-N(R 18 )C(S)N(R 18 )2、-N(R 18 )S(O)2(R 18 ),-S(O)R 18 、-S(O)2R 18 、-S(O)2N(R 18 )2, -NO2, =O, =S, =NR 18 , -N3 and -CN; and

[0158] C 3-12 carbocyclic and 3 to 12 membered heterocyclic rings, any of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2、-C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-N(R 18A )C(O)OR 18A 、-N(R 18A )C(O)N(R 18A)2、-N(R 18A )C(S)N(R 18A )2、-N(R 18A )S(O)2(R 18A ),-S(O)R 18A 、-S(O)2R 18A 、-S(O)2N(R 18A )2, -NO2, =O, =S, =NR 18A 、-N3、-CN、C 1-10 Alkyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-10 Alkyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2、-C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-N(R 18A )C(O)OR 18A 、-N(R 18A )C(O)N(R 18A )2、-N(R 18A )C(S)N(R 18A )2、-N(R 18A )S(O)2(R 18A ),-S(O)R 18A 、-S(O)2R 18A 、-S(O)2N(R 18A )2, -NO2, =O, =S, =NR 18A 、-N3、-CN、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 Carbocyclic ring, -C 3-6 Carbocyclic-(C 1-6 haloalkyl) and a 3- to 6-membered heterocyclic ring; and

[0159] C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18 、-SR 18 、-N(R 18)2、-C(O)R 18 、-NO2、=O、=S、=NR 18 , -N3, -CN; and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2、-C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-N(R 18A )C(O)OR 18A 、-N(R 18A )C(O)N(R 18A )2、-N(R 18A )C(S)N(R 18A )2、-N(R 18A )S(O)2(R 18A ),-S(O)R 18A 、-S(O)2R 18A 、-S(O)2N(R 18A )2, -NO2, =O, =S, =NR 18A 、-N3、-CN、C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, wherein C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2、-C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-N(R 18A )C(O)OR 18A 、-N(R 18A )C(O)N(R 18A )2、-N(R 18A )C(S)N(R 18A )2、-N(R 18A)S(O)2(R 18A ),-S(O)R 18A 、-S(O)2R 18A 、-S(O)2N(R 18A )2, -NO2, =O, =S, =NR 18A , -N3 and -CN;

[0160] R 11 and R 12 Each occurrence is independently selected from hydrogen and C 1-6 Alkyl, where C 1-6 Alkyl is optionally substituted by one or more independently selected from: halogen, -OH, -NH2, -OC 1-6 Alkyl, -OC 1-6 Substitution with haloalkyl, =O and CN substituents;

[0161] R 14 Selected from hydrogen, C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbocyclic ring is optionally substituted by one or more independently selected from halogen, -OH, -NH2, -OC 1-6 Alkyl, -OC 1-6 Substitution with haloalkyl, =O and -CN substituents;

[0162] R 13 independently selected at each occurrence from hydrogen and C 1-6 alkyl;

[0163] R 14a and R 14b Each independently selected from:

[0164] Hydrogen, C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbocyclic ring is optionally substituted by one or more independently selected from halogen, -OH, -NH2, -OC 1-6 Alkyl, -OC 1-6 Substituted with haloalkyl, =O and -CN; or

[0165] R 14a and R 14b Together they form C 3-6 carbocyclic or 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, -OH, -NH2, C 1-6 Alkyl, -C 1-6 Haloalkyl, -OC 1-6 Alkyl, -OC1-6 Substitution with haloalkyl, =O and -CN substituents;

[0166] R 15 is independently selected at each occurrence from hydrogen, halogen, ═O, —CN, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings; or two R 15 Together they form C 3-6 carbon ring;

[0167] R 16 At each occurrence selected from hydrogen and C 1-6 alkyl;

[0168] R 17 independently selected at each occurrence from:

[0169] hydrogen;

[0170] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 21 、-SR 21 、-N(R 21 )2、-C(O)R 21 、-C(O)OR 21 、-OC(O)R 21 、-OC(O)N(R 21 )2、-C(O)N(R 21 )2、-N(R 21 )C(O)R 21 、-NO2、=O、=S、=NR 21 and -CN; and

[0171] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 21 、-SR 21 、-N(R 21 )2、-C(O)R 21 、-C(O)OR 21 、-OC(O)R 21 、-OC(O)N(R 21 )2、-C(O)N(R 21 )2、-N(R 21 )C(O)R 21 、-N(R 21 )C(O)OR 21、-N(R 21 )C(O)N(R 21 )2、-N(R 21 )C(S)N(R 21 )2、-N(R 21 )S(O)2(R 21 ),-S(O)R 21 、-S(O)2R 21 、-S(O)2N(R 21 )2, -NO2, =O, =S, =NR 17 、-CN、C 3-6 carbocyclic rings and 3- to 6-membered heterocyclic rings; and

[0172] R 18 and R 21 Each occurrence is independently selected from hydrogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl and C 1-6 aminoalkyl; and

[0173] R 18A At each occurrence, select from:

[0174] hydrogen;

[0175] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, C 1-6 Alkyl, C 1-6 Haloalkyl, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, and -CN; and

[0176] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OH, C 1-6 Alkyl, C 1-6 Haloalkyl, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-6 carbocyclic rings and 3- to 6-membered heterocyclic rings.

[0177] In some embodiments, B is an optionally substituted 3 to 12 membered heterocycle. In some embodiments, B is an optionally substituted 3 to 12 membered saturated heterocycle. In some embodiments, B is an optionally substituted 3 to 12 membered unsaturated heterocycle. In some embodiments, B is an optionally substituted 6 to 12 membered aromatic heterocycle. In some embodiments, B is selected from a 3-membered heterocycle, a 4-membered heterocycle, a 5-membered heterocycle, a 6-membered heterocycle, a 7-membered heterocycle, an 8-membered heterocycle, a 9-membered heterocycle, a 10-membered heterocycle, an 11-membered heterocycle, and a 12-membered heterocycle, any one of which is optionally substituted. In some embodiments, B is selected from a 3 to 4 membered heterocycle, a 3 to 5 membered heterocycle, a 3 to 6 membered heterocycle, a 3 to 7 membered heterocycle, a 3 to 8 membered heterocycle, a 3 to 9 membered heterocycle, a 3 to 10 membered heterocycle, a 3 to 11 membered heterocycle, and a 3 to 12 membered heterocycle, any one of which is optionally substituted. In some embodiments, B is selected from 3 to 8 membered monocyclic heterocycles and 6 to 12 membered bicyclic heterocycles, any one of which is optionally substituted. In some embodiments, B is an optionally substituted 3 to 8 membered monocyclic heterocycle. In some embodiments, B is an optionally substituted 6 to 12 membered bicyclic heterocycle. In some embodiments, the optionally substituted 6 to 12 membered bicyclic heterocycle of B is selected from 6 to 12 membered bridged heterocycles, 6 to 12 membered spirocyclic heterocycles, and 6 to 12 membered fused heterocycles, any one of which is optionally substituted. In some embodiments, the optional substituents of B are as defined herein. In some embodiments, the optional substituents of B are as defined in formula (I).

[0178] In some embodiments, B is optionally substituted C 3-12 In some embodiments, B is an optionally substituted saturated C 3-12 In some embodiments, B is an optionally substituted unsaturated C 3-12 In some embodiments, B is an optionally substituted aromatic C 8-12 In some embodiments, B is selected from C3 carbocycle, C4 carbocycle, C5 carbocycle, C6 carbocycle, C7 carbocycle, C8 carbocycle, C9 carbocycle, C 10 Carbon ring, C 10 Carbon ring, C 11 Carbon ring and C 12 In some embodiments, B is selected from C 3-4 Carbon ring, C 3-5 Carbon ring, C 3-6 Carbon ring, C 3-7 Carbon ring, C 3-8 Carbon ring, C 3-9 Carbon ring, C 3-10 Carbon ring, C 3-11 Carbon ring and C 3-12 In some embodiments, B is selected from a monocyclic C3-8 Carbocyclic and bicyclic C 6-12 carbocyclic ring, any one of which is optionally substituted. In some embodiments, the optional substituents of B are as defined herein. In some embodiments, the optional substituents of B are as defined in formula (I).

[0179] In some embodiments, for the compound or salt of Formula (I), B is a 3- to 12-membered heterocyclic ring optionally substituted with one or more substituents independently selected from:

[0180] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )C(S)N(R 17 )2、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN;

[0181] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 alkynyl, each of which is optionally substituted with one or more substituents independently selected from:

[0182] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )C(S)N(R 17 )2、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN;

[0183] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 ,-N(R 17 )C(O)N(R 17 )2、-N(R 17 )C(S)N(R 17 )2、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN; and

[0184] C 3-10 carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0185] Halogen, -OR 17 、-SR 17 、-N(R17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )C(S)N(R 17 )2、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN;

[0186] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )C(S)N(R 17 )2、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN; and

[0187] C 3-10Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-NO2、=O、=S、=NR 17 , -N3 and -CN.

[0188] In some embodiments, for the compound or salt of Formula (I), B is a 3- to 12-membered heterocyclic ring optionally substituted with one or more substituents independently selected from:

[0189] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 , -NO2, -CN;

[0190] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-NO2、-CN、C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 , -NO2, -CN; and C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 , -NO2, -CN; and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 17 、-SR17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 , -NO2 and -CN.

[0191] In some embodiments, B is a 6- to 12-membered bicyclic heterocycle selected from a 6- to 12-membered fused heterocycle, a 6- to 12-membered spirocyclic heterocycle, and a 6- to 12-membered bridged heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 , -NO2, -CN; and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 In some embodiments, B is a 6- to 12-membered bridged heterocyclic ring optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 , -NO2, -CN; and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 In some embodiments, B is a 6- to 12-membered fused heterocyclic ring optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 , -NO2, -CN; and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 In some embodiments, B is a 6- to 12-membered spirocyclic heterocycle optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 , -NO2, -CN; and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 In some embodiments, B is a 9- to 12-membered spirocyclic heterocycle optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 17 、-N(R 17 )2、-C(O)R 17 , -NO2, -CN and C 1-6 In some embodiments, B is

[0192] In some embodiments, C is optionally substituted C 3-12 In some embodiments, C is an optionally substituted saturated C 3-12 In some embodiments, C is an optionally substituted unsaturated C 3-12 In some embodiments, C is an optionally substituted aromatic C 8-12 In some embodiments, C is selected from C3 carbocycle, C4 carbocycle, C5 carbocycle, C6 carbocycle, C7 carbocycle, C8 carbocycle, C9 carbocycle, C 10 Carbon ring, C 10 Carbon ring, C 11 Carbon ring and C 12 In some embodiments, C is selected from C 3-4 Carbon ring, C 3-5 Carbon ring, C 3-6 Carbon ring, C 3-7 Carbon ring, C 3-8 Carbon ring, C 3-9 Carbon ring, C 3-10Carbon ring, C 3-11 Carbon ring and C 3-12 In some embodiments, C is selected from C 3-8 Monocyclic carbocyclic ring and C 6-12 In some embodiments, C is an optionally substituted C 3-8 In some embodiments, C is an optionally substituted C 6-12 In some embodiments, the C 6-12 Bicyclic carbocycle selected from C 6-12 Spirocarbon ring, C 6-12 Fused carbocyclic ring and C 6-12 A bridged carbocyclic ring, any one of which is optionally substituted. In some embodiments, the optional substituents for C are as defined herein. In some embodiments, the optional substituents for C are as defined in formula (I).

[0193] In some embodiments, for compounds or salts of Formula (I), C is selected from C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, which are optionally substituted with -OR 18A or -C(O)R 18A Replace; and R 18A Selected from:

[0194] hydrogen;

[0195] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, C 1-6 Alkyl, C 1-6 Haloalkyl, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, and -CN; and

[0196] C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, which are optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OH, C 1-6 Alkyl, C 1-6 Haloalkyl, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-6carbocyclic rings and 3- to 6-membered heterocyclic rings.

[0197] In some embodiments, for compounds or salts of Formula (I), C is selected from C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, which are optionally substituted with -OR 18A or -C(O)R 18A Replacement; R 18A Selected from C 1-6 Alkyl, which is optionally substituted by one or more independently selected from halogen, C 3-10 In some embodiments, C is selected from C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, which are optionally substituted with -OR 18A or -C(O)R 18A Replacement; R 18A Selected from C 1-6 Alkyl, which is optionally substituted by one or more independently selected from halogen, C 3-10 In some embodiments, C is C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, which are optionally substituted with -OR 18A or -C(O)R 18A Replacement; R 18A Selected from C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, which are optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OH, C 1-6 Alkyl, C 1-6 Haloalkyl, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-6 In some embodiments, C is selected from

[0198] In some embodiments, for compounds or salts of Formula (I), C is C 3-12 A carbocyclic ring optionally substituted with one or more substituents independently selected from:

[0199] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R18 、-N(R 18 )C(O)OR 18 、-N(R 18 )C(O)N(R 18 )2、-N(R 18 )C(S)N(R 18 )2、-N(R 18 )S(O)2(R 18 ),-S(O)R 18 、-S(O)2R 18 、-S(O)2N(R 18 )2, -NO2, =O, =S, =NR 18 , -N3 and -CN;

[0200] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 alkynyl, each of which is optionally substituted with one or more substituents independently selected from:

[0201] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 、-N(R 18 )C(O)OR 18 、-N(R 18 )C(O)N(R 18 )2、-N(R 18 )C(S)N(R 18 )2、-N(R 18 )S(O)2(R 18 ),-S(O)R 18 、-S(O)2R 18 、-S(O)2N(R 18 )2, -NO2, =O, =S, =NR 18 , -N3 and -CN; and

[0202] C 3-12 carbocyclic and 3- to 12-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from:

[0203] Halogen, -OR 18A 、-SR18A 、-N(R 18A )2、-C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-N(R 18A )C(O)OR 18A 、-N(R 18A )C(O)N(R 18A )2、-N(R 18A )C(S)N(R 18A )2、-N(R 18A )S(O)2(R 18A ),-S(O)R 18A 、-S(O)2R 18A 、-S(O)2N(R 18A )2, -NO2, =O, =S, =NR 18A 、-N3、-CN、C 1-10 Alkyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-10 Alkyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2、-C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-N(R 18A )C(O)OR 18A 、-N(R 18A )C(O)N(R 18A )2、-N(R 18A )C(S)N(R 18A )2、-N(R 18A )S(O)2(R 18A ),-S(O)R 18A 、-S(O)2R 18A 、-S(O)2N(R 18A )2, -NO2, =O, =S, =NR18A 、-N3、-CN、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 Carbocyclic ring, -C 3-6 Carbocyclic-(C 1-6 haloalkyl) and a 3- to 6-membered heterocyclic ring; and

[0204] C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0205] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-NO2、=O、=S、=NR 18 , -N3, -CN; and

[0206] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2、-C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-N(R 18A )C(O)OR 18A 、-N(R 18A )C(O)N(R 18A )2、-N(R 18A )C(S)N(R 18A )2、-N(R 18A )S(O)2(R 18A ),-S(O)R 18A 、-S(O)2R 18A 、-S(O)2N(R 18A )2, -NO2, =O, =S, =NR 18A 、-N3、-CN、C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, wherein C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A)2、-C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-N(R 18A )C(O)OR 18A 、-N(R 18A )C(O)N(R 18A )2、-N(R 18A )C(S)N(R 18A )2、-N(R 18A )S(O)2(R 18A ),-S(O)R 18A 、-S(O)2R 18A 、-S(O)2N(R 18A )2, -NO2, =O, =S, =NR 18A , -N3 and -CN.

[0207] In some embodiments, for compounds or salts of Formula (I), C is C 3-10 A carbocyclic ring optionally substituted with one or more substituents independently selected from:

[0208] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 , -NO2 and -CN;

[0209] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from:

[0210] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18)2、-N(R 18 )C(O)R 18 , -NO2 and -CN; and

[0211] C 3-12 carbocyclic and 3 to 12 membered heterocyclic rings, any of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2、-C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-NO2、-CN、C 1-6 Alkyl, C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2、-C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-NO2、-CN、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 Carbocyclic ring, -C 3-6 Carbocyclic-(C 1-6 haloalkyl) and a 3- to 6-membered heterocyclic ring; and

[0212] C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0213] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 , -NO2 and -CN; and

[0214] C 1-6Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2、-C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-NO2、-CN、C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, wherein C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2、-C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A , -NO2, -CN.

[0215] In some embodiments, for compounds or salts of Formula (I), C is C 3-6 A carbocyclic ring optionally substituted with one or more substituents independently selected from:

[0216] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 , -NO2 and -CN;

[0217] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from:

[0218] Halogen, -OR 18 、-SR 18 、-N(R18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 , -NO2 and -CN; and

[0219] C 3-12 carbocyclic and 3 to 12 membered heterocyclic rings, any of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2、-C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-NO2、-CN、C 1-6 Alkyl, C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2、-C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-NO2、-CN、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 Carbocyclic ring, -C 3-6 Carbocyclic-(C 1-6 haloalkyl) and a 3- to 6-membered heterocyclic ring; and

[0220] C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0221] Halogen, -OR18 、-SR 18 、-N(R 18 )2、-C(O)R 18 , -NO2 and -CN; and

[0222] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2、-C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-NO2、-CN、C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, wherein C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2、-C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A , -NO2, -CN.

[0223] In some embodiments, for the compound or salt of Formula (I), C is phenyl, optionally substituted with one or more substituents independently selected from:

[0224] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 , -NO2 and -CN; and

[0225] C1-6 Alkyl, optionally substituted with one or more substituents independently selected from:

[0226] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 , -NO2 and -CN; and

[0227] C 3-12 carbocyclic and 3 to 12 membered heterocyclic rings, any of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2、-C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-NO2、-CN、C 1-6 Alkyl, C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2、-C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-NO2、-CN、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 Carbocyclic ring, -C 3-6 Carbocyclic-(C 1-6 haloalkyl) and 3 to 6 membered heterocyclic rings.

[0228] In some embodiments, for the compound or salt of Formula (I), C is phenyl, optionally substituted with one or more substituents independently selected from:

[0229] Halogen, -OR 18 、-N(R 18 )2, -NO2 and -CN; and

[0230] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18 、-N(R 18 )2, -NO2 and -CN; and 3 to 12 membered saturated heterocyclic rings, which are optionally substituted by one or more substituents independently selected from the following: halogen, -OR 18A 、-NO2、-CN、C 1-6 Alkyl, C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-N(R 18A )2、-NO2、-CN、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 Carbocyclic ring, -C 3-6 Carbocyclic-(C 1-6 haloalkyl) and 3 to 6 membered heterocyclic rings.

[0231] In some embodiments, for the compound or salt of Formula (I), C is phenyl, optionally substituted with one or more substituents independently selected from:

[0232] Halogen, -OR 18 、-N(R 18 )2, -NO2 and -CN; and

[0233] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18 、-N(R 18 )2, -NO2 and -CN; and 3 to 7 membered heterocycloalkyl, optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-NO2、-CN、C 1-6 Alkyl, C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-6The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-N(R 18A )2、-NO2、-CN、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 Carbocyclic ring, -C 3-6 Carbocyclic-(C 1-6 haloalkyl) and 3 to 6 membered heterocyclic rings.

[0234] In some embodiments, for the compound or salt of Formula (I), C is phenyl, optionally substituted with one or more substituents independently selected from:

[0235] Halogen, -OR 18 、-N(R 18 )2, -NO2 and -CN; and

[0236] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from:

[0237] Halogen, -OR 18 、-N(R 18 )2, -NO2, -CN; and

[0238] Azetidinyl, piperidinyl, piperazinyl and azapanyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR 18A 、-NO2、-CN、C 1-6 Alkyl, C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-N(R 18A )2、-NO2、-CN、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 Carbocyclic ring, -C 3-6 Carbocyclic-(C 1-6 haloalkyl) and a 3- to 6-membered heterocyclic ring; and R 18 and R 18A Each occurrence is independently selected from hydrogen, halogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl.

[0239] In some embodiments, for compounds or salts of Formula (I), C is phenyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18 、-N(R 18 )2, -NO2 and -CN; and C 1-6 Alkyl, the C 1-6 Alkyl is optionally substituted with piperidinyl, piperazinyl and azepanyl, each of which is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-NO2、-CN、C 1-6 Alkyl, C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-N(R 18A )2、-NO2、-CN、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 Carbocyclic ring, -C 3-6 Carbocyclic-(C 1-6 haloalkyl) and a 3- to 6-membered heterocyclic ring; and R 18 and R 18A Each occurrence is independently selected from hydrogen, halogen, C 1-6 Alkyl and C 1-6 In some embodiments, C is selected from:

[0240]

[0241] In some embodiments, for the compound or salt of Formula (I), C is phenyl, optionally substituted with one or more substituents independently selected from:

[0242] Halogen, -OR 18 、-N(R 18 )2, -NO2 and -CN; and

[0243] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from:

[0244] Halogen, -OR 18 、-N(R 18 )2, -NO2 and -CN; and

[0245] 8 to 12 membered spirocyclic saturated heterocyclic ring, which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A、-NO2、-CN、C 1-6 Alkyl, C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-N(R 18A )2、-NO2、-CN、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 carbocyclic rings and 3- to 6-membered heterocyclic rings.

[0246] In some embodiments, for the compound or salt of Formula (I), C is phenyl, optionally substituted with one or more substituents independently selected from:

[0247] Halogen, -OR 18 、-N(R 18 )2, -NO2 and -CN; and

[0248] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from:

[0249] Halogen, -OR 18 、-N(R 18 )2, -NO2 and -CN; and

[0250] 6-azaspiro[2.5]octyl, 2-oxa-8-azaspiro[4.5]decyl, 3-azaspiro[5.5]undecyl and 2,9-diazaspiro[5.5]undecyl, each of which is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-NO2、-CN、C 1-6 Alkyl, C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-N(R 18A )2、-NO2、-CN、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 carbocyclic and 3- to 6-membered heterocyclic rings; and R 18 and R 18A Each occurrence is independently selected from hydrogen, halogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl.

[0251] In some embodiments, for compounds or salts of Formula (I), C is phenyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18 、-N(R 18 )2, -NO2 and -CN; and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more 6-azaspiro[2.5]octyl, 2-oxa-8-azaspiro[4.5]decyl, 3-azaspiro[5.5]undecyl, and 2,9-diazaspiro[5.5]undecyl, each of which is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-NO2、-CN、C 1-6 Alkyl, C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-N(R 18A )2、-NO2、-CN、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 carbocyclic and 3- to 6-membered heterocyclic rings; and R 18 and R 18A Each occurrence is independently selected from hydrogen, halogen, C 1-6 Alkyl and C 1-6 In some embodiments, C is selected from:

[0252]

[0253] In some embodiments, for the compound or salt of Formula (I), C is phenyl, optionally substituted with one or more substituents independently selected from:

[0254] Halogen, -OR 18 、-N(R 18 )2, -NO2 and -CN; and

[0255] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from:

[0256] Halogen, -OR 18 、-N(R 18 )2, -NO2 and -CN; and

[0257] 8- to 10-membered bridged saturated heterocyclic ring, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A、-NO2、-CN、C 1-6 Alkyl, C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-N(R 18A )2、-NO2、-CN、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 carbocyclic rings and 3- to 6-membered heterocyclic rings.

[0258] In some embodiments, for the compound or salt of Formula (I), C is phenyl, optionally substituted with one or more substituents independently selected from:

[0259] Halogen, -OR 18 、-N(R 18 )2, -NO2 and -CN; and

[0260] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from:

[0261] Halogen, -OR 18 、-N(R 18 )2, -NO2 and -CN; and

[0262] 8-oxa-3-azabicyclo[3.2.1]octyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-NO2、-CN、C 1-6 Alkyl, C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-N(R 18A )2、-NO2、-CN、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 carbocyclic and 3- to 6-membered heterocyclic rings; and R 18 and R 18A Each occurrence is independently selected from hydrogen, halogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl.

[0263] In some embodiments, for the compound or salt of Formula (I), C is phenyl, optionally substituted with one or more substituents independently selected from:

[0264] Halogen, -OR 18 、-N(R 18 )2, -NO2 and -CN; and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with 8-oxa-3-azabicyclo[3.2.1]octyl, which is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-NO2、-CN、C 1-6 Alkyl, C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-N(R 18A )2、-NO2、-CN、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 carbocyclic and 3- to 6-membered heterocyclic rings; and R 18 and R 18A Each occurrence is independently selected from hydrogen, halogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl.

[0265] In some embodiments, for the compound or salt of Formula (I), C is phenyl, optionally substituted with one or more substituents independently selected from: -OR 18 , -CN and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with 8-oxa-3-azabicyclo[3.2.1]octyl, which is optionally substituted with substituents independently selected from the group consisting of halogen, -OR 18A , -NO2, -CN and C 1-6 In some embodiments, C is selected from

[0266] In some embodiments, for the compound or salt of Formula (I), C is phenyl, optionally substituted with one or more substituents independently selected from:

[0267] Halogen, -OR 18 、-N(R 18)2, -NO2 and -CN; and

[0268] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from:

[0269] Halogen, -OR 18 、-N(R 18 )2, -NO2 and -CN; and

[0270] 6- to 10-membered fused saturated heterocyclic ring, optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-NO2、-CN、C 1-6 Alkyl, C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-N(R 18A )2、-NO2、-CN、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 carbocyclic rings and 3- to 6-membered heterocyclic rings.

[0271] In some embodiments, for the compound or salt of Formula (I), C is phenyl, optionally substituted with one or more substituents independently selected from:

[0272] Halogen, -OR 18 、-N(R 18 )2, -NO2 and -CN; and

[0273] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from:

[0274] Halogen, -OR 18 、-N(R 18 )2, -NO2 and -CN; and

[0275] Octahydro-1H-isoindolyl, optionally substituted with one or more substituents independently selected from halogen, -OR 18A 、-NO2、-CN、C 1-6 Alkyl, C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-N(R 18A)2、-NO2、-CN、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 carbocyclic and 3- to 6-membered heterocyclic rings; and R 18 and R 18A Each occurrence is independently selected from hydrogen, halogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl.

[0276] In some embodiments, for compounds or salts of Formula (I), C is phenyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18 、-N(R 18 )2, -NO2 and -CN; and C 1-6 Alkyl, the C 1-6 Alkyl is optionally substituted with one or more substituents independently selected from the group consisting of octahydro-1H-isoindolyl, octahydro-1H-isoindolyl, halogen, -OR 18A , -NO2, -CN and C 1-6 In some embodiments, C is

[0277] In some embodiments, for compounds or salts of Formula (I), C is C 6-12 A carbocyclic ring optionally substituted with one or more substituents independently selected from the group consisting of: 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0278] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-NO2、=O、=S、=NR 18 , -N3, -CN; and

[0279] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2、-C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R18A 、-N(R 18A )C(O)OR 18A 、-N(R 18A )C(O)N(R 18A )2、-N(R 18A )C(S)N(R 18A )2、-N(R 18A )S(O)2(R 18A ),-S(O)R 18A 、-S(O)2R 18A 、-S(O)2N(R 18A )2, -NO2, =O, =S, =NR 18A 、-N3、-CN、C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, wherein C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2、-C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-N(R 18A )C(O)OR 18A 、-N(R 18A )C(O)N(R 18A )2、-N(R 18A )C(S)N(R 18A )2、-N(R 18A )S(O)2(R 18A ),-S(O)R 18A 、-S(O)2R 18A 、-S(O)2N(R 18A )2, -NO2, =O, =S, =NR 18A , -N3 and -CN.

[0280] In some embodiments, for compounds or salts of Formula (I), C is C 8-12 a fused carbocyclic ring optionally substituted with one or more substituents independently selected from the group consisting of a 5- to 6-membered heteroaryl group optionally substituted with one or more substituents independently selected from the group consisting of:

[0281] Halogen, -OR 18 、-SR18 、-N(R 18 )2, -NO2, -CN; and

[0282] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-N(R 18A )2、-NO2、-CN、C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, wherein C 3-6 The carbocyclic ring and the 3 to 6 membered heterocyclic ring are each optionally substituted by one or more independently selected from halogen, -OR 18A 、-N(R 18A )2, -NO2, -CN; and R 18 and R 18A Each occurrence is independently selected from hydrogen, halogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl.

[0283] In some embodiments, for compounds or salts of Formula (I), C is C 8-12 A fused carbocyclic ring optionally substituted with one or more substituents independently selected from the group consisting of 5- to 6-membered heteroaryl, optionally substituted with one or more substituents independently selected from the group consisting of C 1-6 Alkyl, the C 1-6 Alkyl is optionally substituted by one or more independently selected from halogen, C 3-6 The substituents of carbocyclic and 3 to 6 membered heterocyclic rings are substituted, wherein C 3-6 The carbocyclic ring and the 3 to 6 membered heterocyclic ring are each optionally substituted by one or more substituents independently selected from halogen. In some embodiments, for the compound or salt of formula (I), C is

[0284] In some embodiments, C is an optionally substituted 3 to 12 membered heterocycle. In some embodiments, C is an optionally substituted 3 to 12 membered saturated heterocycle. In some embodiments, C is an optionally substituted 3 to 12 membered unsaturated heterocycle. In some embodiments, C is an optionally substituted 6 to 12 membered aromatic heterocycle. In some embodiments, C is selected from a 3-membered heterocycle, a 4-membered heterocycle, a 5-membered heterocycle, a 6-membered heterocycle, a 7-membered heterocycle, an 8-membered heterocycle, a 9-membered heterocycle, a 10-membered heterocycle, an 11-membered heterocycle, and a 12-membered heterocycle, any one of which is optionally substituted. In some embodiments, C is selected from a 3 to 4 membered heterocycle, a 3 to 5 membered heterocycle, a 3 to 6 membered heterocycle, a 3 to 7 membered heterocycle, a 3 to 8 membered heterocycle, a 3 to 9 membered heterocycle, a 3 to 10 membered heterocycle, a 3 to 11 membered heterocycle, and a 3 to 12 membered heterocycle, any one of which is optionally substituted. In some embodiments, C is selected from 3 to 8 membered monocyclic heterocycles and 6 to 12 membered bicyclic heterocycles, any one of which is optionally substituted. In some embodiments, C is an optionally substituted 3 to 8 membered monocyclic heterocycle. In some embodiments, C is an optionally substituted 6 to 12 membered bicyclic heterocycle. In some embodiments, the optionally substituted 6 to 12 membered bicyclic heterocycle of C is selected from 6 to 12 membered bridged heterocycles, 6 to 12 membered spirocyclic heterocycles and 6 to 12 membered fused heterocycles, any one of which is optionally substituted. In some embodiments, the optional substituents of C are as defined herein. In some embodiments, the optional substituents of C are as defined in formula (I).

[0285] In some embodiments, for the compound or salt of Formula (I), C is a 3- to 12-membered heterocyclic ring optionally substituted with one or more substituents independently selected from:

[0286] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 、-N(R 18 )C(O)OR 18 、-N(R 18 )C(O)N(R 18 )2、-N(R 18 )C(S)N(R 18 )2、-N(R 18 )S(O)2(R 18 ),-S(O)R 18 、-S(O)2R18 、-S(O)2N(R 18 )2, -NO2, =O, =S, =NR 18 , -N3 and -CN;

[0287] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 alkynyl, each of which is optionally substituted with one or more substituents independently selected from:

[0288] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 、-N(R 18 )C(O)OR 18 、-N(R 18 )C(O)N(R 18 )2、-N(R 18 )C(S)N(R 18 )2、-N(R 18 )S(O)2(R 18 ),-S(O)R 18 、-S(O)2R 18 、-S(O)2N(R 18 )2, -NO2, =O, =S, =NR 18 , -N3 and -CN; and

[0289] C 3-12 carbocyclic and 3- to 12-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from:

[0290] Halogen, -OR 18A 、-SR 18A 、-N(R 18A )2、-C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-N(R 18A)C(O)OR 18A 、-N(R 18A )C(O)N(R 18A )2、-N(R 18A )C(S)N(R 18A )2、-N(R 18A )S(O)2(R 18A ),-S(O)R 18A 、-S(O)2R 18A 、-S(O)2N(R 18A )2, -NO2, =O, =S, =NR 18A 、-N3、-CN、C 1-10 Alkyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-10 Alkyl, C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2、-C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-N(R 18A )C(O)OR 18A 、-N(R 18A )C(O)N(R 18A )2、-N(R 18A )C(S)N(R 18A )2、-N(R 18A )S(O)2(R 18A ),-S(O)R 18A 、-S(O)2R 18A 、-S(O)2N(R 18A )2, -NO2, =O, =S, =NR 18A 、-N3、-CN、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 Carbocyclic ring, -C 3-6 Carbocyclic-(C 1-6 haloalkyl) and a 3- to 6-membered heterocyclic ring; and

[0291] C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0292] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-NO2、=O、=S、=NR 18 , -N3, -CN; and

[0293] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2、-C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-N(R 18A )C(O)OR 18A 、-N(R 18A )C(O)N(R 18A )2、-N(R 18A )C(S)N(R 18A )2、-N(R 18A )S(O)2(R 18A ),-S(O)R 18A 、-S(O)2R 18A 、-S(O)2N(R 18A )2, -NO2, =O, =S, =NR 18A 、-N3、-CN、C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, wherein C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2、-C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-N(R 18A )C(O)OR 18A 、-N(R18A )C(O)N(R 18A )2、-N(R 18A )C(S)N(R 18A )2、-N(R 18A )S(O)2(R 18A ),-S(O)R 18A 、-S(O)2R 18A 、-S(O)2N(R 18A )2, -NO2, =O, =S, =NR 18A , -N3 and -CN.

[0294] In some embodiments, for the compound or salt of Formula (I), C is pyridinyl, optionally substituted with one or more substituents independently selected from:

[0295] Halogen, -OR 18 、-N(R 18 )2、-C(O)R 18 , -NO2 and -CN; and

[0296] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from:

[0297] Halogen, -OR 18 、-N(R 18 )2、-C(O)R 18 , -NO2 and -CN; and

[0298] C 3-12 carbocyclic and 3- to 12-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from:

[0299] Halogen, -OR 18A 、-N(R 18A )2、-C(O)R 18A 、-NO2、-CN、C 1-6 Alkyl, C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-N(R 18A )2、-C(O)R 18A 、-NO2、-CN、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 Carbocyclic ring, -C 3-6 Carbocyclic-(C 1-6haloalkyl) and a 3- to 6-membered heterocyclic ring; and

[0300] R 18 and R 18A Each occurrence is independently selected from hydrogen, halogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl.

[0301] In some embodiments, for the compound or salt of Formula (I), C is pyridinyl, optionally substituted with one or more substituents independently selected from:

[0302] Halogen, -OR 18 , -NO2 and -CN; and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of: 3-12 carbocyclic and 3- to 12-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from:

[0303] Halogen, C 1-6 Alkyl, C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-N(R 18A )2、-NO2、-CN、C 1-6 Alkyl, C 1-6 haloalkyl; and R 18 and R 18A Each occurrence is independently selected from hydrogen, halogen, C 1-6 Alkyl and C 1-6 In some embodiments, C is selected from:

[0304]

[0305] In some embodiments, for the compound or salt of Formula (I), C is selected from an 8- to 12-membered bicyclic heterocycle, optionally substituted with one or more substituents independently selected from:

[0306] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R18 )2、-N(R 18 )C(O)R 18 , =O, -NO2 and -CN;

[0307] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from:

[0308] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 , -NO2 and -CN; and

[0309] C 3-12 carbocyclic and 3 to 12 membered heterocyclic rings, any of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2、-C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-NO2、-CN、C 1-6 Alkyl, C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2、-C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-NO2、-CN、C 1-6Alkyl, C 1-6 Halogenated alkyl, C 3-6 Carbocyclic ring, -C 3-6 Carbocyclic-(C 1-6 haloalkyl) and a 3- to 6-membered heterocyclic ring; and

[0310] C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0311] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 , -NO2 and -CN; and

[0312] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2、-C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-NO2、-CN、C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, wherein C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2、-C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A , -NO2, -CN.

[0313] In some embodiments, for the compound or salt of Formula (I), C is an 8- to 12-membered bicyclic heterocycle optionally substituted with one or more substituents independently selected from:

[0314] Halogen, -OR 18 、-SR 18 、-N(R18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 , -NO2 and -CN; and

[0315] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from:

[0316] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 , =O, -NO2 and -CN; and

[0317] C 3-12 carbocyclic and 3 to 12 membered heterocyclic rings, any of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2、-C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-NO2、-CN、C 1-6 Alkyl, C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2、-C(O)R 18A 、-C(O)OR 18A 、-OC(O)R18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-NO2、-CN、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 Carbocyclic ring, -C 3-6 Carbocyclic-(C 1-6 haloalkyl) and 3 to 6 membered heterocyclic rings.

[0318] In some embodiments, for the compound or salt of Formula (I), C is an 8- to 12-membered bicyclic heterocycle optionally substituted with one or more substituents independently selected from:

[0319] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 , =O, -NO2 and -CN; and

[0320] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from:

[0321] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 , -NO2 and -CN; and

[0322] 3 to 8 membered monocyclic heterocycloalkyl, optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2、-C(O)R 18A 、-C(O)OR 18A、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-NO2、-CN、C 1-6 Alkyl, C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2、-C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-NO2、-CN、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 Carbocyclic ring, -C 3-6 Carbocyclic-(C 1-6 haloalkyl) and 3 to 6 membered heterocyclic rings.

[0323] In some embodiments, for the compound or salt of Formula (I), C is an 8- to 12-membered bicyclic heterocycle optionally substituted with one or more substituents independently selected from:

[0324] Halogen, -OR 18 、-N(R 18 )2、-C(O)R 18 , =O, -NO2 and -CN; and

[0325] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from:

[0326] Halogen, -OR 18 、-N(R 18 )2、-C(O)R 18 , -NO2 and -CN; and

[0327] 3 to 8 membered monocyclic heterocycloalkyl, optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-N(R 18A )2、-C(O)R18A 、-NO2、-CN、C 1-6 Alkyl, C 3-6 carbocyclic rings and 3- to 6-membered heterocyclic rings.

[0328] In some embodiments, for the compound or salt of Formula (I), C is an 8- to 12-membered bicyclic heterocycle optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18 、-N(R 18 )2、-C(O)R 18 , =O, -NO2 and -CN; and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted by one or more substituents independently selected from the group consisting of 3 to 8 membered monocyclic heterocycloalkyl, said 3 to 8 membered monocyclic heterocycloalkyl being optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 3-6 In some embodiments, C is selected from

[0329] In some embodiments, for the compound or salt of Formula (I), C is an 8- to 12-membered bicyclic heterocycle optionally substituted with one or more substituents independently selected from:

[0330] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 , =O, -NO2 and -CN; and

[0331] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from:

[0332] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R18 )C(O)R 18 , -NO2 and -CN; and

[0333] 3 to 12 membered bicyclic heterocycle, optionally substituted by one or more substituents independently selected from halogen, -OR 18A 、-SR 18A 、-N(R 18A )2、-C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-NO2、-CN、C 1-6 Alkyl, C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2、-C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-NO2、-CN、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 Carbocyclic ring, -C 3-6 Carbocyclic-(C 1-6 haloalkyl) and 3 to 6 membered heterocyclic rings.

[0334] In some embodiments, for the compound or salt of Formula (I), C is an 8- to 12-membered bicyclic heterocycle optionally substituted with one or more substituents independently selected from:

[0335] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R18 )2、-N(R 18 )C(O)R 18 , =O, -NO2 and -CN; and

[0336] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from:

[0337] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 , -NO2 and -CN; and

[0338] 6 to 12 membered spirocyclic heterocycle, optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2、-C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-NO2、-CN、C 1-6 Alkyl, C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2、-C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-NO2、-CN、C 1-6 Alkyl, C 1-6Halogenated alkyl, C 3-6 Carbocyclic ring, -C 3-6 Carbocyclic-(C 1-6 haloalkyl) and 3 to 6 membered heterocyclic rings.

[0339] In some embodiments, for the compound or salt of Formula (I), C is an 8- to 12-membered bicyclic heterocycle optionally substituted with one or more substituents independently selected from:

[0340] Halogen, -OR 18 、-N(R 18 )2、-C(O)R 18 , =O, -NO2 and -CN; and

[0341] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from:

[0342] Halogen, -OR 18 、-N(R 18 )2、-C(O)R 18 , -NO2 and -CN; and

[0343] 6 to 12 membered spirocyclic heterocycle, optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-N(R 18A )2、-C(O)R 18A 、-NO2、-CN、C 1-6 Alkyl, C 3-6 carbocyclic rings and 3- to 6-membered heterocyclic rings.

[0344] In some embodiments, for compounds or salts of Formula (I), C is an 8- to 12-membered bicyclic heterocycle optionally substituted by one or more independently selected from C 1-6 The alkyl group is substituted with a substituent, the C 1-6 Alkyl is optionally substituted with one or more substituents independently selected from 6 to 12 membered spirocyclic heterocycles, which are optionally substituted with one or more substituents independently selected from halogen, -OR 18A 、-N(R 18A )2、-C(O)R 18A 、-NO2、-CN、C 1-6 Alkyl, C 3-6 In some embodiments, C is selected from

[0345] In some embodiments, for the compound or salt of Formula (I), C is an 8- to 12-membered bicyclic heterocycle optionally substituted with one or more substituents independently selected from:

[0346] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 , =O, -NO2 and -CN; and

[0347] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from:

[0348] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 , -NO2 and -CN; and

[0349] 6 to 12 membered bridged heterocyclic ring, optionally substituted with one or more substituents independently selected from halogen, -OR 18A 、-SR 18A 、-N(R 18A )2、-C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-NO2、-CN、C 1-6 Alkyl, C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2、-C(O)R18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-NO2、-CN、C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 Carbocyclic ring, -C 3-6 Carbocyclic-(C 1-6 haloalkyl) and 3 to 6 membered heterocyclic rings.

[0350] In some embodiments, for the compound or salt of Formula (I), C is an 8- to 12-membered bicyclic heterocycle optionally substituted with one or more substituents independently selected from:

[0351] Halogen, -OR 18 、-N(R 18 )2、-C(O)R 18 , =O, -NO2 and -CN; and

[0352] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from:

[0353] Halogen, -OR 18 、-N(R 18 )2、-C(O)R 18 , -NO2 and -CN; and

[0354] 6 to 12 membered bridged heterocyclic ring, optionally substituted with one or more substituents independently selected from halogen, -OR 18A 、-N(R 18A )2、-C(O)R 18A 、-NO2、-CN、C 1-6 Alkyl, C 3-6 carbocyclic rings and 3- to 6-membered heterocyclic rings.

[0355] In some embodiments, for compounds or salts of Formula (I), C is an 8- to 12-membered bicyclic heterocycle optionally substituted by one or more independently selected from C 1-6 The alkyl group is substituted with a substituent, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from a 6- to 12-membered bridged heterocycle, which is optionally substituted with one or more substituents independently selected from halogen, -OR 18A 、-N(R 18A )2、-C(O)R18A 、-NO2、-CN、C 1-6 Alkyl, C 3-6 In some embodiments, C is selected from

[0356] In one aspect, provided herein is a compound having the structure of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof:

[0357]

[0358] or a pharmaceutically acceptable salt thereof, wherein:

[0359] A is selected from:

[0360]

[0361] X 1 、X 2 、X 3 and X 4 Each independently selected from N and C(R 2 ), where X 1 、X 2 and X 3 At least one of them is C(R 2 );

[0362] represents a single bond or a double bond;

[0363] m is 0, 1, 2, or 3;

[0364] n is 0, 1, or 2;

[0365] p is 0, 1, 2, 3, 4, or 5;

[0366] R 1 Each independently selected from:

[0367] Halogen, -OR 11 、-SR 11 、-N(R 11 )2、-C(O)R 11 、-C(O)OR 11 、-OC(O)R 11 、-OC(O)N(R 11 )2、-C(O)N(R 11 )2、-N(R 11 )C(O)R 11 、-N(R 11 )C(O)OR 11 、-N(R 11 )C(O)N(R11 )2、-N(R 11 )C(S)N(R 11 )2、-N(R 11 )S(O)2(R 11 ),-S(O)R 11 、-S(O)2R 11 、-S(O)2N(R 11 )2, -NO2 and -CN;

[0368] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl, each of which is optionally substituted by one or more independently selected from halogen, -OR 11 、-SR 11 、-N(R 11 )2, substituted by =O, =S and -CN;

[0369] C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-4 Alkyl, C 1-4 Haloalkyl, -OR 11 、-SR 11 、-N(R 11 )2, substituted by =O, =S and -CN;

[0370] R2 are each independently selected from:

[0371] Hydrogen, halogen, -OR 12 、-SR 12 、-N(R 12 )2、-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )2、-C(O)N(R 12 )2、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )2、-N(R 12 )C(S)N(R 12 )2、-N(R 12 )S(O)2(R 12 ),-S(O)R 12 、-S(O)2R 12 、-S(O)2N(R12 )2, -NO2 and -CN;

[0372] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl, each of which is optionally substituted by one or more independently selected from halogen, -OR 12 、-SR 12 、-N(R 12 )2, =O, =S and -CN substituents; and

[0373] C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-4 Alkyl, C 1-4 Haloalkyl, -OR 12 、-SR 12 、-N(R 12 )2, =O, =S and -CN;

[0374] R 3 is hydrogen or C 1-6 alkyl;

[0375] R 4a and R 4b Each independently selected from:

[0376] Hydrogen, halogen, -OR 13 、-SR 13 、-N(R 13 )2、-C(O)R 13 , -NO2, -CN and C 1-6 Alkyl, the C 1-6 Alkyl is optionally substituted by one or more independently selected from halogen, -OR 13 、-SR 13 、-N(R 13 )2、-C(O)R 13 , -NO2 and -CN substituents;

[0377] R 5 is hydrogen or C 1-6 alkyl;

[0378] Y is a bond, -O-, -N(R 14 )-or-C(R 14a )(R 14b )-;

[0379] Z is selected from:

[0380] bond, -C(O)-, -C(R 15 )2-、-C(O)C(R15 )2-、-C(O)[C(R 15 )2] q S-, -C(=N-CN)-, -C(O)O-, -C(O)N(R 16 )-、-C(S)-、-C(S)N(R 16 )-, -S(O)- and -S(O)2-;

[0381] wherein q is selected from 1, 2, and 3;

[0382] B is selected from C 3-10 carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0383] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )C(S)N(R 17 )2、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN;

[0384] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 alkynyl, each of which is optionally substituted with one or more substituents independently selected from:

[0385] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )C(S)N(R 17 )2、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN;

[0386] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 ,-N(R 17 )C(O)N(R 17 )2、-N(R 17 )C(S)N(R 17 )2、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN; and

[0387] C 3-10carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0388] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )C(S)N(R 17 )2、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN;

[0389] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )C(S)N(R 17 )2、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN; and

[0390] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-NO2、=O、=S、=NR 17 , -N3 and -CN;

[0391] C is selected from C 5-10 Carbocyclic and 5- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0392] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 、-N(R 18 )C(O)OR 18 、-N(R 18 )C(O)N(R 18 )2、-N(R 18 )C(S)N(R 18 )2、-N(R 18 )S(O)2(R 18 ),-S(O)R 18 、-S(O)2R 18 、-S(O)2N(R 18 )2, -NO2, =O, =S, =NR 18 , -N3 and -CN;

[0393] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 alkynyl, each of which is optionally substituted with one or more substituents independently selected from:

[0394] Halogen, -OR18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 、-N(R 18 )C(O)OR 18 、-N(R 18 )C(O)N(R 18 )2、-N(R 18 )C(S)N(R 18 )2、-N(R 18 )S(O)2(R 18 ),-S(O)R 18 、-S(O)2R 18 、-S(O)2N(R 18 )2, -NO2, =O, =S, =NR 18 , -N3 and -CN; and

[0395] C 3-6 carbocyclic and 3 to 6 membered heterocyclic rings, any of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-4 Alkyl and C 1-4 haloalkyl; and

[0396] C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl,

[0397] -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-NO2、=O、=S、=NR 18 , -N3 and -CN;

[0398] R 11 and R 12 Each occurrence is independently selected from hydrogen and C 1-6 Alkyl, where C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -NH2, -OC 1-6 Alkyl, -OC1-6 Haloalkyl, =O and CN;

[0399] R 13 independently selected at each occurrence from hydrogen and C 1-6 alkyl;

[0400] R 14 Selected from hydrogen, C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbocyclic ring is optionally substituted by one or more independently selected from halogen, -OH, -NH2, -OC 1-6 Alkyl, -OC 1-6 Substitution with haloalkyl, =O and -CN substituents;

[0401] R 14a and R 14b Each independently selected from:

[0402] Hydrogen, C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbocyclic ring is optionally substituted by one or more independently selected from halogen, -OH, -NH2, -OC 1-6 Alkyl, -OC 1-6 Substituted with haloalkyl, =O and -CN; or

[0403] R 14a and R 14b Together they form C 3-6 carbocyclic or 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, -OH, -NH2, C 1-6 Alkyl, -C 1-6 Haloalkyl, -OC 1-6 Alkyl, -OC 1-6 Substitution with haloalkyl, =O and -CN substituents;

[0404] R 15 is independently selected at each occurrence from hydrogen, halogen, ═O, —CN, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings; or two R 15 Together they form C 3-6 carbon ring;

[0405] R 16 At each occurrence selected from hydrogen and C 1-6 alkyl;

[0406] R17 independently selected at each occurrence from:

[0407] hydrogen;

[0408] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 21 、-SR 21 、-N(R 21 )2、-C(O)R 21 、-C(O)OR 21 、-OC(O)R 21 、-OC(O)N(R 21 )2、-C(O)N(R 21 )2、-N(R 21 )C(O)R 21 、-NO2、=O、=S、=NR 21 and -CN; and

[0409] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 21 、-SR 21 、-N(R 21 )2、-C(O)R 21 、-C(O)OR 21 、-OC(O)R 21 、-OC(O)N(R 21 )2、-C(O)N(R 21 )2、-N(R 21 )C(O)R 21 、-N(R 21 )C(O)OR 21 、-N(R 21 )C(O)N(R 21 )2、-N(R 21 )C(S)N(R 21 )2、-N(R 21 )S(O)2(R 21 ),-S(O)R 21 、-S(O)2R 21 、-S(O)2N(R 21 )2, -NO2, =O, =S, =NR 17 、-CN、C 3-6 carbocyclic rings and 3- to 6-membered heterocyclic rings; and

[0410] R 18 and R21 Each occurrence is independently selected from hydrogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl and C 1-6 Aminoalkyl.

[0411] In one aspect, provided herein is a compound having the structure of Formula (II), or a pharmaceutically acceptable salt or solvate thereof:

[0412]

[0413] or a pharmaceutically acceptable salt thereof, wherein:

[0414] X 1 、X 2 and X 3 Each independently selected from N and C(R 2 ), where X 1 、X 2 and X 3 At least one of them is C(R 2 );

[0415] m is 0, 1, 2, or 3;

[0416] R 1 Each independently selected from:

[0417] Halogen, -OR 11 、-SR 11 、-N(R 11 )2、-C(O)R 11 、-C(O)OR 11 、-OC(O)R 11 、-OC(O)N(R 11 )2、-C(O)N(R 11 )2、-N(R 11 )C(O)R 11 、-N(R 11 )C(O)OR 11 、-N(R 11 )C(O)N(R 11 )2、-N(R 11 )C(S)N(R 11 )2、-N(R 11 )S(O)2(R 11 ),-S(O)R 11 、-S(O)2R 11 、-S(O)2N(R 11 )2, -NO2 and -CN;

[0418] C1-6 Alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl, each of which is optionally substituted by one or more independently selected from halogen, -OR 11 、-SR 11 、-N(R 11 )2, =O, =S and -CN substituents; and

[0419] C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-4 Alkyl, C 1-4 Haloalkyl, -OR 11 、-SR 11 、-N(R 11 )2, substituted by =O, =S and -CN;

[0420] R 2 Each independently selected from:

[0421] Hydrogen, halogen, -OR 12 、-SR 12 、-N(R 12 )2、-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )2、-C(O)N(R 12 )2、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )2、-N(R 12 )C(S)N(R 12 )2、-N(R 12 )S(O)2(R 12 ),-S(O)R 12 、-S(O)2R 12 、-S(O)2N(R 12 )2, -NO2 and -CN;

[0422] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl, each of which is optionally substituted by one or more independently selected from halogen, -OR 12 、-SR 12 、-N(R 12 )2, substituted by =O, =S and -CN;

[0423] as well as

[0424] C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-4 Alkyl, C 1-4 Haloalkyl, -OR 12 、-SR 12 、-N(R 12 )2, =O, =S and -CN;

[0425] R 3 is hydrogen or C 1-6 alkyl;

[0426] R 4a and R 4b Each independently selected from:

[0427] Hydrogen, halogen, -OR 13 、-SR 13 、-N(R 13 )2、-C(O)R 13 , -NO2 and -CN; and

[0428] C 1-6 Alkyl, which is optionally substituted by one or more independently selected from halogen, -OR 13 、

[0429] -SR 13 、-N(R 13 )2、-C(O)R 13 , -NO2 and -CN substituents; R 5 is hydrogen or C 1-6 Alkyl; Z is selected from:

[0430] bond, -C(O)-, -C(R 15 )2-、-C(O)C(R 15 )2-、-C(O)[C(R 15 )2] q S-, -C(=N-CN)-, -C(O)O-, -C(O)N(R 16 )-、-C(S)-、-C(S)N(R 16 )-, -S(O)- and -S(O)2-;

[0431] wherein q is selected from 1, 2, and 3;

[0432] B is selected from C 3-10 carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0433] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )C(S)N(R 17 )2、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN;

[0434] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 alkynyl, each of which is optionally substituted with one or more substituents independently selected from:

[0435] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )C(S)N(R 17 )2、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN;

[0436] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )C(S)N(R 17 )2、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN; and

[0437] C 3-10 carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0438] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )C(S)N(R 17 )2、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN;

[0439] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )C(S)N(R 17 )2、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN; and

[0440] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-NO2、=O、=S、=NR 17 , -N3 and -CN;

[0441] C is selected from C 5-10 Carbocyclic and 5- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0442] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 、-N(R 18 )C(O)OR 18 、-N(R 18 )C(O)N(R 18 )2、-N(R 18 )C(S)N(R 18 )2、-N(R 18 )S(O)2(R 18 ),-S(O)R 18 、-S(O)2R 18 、-S(O)2N(R 18 )2, -NO2, =O, =S, =NR 18 , -N3 and -CN;

[0443] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 alkynyl, each of which is optionally substituted with one or more substituents independently selected from:

[0444] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 、-N(R 18 )C(O)OR 18 、-N(R 18 )C(O)N(R 18 )2、-N(R 18 )C(S)N(R18 )2、-N(R 18 )S(O)2(R 18 ),-S(O)R 18 、-S(O)2R 18 、-S(O)2N(R 18 )2, -NO2, =O, =S, =NR 18 、-N3、-CN、C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, wherein C 3-6 The carbocyclic and 3- to 6-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from the group consisting of halogen, C 1-4 Alkyl and C 1-4 haloalkyl; and

[0445] C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 18 、-SR 18 、-N(R 18 )2.

[0446] -C(O)R 18 、-NO2、=O、=S、=NR 18 , -N3 and -CN substituents;

[0447] R 11 and R 12 Each occurrence is independently selected from hydrogen and C 1-6 Alkyl, where C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -NH2, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, =O and -CN;

[0448] R 13 independently selected at each occurrence from hydrogen and C 1-6 alkyl;

[0449] R 15 is independently selected at each occurrence from hydrogen, halogen, ═O, —CN, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings; or two R 15 Together they form C 3-6 carbon ring;

[0450] R 16 At each occurrence selected from hydrogen and C 1-6alkyl;

[0451] R 17 independently selected at each occurrence from:

[0452] hydrogen;

[0453] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 21 、-SR 21 、-N(R 21 )2、-C(O)R 21 、-C(O)OR 21 、-OC(O)R 21 、-OC(O)N(R 21 )2、-C(O)N(R 21 )2、-N(R 21 )C(O)R 21 、-NO2、=O、=S、=NR 21 and -CN; and

[0454] C 3-10 carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0455] Halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 21 、-SR 21 、-N(R 21 )2、-C(O)R 21 、-C(O)OR 21 、-OC(O)R 21 、-OC(O)N(R 21 )2、-C(O)N(R 21 )2、-N(R 21 )C(O)R 21 、-N(R 21 )C(O)OR 21 、-N(R 21 )C(O)N(R 21 )2、-N(R 21 )C(S)N(R 21 )2、-N(R 21 )S(O)2(R 21 ),-S(O)R 21 、-S(O)2R 21 、-S(O)2N(R 21 )2, -NO2, =O, =S, =NR 17 、-CN、C3-6 carbocyclic rings and 3- to 6-membered heterocyclic rings; and

[0456] R 18 and R 21 Each occurrence is independently selected from hydrogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl and C 1-6 Aminoalkyl.

[0457] In one aspect, provided herein is a compound having the structure of Formula (III), or a pharmaceutically acceptable salt or solvate thereof:

[0458]

[0459] or a pharmaceutically acceptable salt thereof, wherein:

[0460] X 4 Selected from N and C(R 2 ),

[0461] represents a single bond or a double bond;

[0462] n is 0, 1, or 2;

[0463] p is 0, 1, 2, 3, 4, or 5;

[0464] R 1 Each independently selected from:

[0465] Halogen, -OR 11 、-SR 11 、-N(R 11 )2、-C(O)R 11 、-C(O)OR 11 、-OC(O)R 11 、-OC(O)N(R 11 )2、-C(O)N(R 11 )2、-N(R 11 )C(O)R 11 、-N(R 11 )C(O)OR 11 、-N(R 11 )C(O)N(R 11 )2、-N(R 11 )C(S)N(R 11 )2、-N(R 11 )S(O)2(R 11 ),-S(O)R 11 、-S(O)2R 11 、-S(O)2N(R 11)2, -NO2 and -CN;

[0466] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl, each of which is optionally substituted by one or more independently selected from halogen, -OR 11 、-SR 11 、-N(R 11 )2, =O, =S and -CN substituents; and

[0467] C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-4 Alkyl, C 1-4 Haloalkyl, -OR 11 、-SR 11 、-N(R 11 )2, substituted by =O, =S and -CN;

[0468] R 2 Each independently selected from:

[0469] Hydrogen, halogen, -OR 12 、-SR 12 、-N(R 12 )2、-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )2、-C(O)N(R 12 )2、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )2、-N(R 12 )C(S)N(R 12 )2、-N(R 12 )S(O)2(R 12 ),-S(O)R 12 、-S(O)2R 12 、-S(O)2N(R 12 )2, -NO2 and -CN;

[0470] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl, each of which is optionally substituted by one or more independently selected from halogen, -OR 12 、-SR 12、-N(R 12 )2, =O, =S and -CN substituents; and

[0471] C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-4 Alkyl, C 1-4 Halogenated alkyl,

[0472] -OR 12 、-SR 12 、-N(R 12 )2, =O, =S and -CN;

[0473] R 3 is hydrogen or C 1-6 alkyl;

[0474] R 4a and R 4b Each independently selected from:

[0475] Hydrogen, halogen, -OR 13 、-SR 13 、-N(R 13 )2、-C(O)R 13 , -NO2 and -CN; and

[0476] C 1-6 Alkyl, which is optionally substituted by one or more independently selected from halogen, -OR 13 、-SR 13 、-N(R 13 )2、-C(O)R 13 , -NO2 and -CN substituents;

[0477] R 5 is hydrogen or C 1-6 alkyl;

[0478] Z is selected from:

[0479] bond, -C(O)-, -C(R 15 )2-、-C(O)C(R 15 )2-、-C(O)[C(R 15 )2] q S-, -C(=N-CN)-, -C(O)O-, -C(O)N(R 16 )-、-C(S)-、-C(S)N(R 16 )-, -S(O)- and -S(O)2-;

[0480] wherein q is selected from 1, 2, and 3;

[0481] B is selected from C3-10 carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0482] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )C(S)N(R 17 )2、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN;

[0483] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 alkynyl, each of which is optionally substituted with one or more substituents independently selected from:

[0484] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )C(S)N(R 17 )2、-N(R17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN;

[0485] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )C(S)N(R 17 )2、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN; and

[0486] C 3-10 carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0487] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )C(S)N(R 17 )2、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN;

[0488] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )C(S)N(R 17 )2、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN; and

[0489] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 17 、-SR 17 、-N(R 17)2、-C(O)R 17 、-NO2、=O、=S、=NR 17 , -N3 and -CN;

[0490] C is selected from C 5-10 Carbocyclic and 5- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0491] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 、-N(R 18 )C(O)OR 18 、-N(R 18 )C(O)N(R 18 )2、-N(R 18 )C(S)N(R 18 )2、-N(R 18 )S(O)2(R 18 ),-S(O)R 18 、-S(O)2R 18 、-S(O)2N(R 18 )2, -NO2, =O, =S, =NR 18 , -N3 and -CN;

[0492] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 alkynyl, each of which is optionally substituted with one or more substituents independently selected from:

[0493] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 、-N(R 18 )C(O)OR 18、-N(R 18 )C(O)N(R 18 )2、-N(R 18 )C(S)N(R 18 )2、-N(R 18 )S(O)2(R 18 ),-S(O)R 18 、-S(O)2R 18 、-S(O)2N(R 18 )2, -NO2, =O, =S, =NR 18 、-N3、-CN、C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, wherein C 3-6 The carbocyclic and 3- to 6-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from the group consisting of halogen, C 1-4 Alkyl and C 1-4 haloalkyl; and

[0494] C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl,

[0495] -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-NO2、=O、=S、=NR 18 、

[0496] -N3 and -CN;

[0497] R 11 and R 12 Each occurrence is independently selected from hydrogen and C 1-6 Alkyl, where C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -NH2, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, =O and -CN;

[0498] R 13 independently selected at each occurrence from hydrogen and C 1-6 alkyl;

[0499] R 15 is independently selected at each occurrence from hydrogen, halogen, ═O, —CN, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6Carbocyclic and 3- to 6-membered heterocyclic rings; or two R 15 Together they form C 3-6 carbon ring;

[0500] R 16 At each occurrence selected from hydrogen and C 1-6 alkyl;

[0501] R 17 independently selected at each occurrence from:

[0502] hydrogen;

[0503] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 21 、-SR 21 、-N(R 21 )2、-C(O)R 21 、-C(O)OR 21 、-OC(O)R 21 、-OC(O)N(R 21 )2、-C(O)N(R 21 )2、-N(R 21 )C(O)R 21 、-NO2、=O、=S、=NR 21 and -CN; and

[0504] C 3-10 carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0505] Halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 21 、-SR 21 、-N(R 21 )2、-C(O)R 21 、-C(O)OR 21 、-OC(O)R 21 、-OC(O)N(R 21 )2、-C(O)N(R 21 )2、-N(R 21 )C(O)R 21 、-N(R 21 )C(O)OR 21 、-N(R 21 )C(O)N(R 21 )2、-N(R 21 )C(S)N(R 21 )2、-N(R 21 )S(O)2(R21 ),-S(O)R 21 、-S(O)2R 21 、-S(O)2N(R 21 )2, -NO2, =O, =S, =NR 17 、-CN、C 3-6 carbocyclic rings and 3- to 6-membered heterocyclic rings; and

[0506] R 18 and R 21 Each occurrence is independently selected from hydrogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl and C 1-6 Aminoalkyl.

[0507] In some embodiments, for the compound or salt of Formula (I), (la), (II), or (III), m is 0, 1, 2, or 3. In some embodiments, m is 0, 1, or 2. In some embodiments, m is 0 or 1. In some embodiments, m is 1, 2, or 3. In some embodiments, m is 1 or 2. In some embodiments, m is 0. In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, m is 3.

[0508] In some embodiments, for the compound or salt of Formula (I), (la), (II), or (III), n is 0, 1, or 2. In some embodiments, n is 0 or 1. In some embodiments, n is 1 or 2. In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n is 2.

[0509] In some embodiments, for the compound or salt of Formula (I), (la), (II), or (III), p is 0, 1, 2, 3, or 4. In some embodiments, p is 0, 1, 2, or 3. In some embodiments, p is 0, 1, or 2. In some embodiments, p is 0 or 1. In some embodiments, p is 1, 2, or 3. In some embodiments, p is 1 or 2. In some embodiments, p is 2 or 3. In some embodiments, p is 0. In some embodiments, p is 1. In some embodiments, p is 2. In some embodiments, p is 3. In some embodiments, p is 4. In some embodiments, p is 5.

[0510] In some embodiments, for the compound or salt of Formula (I), A is selected from In some embodiments, A is In some embodiments, A is selected from In some embodiments, A is selected from In some embodiments, A is In some embodiments, A is

[0511] In some embodiments, for the compound or salt of Formula (I), A is In some embodiments, A is and n is 0 or 1. In some embodiments, A is and n is 0. In some embodiments, A is and n is 1. In some embodiments, A is and n is 0 or 1. In some embodiments, A is and n is 0. In some embodiments, A is And n is 1.

[0512] In some embodiments, for the compound or salt of Formula (I) or (II), X 1 、X 2 and X 3 Each independently selected from N and C(R 2 ), where X 1 、X 2 and X 3 At least one of them is C(R 2 ). In some embodiments, X 1 is N, and X 2 and X 3 Each independently selected from N and C(R 2 ), where X 2 and X 3 At least one of them is C(R 2 ). In some embodiments, X 2 is N, and X 1 and X 3 Each independently selected from N and C(R 2 ), where X 1 and X 3 At least one of them is C(R 2 ). In some embodiments, X 3 is N, and X 2 and X 3 Each independently selected from N and C(R 2 ), where X 2 and X 3 At least one of them is C(R 2 ). In some embodiments, X 1 C(R 2 ), and X 2 and X 3Each independently selected from N and C(R 2 ). In some embodiments, X 2 C(R 2 ), and X 1 and X 3 Each independently selected from N and C(R 2 ). In some embodiments, X 3 C(R 2 ), and X 2 and X 3 Each independently selected from N and C(R 2 ).

[0513] In some embodiments, for the compound or salt of Formula (I) or (III), X 4 Selected from N and C(R 2 ). In some embodiments, X 4 C(R 2 ). In some embodiments, X 4 is N. In some embodiments, Indicates a single bond.

[0514] In some embodiments, for the compound or salt of Formula (I), Y is a bond, -O-, -N(R 14 )-or-C(R 14a )(R 14b )-. In some embodiments, Y is a bond, -N(R 14 )-or-C(R 14a )(R 14b )-. In some embodiments, Y is a bond, -O-, or -C(R 14a )(R 14b )-. In some embodiments, Y is a bond or -C(R 14a )(R 14b )-. In some embodiments, Y is a bond.

[0515] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), R 1 Each independently selected from:

[0516] Halogen, -OR 11 、-SR 11 、-N(R 11 )2、-C(O)R 11 、-C(O)OR 11 、-OC(O)R 11 、-OC(O)N(R 11 )2、-C(O)N(R 11 )2、-N(R11 )C(O)R 11 、-N(R 11 )C(O)OR 11 、-N(R 11 )C(O)N(R 11 )2、-N(R 11 )C(S)N(R 11 )2、-N(R 11 )S(O)2(R 11 ),-S(O)R 11 、-S(O)2R 11 、-S(O)2N(R 11 )2, -NO2 and -CN;

[0517] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl, each of which is optionally substituted by one or more independently selected from halogen, -OR 11 、-SR 11 、-N(R 11 )2, =O, =S and -CN substituents; and

[0518] C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-4 Alkyl, C 1-4 Haloalkyl, -OR 11 、-SR 11 、-N(R 11 )2, =O, =S and -CN substituents.

[0519] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), R 1 Each independently selected from:

[0520] Halogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, -OR 11 、-SR 11 、-N(R 11 )2、-C(O)R 11 、-C(O)OR 11 、-OC(O)R 11 、-OC(O)N(R 11 )2、-C(O)N(R 11 )2、-N(R 11 )C(O)R 11, -NO2 and -CN; and

[0521] C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-4 Alkyl, C 1-4 Haloalkyl, -OR 11 、-SR 11 、-N(R 11 )2, =O, =S and -CN substituents.

[0522] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), R 1 Each independently selected from: halogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, -OR 11 、-SR 11 、-N(R 11 )2、-C(O)R 11 、-C(O)OR 11 、-OC(O)R 11 、-OC(O)N(R 11 )2、-C(O)N(R 11 )2、-N(R 11 )C(O)R 11 , -NO2 and -CN. In some embodiments, R 1 Each independently selected from: halogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, -OR 11 、-N(R 11 )2、-C(O)R 11 、-C(O)OR 11 、-OC(O)R 11 、-C(O)N(R 11 )2、-N(R 11 )C(O)R 11 , -NO2 and -CN. In some embodiments, R 1 Each independently selected from: halogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, -OR 11 、-N(R 11 )2, -NO2 and -CN. In some embodiments, R1 Each independently selected from: halogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, -OR 11 In some embodiments, R 1 Each independently selected from: halogen, C 1-6 Alkyl and C 1-6 In some embodiments, R 1 are each independently selected from halogen and C 1-6 In some embodiments, R 1 are each independently selected from halogen. In some embodiments, R 1 Each independently selected from C 1-6 alkyl.

[0523] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), R 1 Each independently selected from C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-4 Alkyl, C 1-4 Haloalkyl, -OR 11 、-SR 11 、-N(R 11 )2, =O, =S and -CN. In one aspect, provided herein are compounds having the structure of formula (I), (Ia), (II) or (III), or pharmaceutically acceptable salts or solvates thereof, wherein R 1 Each independently selected from C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-4 Alkyl, C 1-4 Haloalkyl, -OR 11 、-N(R 11 )2, =O and -CN. In some embodiments, R 1 Each independently selected from C 3-4 Carbocyclic and 3 to 4 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-4 Alkyl, C 1-4 Haloalkyl, -OR 11 、-SR 11 、-N(R 11 )2, =O, =S and -CN. In some embodiments, R 1 Each independently selected from C 3-4Carbocyclic and 3 to 4 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-4 Alkyl, C 1-4 Haloalkyl, -OR 11 、-SR 11 、-N(R 11 )2, =O, =S and -CN. In some embodiments, R 1 Each independently selected from C 3-4 Carbocyclic and 3 to 4 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-4 Alkyl, C 1-4 Haloalkyl, -OR 11 、-N(R 11 )2, =O and -CN. In some embodiments, R 1 Each independently selected from C 3-4 Carbocyclic and 3 to 4 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-4 Alkyl and C 1-4 In some embodiments, R 1 Each independently selected from C 3-4 Carbocyclic and 3 to 4 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen and C 1-4 The alkyl group is substituted with a substituent.

[0524] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), R 2 Each independently selected from:

[0525] Hydrogen, halogen, -OR 12 、-SR 12 、-N(R 12 )2、-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )2、-C(O)N(R 12 )2、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )2、-N(R 12 )C(S)N(R 12 )2、-N(R 12 )S(O)2(R 12 ),-S(O)R12 、-S(O)2R 12 、-S(O)2N(R 12 )2, -NO2 and -CN;

[0526] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl, each of which is optionally substituted by one or more independently selected from halogen, -OR 12 、-SR 12 、-N(R 12 )2, =O, =S and -CN substituents; and

[0527] C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from: halogen, C 1-4 Alkyl, C 1-4 Haloalkyl, -OR 12 、-SR 12 、-N(R 12 )2, =O, =S and -CN substituents.

[0528] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), R 2 Each independently selected from: hydrogen, halogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, -OR 12 、-SR 12 、-N(R 12 )2、-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )2、-C(O)N(R 12 )2、-N(R 12 )C(O)R 12 , -NO2 and -CN. In some embodiments, R 2 Each independently selected from: halogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, -OR 12 、-N(R 12 )2、-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-C(O)N(R12 )2、-N(R 12 )C(O)R 12 , -NO2 and -CN. In some embodiments, R 2 Each independently selected from: halogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, -OR 12 、-N(R 12 )2, -NO2 and -CN. In some embodiments, R 2 Each independently selected from: halogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, -OR 12 In some embodiments, R 2 Each independently selected from: halogen, C 1-6 Alkyl and C 1-6 In some embodiments, R 2 are each independently selected from halogen and C 1-6 In some embodiments, R 2 are each independently selected from halogen. In some embodiments, R 2 Each independently selected from C 1-6 alkyl.

[0529] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), R 2 Each independently selected from C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-4 Alkyl, C 1-4 Haloalkyl, -OR 12 、-SR 12 、-N(R 12 )2, =O, =S and -CN. In one aspect, provided herein are compounds having the structure of formula (I), (Ia), (II) or (III), or pharmaceutically acceptable salts or solvates thereof, wherein R 2 Each independently selected from C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-4 Alkyl, C 1-4 Haloalkyl, -OR 12 、-N(R 12 )2, =O and -CN. In some embodiments, R 2Each independently selected from C 3-4 Carbocyclic and 3 to 4 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-4 Alkyl, C 1-4 Haloalkyl, -OR 12 、-SR 12 、-N(R 12 )2, =O, =S and -CN. In some embodiments, R 2 Each independently selected from C 3-4 Carbocyclic and 3 to 4 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-4 Alkyl, C 1-4 Haloalkyl, -OR 12 、-SR 12 、-N(R 12 )2, =O, =S and -CN. In some embodiments, R 2 Each independently selected from C 3-4 Carbocyclic and 3 to 4 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-4 Alkyl, C 1-4 Haloalkyl, -OR 12 、-N(R 12 )2, =O and -CN. In some embodiments, R 2 Each independently selected from C 3-4 Carbocyclic and 3 to 4 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-4 Alkyl and C 1-4 In some embodiments, R 2 Each independently selected from C 3-4 Carbocyclic and 3 to 4 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen and C 1-4 The alkyl group is substituted with a substituent.

[0530] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), R 3 independently selected from hydrogen and C 1-6 In some embodiments, R 3 In some embodiments, R 3 In some embodiments, R 3 In some embodiments, R 3 In some embodiments, R 3 Selected from methyl.

[0531] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), R 4a and R 4b are each independently selected from hydrogen, halogen, -OR 13 、-SR 13 、-N(R 13 )2、-C(O)R 13 , -NO2, -CN and C 1-6 Alkyl, the C 1-6 Alkyl is optionally substituted by one or more independently selected from halogen, -OR 13 、-SR 13 、-N(R 13 )2、-C(O)R 13 In some embodiments, R 4a and R 4b are each independently selected from hydrogen, halogen, -OR 13 、-SR 13 、-N(R 13 )2、-C(O)R 13 , -NO2, -CN and C 1-6 In some embodiments, R 4a and R 4b are each independently selected from hydrogen, halogen, -OR 13 、-N(R 13 )2, -NO2, -CN and C 1-6 In some embodiments, R 4a and R 4b are each independently selected from hydrogen, halogen, -OR 13 、-N(R 13 )2, -CN and C 1-6 In some embodiments, R 4a and R 4b are each independently selected from hydrogen, halogen, -CN and C 1-6 In some embodiments, R 4a and R4b are each independently selected from hydrogen, halogen and C 1-6 In some embodiments, R 4a and R 4b are each independently selected from hydrogen, halogen, C 1-3 Alkyl and C 1-3 In some embodiments, R 4a and R 4b are each independently selected from hydrogen and halogen. 4a and R 4bEach is hydrogen.

[0532] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), R 5 independently selected from hydrogen and C 1-6 In some embodiments, R 5 In some embodiments, R 5 In some embodiments, R 5 It is a methyl group.

[0533] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), Z is selected from a bond, -C(O)-, -C(R 15 )2-、-C(O)C(R 15 )2-、-C(O)[C(R 15 )2] q S-, -C(=N-CN)-, -C(O)O-, -C(O)N(R 16 )-、-C(S)-、-C(S)N(R 16 )-, -S(O)-, and -S(O)2-. In some embodiments, Z is selected from a bond, -C(O)-, -C(R 15 )2-、-C(O)C(R 15 )2-、-C(O)[C(R 15 )2] q S-, -C(=N-CN)-, -C(O)O-, -C(O)N(R 16 )-、-C(S)N(R 16 )- and -S(O)2-. In some embodiments, Z is selected from a bond, -C(O)-, -C(R 15 )2-、-C(O)C(R 15 )2-、-C(O)[C(R 15 )2] q In some embodiments, Z is selected from a bond, -C(O)-, -C(R 15 )2-、-C(O)C(R 15 )2-、-C(O)[C(R 15 )2] q In some embodiments, Z is selected from -C(O)-, -C(R 15 )2-、-C(O)C(R 15 )2-、-C(O)[C(R 15 )2] qS- and -C(=N-CN)-. In some embodiments, Z is -C(O)-. In some embodiments, Z is -C(R 15 )2-. In some embodiments, Z is -C(O)C(R 15 )2-. In some embodiments, Z is -C(O)[C(R 15 )2] q S-. In some embodiments, Z is -C(=N-CN)-.

[0534] In some embodiments, for compounds or salts of Formula (I), (la), (II), or (III), q is selected from 1, 2, and 3. In some embodiments, q is selected from 1 and 2. In some embodiments, q is 1. In some embodiments, q is 2.

[0535] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), R 11 and R 12 Each occurrence is independently selected from hydrogen and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -NH2, -OC 1-6 Alkyl, -OC 1-6 In some embodiments, R 11 and R 12 Each occurrence is independently selected from hydrogen and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -NH2, =O, and -CN. 11 and R 12 Each occurrence is independently selected from hydrogen and C 1-6 Alkyl, the C 1-6 Alkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -NH2, and =O. In some embodiments, R 11 and R 12 Each occurrence is independently selected from hydrogen and C 1-6 Alkyl, the C 1-6 Alkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, and =0. In some embodiments, R 11 and R 12 Each occurrence is independently selected from hydrogen and C 1-6 Alkyl, the C 1-6Alkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen and =0. In some embodiments, R 11 and R 12 Each occurrence is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 In some embodiments, R 11 and R 12 Each occurrence is independently selected from hydrogen and C 1-6 In some embodiments, R 11 and R 12 is independently hydrogen at each occurrence.

[0536] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), R 13 independently selected at each occurrence from hydrogen and C 1-6 In some embodiments, R 13 independently selected at each occurrence from hydrogen and C 1-4 In some embodiments, each R 13 For hydrogen.

[0537] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), R 14 Selected from hydrogen, C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbocyclic ring is optionally substituted by one or more independently selected from halogen, -OH, -NH2, -OC 1-6 Alkyl, -OC 1-6 In some embodiments, R 14 Selected from hydrogen, C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbocyclic ring is optionally substituted by one or more independently selected from halogen, -OH, -NH2, -OC 1-6 Alkyl, -OC 1-6 In some embodiments, R 14 Selected from hydrogen, C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbocyclic ring is optionally substituted by one or more independently selected from halogen, -OH, -OC 1-6In some embodiments, R 14 Selected from hydrogen, C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbocyclic ring is optionally substituted by one or more independently selected from halogen, -OH, -OC 1-6 In some embodiments, R 14 Selected from hydrogen and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted by one or more independently selected from halogen, -OH, -OC 1-6 In some embodiments, R 14 Selected from hydrogen, C 1-6 Alkyl and C 1-6 In some embodiments, R 14 Selected from hydrogen.

[0538] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), R 14a and R 14b are each independently selected from hydrogen, C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbocyclic ring is optionally substituted by one or more independently selected from halogen, -OH, -NH2, -OC 1-6 Alkyl, -OC 1-6 substituted with haloalkyl, =O and -CN; or R 14a and R 14b Together they form C 3-6 carbocyclic or 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, -OH, C 1-6 Alkyl, -C 1-6 Haloalkyl, -OC 1-6 Alkyl, -OC 1-6 In some embodiments, R 14a and R 14b are each independently selected from hydrogen, C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbocyclic ring is optionally substituted by one or more independently selected from halogen, -OH, -OC 1-6 Alkyl, =O and -CN substituents; or R 14a and R 14bTogether they form C 3-6 carbocyclic or 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, -OH, C 1-6 Alkyl, -C 1-6 Haloalkyl, -OC 1-6 Alkyl, -OC 1-6 In some embodiments, R 14a and R 14b are each independently selected from hydrogen, C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbocyclic ring is optionally substituted with one or more substituents independently selected from halogen, -OH and =0; or R 14a and R 14b Together they form C 3-6 carbocyclic or 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, -OH, C 1-6 Alkyl, -C 1-6 The substituents are substituted with haloalkyl and =O.

[0539] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), R 14a and R 14b Each independently selected from:

[0540] Hydrogen and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted by one or more independently selected from halogen, -OH, -NH2, -OC 1-6 Alkyl, -OC 1-6 Substituted with haloalkyl, =O and -CN; or

[0541] R 14a and R 14b Together they form C 3-6 carbocyclic or 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, -OH, -NH2, C 1-6 Alkyl, -C 1-6 Haloalkyl, -OC 1-6 Alkyl, -OC 1-6 The substituents are substituted with haloalkyl, =O and -CN.

[0542] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), R 14a and R 14b Each independently selected from:

[0543] Hydrogen and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted by one or more independently selected from halogen, -OH, -NH2, -OC 1-6 Alkyl, -OC 1-6 Substituted with haloalkyl, =O and -CN; or

[0544] R 14a and R 14b Together they form C 3-6 carbocyclic ring or 3- to 6-membered heterocyclic ring.

[0545] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), R 14a and R 14b are each independently selected from: hydrogen and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted by one or more independently selected from halogen, -OH, -NH2, -OC 1-6 Alkyl, -OC 1-6 In some embodiments, R 14a and R 14b are each independently selected from: hydrogen and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted by one or more independently selected from halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 In some embodiments, R 14a and R 14b are each independently selected from: hydrogen and C 1-6 Alkyl, the C 1-6 Alkyl is optionally substituted with one or more substituents independently selected from halogen and =0. In some embodiments, R 14a and R 14b are each independently selected from: hydrogen and C 1-6 In some embodiments, R 14a and R 14b are each independently hydrogen.

[0546] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), R 15 is independently selected at each occurrence from hydrogen, halogen, ═O, —CN, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings; or two R 15 Together they form C 3-6In some embodiments, R 15 is independently selected at each occurrence from hydrogen, halogen, ═O, —CN, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 In some embodiments, R 15 is independently selected at each occurrence from hydrogen, halogen, ═O, —CN, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 In some embodiments, R 15 is independently selected at each occurrence from hydrogen, halogen, ═O, —CN, C 1-6 Alkyl, C 1-6 In some embodiments, R 15 is independently selected at each occurrence from hydrogen, halogen, ═O, C 1-6 Alkyl, C 1-6 In some embodiments, R 15 is independently selected at each occurrence from hydrogen, halogen, C 1-6 Alkyl, C 1-6 In some embodiments, R 15 is independently selected at each occurrence from hydrogen, halogen, C 1-6 In some embodiments, R 15 is independently selected at each occurrence from hydrogen, halogen and C 1-6 In some embodiments, R 15 independently selected at each occurrence from hydrogen and C 1-6 In some embodiments, R 15 is independently selected from hydrogen and halogen at each occurrence. 15 For hydrogen.

[0547] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), R 16 At each occurrence selected from hydrogen and C 1-6 In some embodiments, R 16 At each occurrence selected from hydrogen and C 1-4 In some embodiments, R 16 At each occurrence selected from hydrogen and C 1-4 In some embodiments, each R 16 For hydrogen.

[0548] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), B is selected from C 3-10 carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0549] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )C(S)N(R 17 )2、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN;

[0550] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 alkynyl, each of which is optionally substituted with one or more substituents independently selected from:

[0551] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17)2、-N(R 17 )C(S)N(R 17 )2、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN;

[0552] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )C(S)N(R 17 )2、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN; and

[0553] C 3-10 carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0554] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )C(S)N(R 17 )2、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN;

[0555] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )C(S)N(R 17 )2、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN; and

[0556] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 17 、-SR17 、-N(R 17 )2、-C(O)R 17 、-NO2、=O、=S、=NR 17 , -N3 and -CN substituents.

[0557] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), B is selected from C 3-10 carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0558] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 )、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S and -CN;

[0559] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 alkynyl, each of which is optionally substituted with one or more substituents independently selected from:

[0560] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 )、-S(O)2R 17 、-S(O)2N(R 17 )2, =O and -CN;

[0561] C 3-10Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 )、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 and -CN; and

[0562] C 3-10 carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0563] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 )、-S(O)2R 17 、-S(O)2N(R 17 )2, =O, =S and -CN;

[0564] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17、-N(R 17 )S(O)2(R 17 )、-S(O)2N(R 17 )2, =O and -CN; and

[0565] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 17 、-N(R 17 )2, substituted by =O and -CN substituents.

[0566] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), B is selected from C 3-10 carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0567] Halogen, -OR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 )、-S(O)2R 17 、-S(O)2N(R 17 )2, =O and -CN;

[0568] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 alkynyl, each of which is optionally substituted with one or more substituents independently selected from:

[0569] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 , =O and -CN;

[0570] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 17、-N(R 17 )2、-C(O)R 17 =O and -CN; and

[0571] C 3-10 carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0572] Halogen, -OR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 , =O and -CN;

[0573] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 , =O and -CN; and

[0574] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Haloalkyl and -CN.

[0575] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), B is selected from C 3-10 carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0576] Halogen, -OR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )S(O)2(R 17 )、-S(O)2R 17 and -CN;

[0577] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -SR 17 、C 3-10Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl and C 1-6 haloalkyl; and

[0578] C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from: =O; -CN; C 1-6 Alkyl, which is optionally substituted by one or more independently selected from halogen and -OR 17 substituted with a substituent; and C 3-10 Carbon ring.

[0579] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), R 17 independently selected at each occurrence from:

[0580] hydrogen;

[0581] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 21 、-SR 21 、-N(R 21 )2、-C(O)R 21 、-C(O)OR 21 、-OC(O)R 21 、-OC(O)N(R 21 )2、-C(O)N(R 21 )2、-N(R 21 )C(O)R 21 、-NO2、=O、=S、=NR 21 and -CN; and

[0582] C 3-10 carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0583] Halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 21 、-SR 21 、-N(R 21 )2、-C(O)R 21 、-C(O)OR 21 、-OC(O)R 21 、-OC(O)N(R 21 )2、-C(O)N(R 21 )2、-N(R21 )C(O)R 21 、-N(R 21 )C(O)OR 21 、-N(R 21 )C(O)N(R 21 )2、-N(R 21 )C(S)N(R 21 )2、-N(R 21 )S(O)2(R 21 ),-S(O)R 21 、-S(O)2R 21 、-S(O)2N(R 21 )2, -NO2, =O, =S, =NR 17 、-CN、C 3-6 carbocyclic rings and 3- to 6-membered heterocyclic rings.

[0584] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), R 17 independently selected at each occurrence from:

[0585] hydrogen;

[0586] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 21 、-N(R 21 )2、-C(O)R 21 、-C(O)OR 21 、-OC(O)R 21 、-C(O)N(R 21 )2、-N(R 21 )C(O)R 21 , =O and -CN; and

[0587] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 21 、-N(R 21 )2、-C(O)R 21 、-C(O)OR 21 、-OC(O)R 21 、-C(O)N(R 21 )2、-N(R 21 )C(O)R 21 、-N(R 21 )S(O)2(R 21 ),-S(O)R21 、-S(O)2R 21 、-S(O)2N(R 21 )2、=O、-CN、C 3-6 carbocyclic rings and 3- to 6-membered heterocyclic rings.

[0588] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), R 17 independently selected at each occurrence from:

[0589] hydrogen;

[0590] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 21 、-N(R 21 )2、-C(O)N(R 21 )2、-N(R 21 )C(O)R 21 , =O and -CN; and

[0591] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 21 、-N(R 21 )2、-C(O)R 21 、-C(O)N(R 21 )2、-N(R 21 )C(O)R 21 , =O, C 3-6 carbocyclic rings and 3- to 6-membered heterocyclic rings.

[0592] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), R 17 independently selected at each occurrence from:

[0593] hydrogen;

[0594] C 1-6 Alkyl, which is optionally substituted by one or more independently selected from halogen, -OR 21 、-SR 21 、-N(R 21 )2 and -CN are substituted; and

[0595] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6Haloalkyl, -OC(O)N(R 21 )2 and C 3-6 Carbon ring.

[0596] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), R 17 is independently selected at each occurrence from: hydrogen; C 1-6 Alkyl, which is optionally substituted by one or more independently selected from halogen and -N(R 21 ) 2 is substituted with a substituent; and C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from -OC(O)N(R 21 )2 and C 3-6 In some embodiments, R 17 is independently selected at each occurrence from: hydrogen and C 1-6 Alkyl, the C 1-6 Alkyl is optionally substituted by one or more independently selected from halogen, -OR 21 、-SR 21 、-N(R 21 )2 and -CN are substituted. In some embodiments, R 17 is independently selected at each occurrence from: hydrogen and C 1-6 Alkyl, the C 1-6 Alkyl is optionally substituted by one or more independently selected from halogen, -N(R 21 )2 and -CN are substituted. In some embodiments, R 17 is independently selected at each occurrence from: hydrogen and C 1-6 Alkyl, the C 1-6 Alkyl is optionally substituted by one or more independently selected from halogen and -N(R 21 ) 2 is substituted with a substituent. In some embodiments, R 17 is independently selected at each occurrence from: hydrogen; and C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OC(O)N(R 21 )2 and C 3-6 In some embodiments, R 17 is independently selected at each occurrence from: hydrogen; and C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, -OC(O)N(R 21 )2 and C 3-6In some embodiments, R 17 is independently selected at each occurrence from: hydrogen; and C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from -OC(O)N(R 21 )2 and C 3-6 The carbocyclic ring is substituted with a substituent.

[0597] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), R 18 and R 21 Each occurrence is independently selected from hydrogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Hydroxyalkyl and C 1-6 In some embodiments, for compounds or salts of Formula (I), (Ia), (II) or (III), R 18 and R 21 Each occurrence is independently selected from hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl and C 1-6 In some embodiments, R 18 and R 21 Each occurrence is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 In some embodiments, R 18 and R 21 Each occurrence is independently selected from hydrogen and C 1-6 alkyl.

[0598] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), R 21 independently selected at each occurrence from hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl and C 1-6 In some embodiments, R 21 independently selected at each occurrence from hydrogen, C 1-6 Alkyl and C 1-6 In some embodiments, R 21 independently selected at each occurrence from hydrogen and C 1-6 In some embodiments, R 21 In each occurrence, independently selected from C 1-6 In some embodiments, each R 21 For hydrogen.

[0599] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), B is selected from C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, OC 1-6 Alkyl, -OC 1-6 Haloalkyl, =O, -CN, acetyl, difluoroacetyl,

[0600] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), B is selected from C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, OC 1-6 Alkyl, -OC 1-6 Haloalkyl, =O, -CN, acetyl, difluoroacetyl,

[0601] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), B is selected from the group consisting of: phenyl, naphthyl, C 3-10 In some embodiments, B is selected from the group consisting of: phenyl, C 3-7 Monocyclic cycloalkyl and 5 to 6 membered monocyclic heterocycle, any of which is optionally substituted. In some embodiments, B is selected from: naphthyl, C 7-10 In some embodiments, B is an optionally substituted phenyl. In some embodiments, B is an optionally substituted naphthyl. In some embodiments, B is an optionally substituted C 3-10 In some embodiments, B is an optionally substituted 5- to 6-membered monocyclic heterocycle. In some embodiments, B is an optionally substituted 7- to 10-membered bicyclic heterocycle.

[0602] In some embodiments, for compounds or salts of Formula (I), (la), (II), or (III), B is selected from the group consisting of phenyl, naphthyl, cyclopropyl, cyclohexyl, bicyclo[2.2.2]octane, adamantane, thiazole, pyrrole, pyrazole, pyridine, pyrimidine, pyrazine, indole, indazole, benzimidazole, indoline, azaindole, azaindoline, 1,3-dihydrobenzo[c]isothiazole, tetrahydropyran, azetidine, pyrrolidine, piperidine, quinuclidine, azepane, and 8-azabicyclo[3.2.1]octane, any of which is optionally substituted. In some embodiments, B is selected from the group consisting of phenyl, naphthyl, cyclopropyl, cyclohexyl, bicyclo[2.2.2]octane, adamantane, thiazole, pyrazole, pyridine, indole, indazole, benzimidazole, indoline, 1,3-dihydrobenzo[c]isothiazole, tetrahydropyran, azetidine, pyrrolidine, piperidine, quinuclidine, azepane, and 8-azabicyclo[3.2.1]octane, any of which is optionally substituted. In some embodiments, B is selected from the group consisting of phenyl, cyclohexyl, pyrazole, pyridine, indole, indazole, benzimidazole, indoline, 1,3-dihydrobenzo[c]isothiazole, pyrrolidine, piperidine, pyrrolidine, and piperidine, any of which is optionally substituted. In some embodiments, B is selected from the group consisting of phenyl, indole, indazole, benzimidazole, and 1,3-dihydrobenzo[c]isothiazole, any of which is optionally substituted. In some embodiments, B is optionally substituted phenyl.

[0603] In some embodiments, for compounds or salts of Formula (I), (Ia), (II) or (III), B is selected from the group consisting of phenyl, cyclopropyl, cyclohexyl, thiazole, pyrrole, pyrazole, pyridine, pyrimidine, pyrazine, indole, indazole, tetrahydropyran, azetidine, pyrrolidine, piperidine and azepane, any one of which is optionally substituted. In some embodiments, B is selected from the group consisting of phenyl, cyclopropyl, cyclohexyl, thiazole, pyrrole, pyrazole, pyridine, indole, indazole, tetrahydropyran, azetidine, pyrrolidine, piperidine and azepane, any one of which is optionally substituted. In some embodiments, B is selected from the group consisting of naphthyl, bicyclo[2.2.2]octane, adamantane, indole, indazole, benzimidazole, indoline, azaindole, azaindoline, 1,3-dihydrobenzo[c]isothiazole, quinuclidine, and 8-azabicyclo[3.2.1]octane, any of which is optionally substituted. In some embodiments, B is selected from the group consisting of naphthyl, bicyclo[2.2.2]octane, adamantane, indole, indazole, benzimidazole, indoline, 1,3-dihydrobenzo[c]isothiazole, quinuclidine, and 8-azabicyclo[3.2.1]octane, any of which is optionally substituted.

[0604] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), any substituent on B is independently selected at each occurrence from:

[0605] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )C(S)N(R 17 )2、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN;

[0606] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 alkynyl, each of which is optionally substituted with one or more substituents independently selected from:

[0607] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )C(S)N(R 17 )2、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN;

[0608] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )C(S)N(R 17 )2、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN; and

[0609] C 3-10 carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0610] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )C(S)N(R 17 )2、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN;

[0611] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )C(S)N(R 17 )2、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN; and

[0612] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-NO2、=O、=S、=NR 17 , -N3 and -CN substituents.

[0613] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), any substituent on B is independently selected at each occurrence from:

[0614] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )C(S)N(R 17 )2、-N(R 17 )S(O)2(R 17 ), -S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2 and -CN;

[0615] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from:

[0616] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )S(O)2(R 17 )、-S(O)2N(R 17 )2, =O, -CN; and

[0617] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 17 、-SR 17、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-C(O)N(R 17 )2、-N(R 17 )S(O)2(R 17 )、-S(O)2R 17 , =O, =S and -CN; and

[0618] C 3-10 carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0619] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-C(O)N(R 17 )2、-(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 , =O, =S, -CN; and

[0620] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 17 、-SR 17 、-N(R 17 )2, =O, =S and -CN.

[0621] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), any substituent on B is independently selected at each occurrence from:

[0622] Halogen, -OR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )S(O)2(R 17 )、-S(O)2R 17 and -CN;

[0623] C 1-6 Alkyl, which is optionally substituted by one or more substituents independently selected from the group consisting of halogen and a 3- to 10-membered heterocyclic ring, which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl and C1-6 Substitution of the haloalkyl group by a substituent; and

[0624] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl.

[0625] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), any substituent on B is independently selected at each occurrence from:

[0626] Halogen, -N(R 17 )2、-N(R 17 )S(O)2(R 17 ) and -CN;

[0627] C 1-6 Alkyl, which is optionally substituted with one or more substituents independently selected from halogen and 3 to 10 membered heterocyclic rings, which are optionally substituted with one or more substituents independently selected from halogen and C 1-6 Substitution of the alkyl group by a substituent; and

[0628] 3 to 10 membered heterocyclic ring, which is optionally substituted by one or more independently selected from C 1-6 Alkyl and C 1-6 The substituents of the haloalkyl group are substituted.

[0629] In some embodiments, for compounds or salts of Formula (I), (Ia), (II) or (III), B is substituted with 1, 2, 3, 4 or 5 substituents. In some embodiments, B is substituted with 1, 2, 3 or 4 substituents. In some embodiments, B is substituted with 1, 2 or 3 substituents. In some embodiments, B is substituted with 2 or 3 substituents. In some embodiments, B is substituted with 1 or 2 substituents. In some embodiments, B is substituted with 1 substituent. In some embodiments, B is substituted with 2 substituents. In some embodiments, B is substituted with 3 substituents. In some embodiments, B is substituted with 4 substituents. In some embodiments, B is substituted with 5 substituents.

[0630] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), B is selected from the group consisting of: phenyl, naphthyl, C 3-10 Cycloalkyl, 5- to 6-membered monocyclic heterocycle, and 7- to 10-membered bicyclic heterocycle, any of which is optionally substituted with one or more substituents independently selected from:

[0631] Halogen, -OR 17 、-SR17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 )、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S and -CN;

[0632] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 alkynyl, each of which is optionally substituted with one or more substituents independently selected from:

[0633] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 )、-S(O)2R 17 、-S(O)2N(R 17 )2, =O and -CN;

[0634] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 )、-S(O)2R17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 and -CN; and

[0635] C 3-10 carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0636] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 )、-S(O)2R 17 、-S(O)2N(R 17 )2, =O, =S and -CN;

[0637] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 )、-S(O)2N(R 17 )2, =O and -CN; and

[0638] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 17 、-N(R 17 )2, substituted by =O and -CN substituents.

[0639] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), B is selected from the group consisting of: phenyl, naphthyl, C 3-10 Cycloalkyl, 5- to 6-membered monocyclic heterocycle, and 7- to 10-membered bicyclic heterocycle, any of which is optionally substituted with one or more substituents independently selected from:

[0640] Halogen, -OR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 )、-S(O)2R 17 、-S(O)2N(R 17 )2, =O and -CN;

[0641] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 alkynyl, each of which is optionally substituted with one or more substituents independently selected from:

[0642] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 , =O and -CN;

[0643] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 17 、-N(R 17 )2、-C(O)R 17 =O and -CN; and

[0644] C 3-10 carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0645] Halogen, -OR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)N(R 17 )2、-N(R17 )C(O)R 17 , =O and -CN;

[0646] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 , =O and -CN; and

[0647] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, C 1-6 The substituents are substituted with haloalkyl and -CN.

[0648] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), B is selected from the group consisting of: phenyl, naphthyl, C 3-10 Cycloalkyl, 5- to 6-membered monocyclic heterocycle, and 7- to 10-membered bicyclic heterocycle, any of which is optionally substituted with one or more substituents independently selected from:

[0649] Halogen, -OR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )S(O)2(R 17 )、-S(O)2R 17 and -CN;

[0650] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -SR 17 、C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl and C 1-6 haloalkyl; and

[0651] C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from: =O; -CN; C 1-6 Alkyl, which is optionally substituted by one or more independently selected from halogen and -OR17 substituted with a substituent; and C 3-10 Carbon ring.

[0652] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), B is selected from the group consisting of: phenyl, naphthyl, C 3-10 Cycloalkyl, 5- to 6-membered monocyclic heterocycle and 7- to 10-membered bicyclic heterocycle, any of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, OC 1-6 Alkyl, -OC 1-6 Haloalkyl, =O, -CN, acetyl, difluoroacetyl,

[0653] In some embodiments, for compounds or salts of Formula (I), (la), (II), or (III), B is selected from the group consisting of phenyl, naphthyl, cyclopropyl, cyclohexyl, bicyclo[2.2.2]octane, adamantane, thiazole, pyrazole, pyridine, indole, indazole, benzimidazole, indoline, 1,3-dihydrobenzo[c]isothiazole, tetrahydropyran, azetidine, pyrrolidine, piperidine, quinuclidine, azepane, and 8-azabicyclo[3.2.1]octane, any of which is optionally substituted with one or more substituents independently selected from:

[0654] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 )、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S and -CN;

[0655] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 alkynyl, each of which is optionally substituted with one or more substituents independently selected from:

[0656] Halogen, -OR 17 、-SR 17 、-N(R 17)2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 )、-S(O)2R 17 、-S(O)2N(R 17 )2, =O and -CN;

[0657] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 )、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 and -CN; and

[0658] C 3-10 carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0659] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 )、-S(O)2R 17 、-S(O)2N(R 17)2, =O, =S and -CN;

[0660] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 )、-S(O)2N(R 17 )2, =O and -CN; and

[0661] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 17 、-N(R 17 )2, substituted by =O and -CN substituents.

[0662] In some embodiments, for compounds or salts of Formula (I), (la), (II), or (III), B is selected from the group consisting of phenyl, naphthyl, cyclopropyl, cyclohexyl, bicyclo[2.2.2]octane, adamantane, thiazole, pyrazole, pyridine, indole, indazole, benzimidazole, indoline, 1,3-dihydrobenzo[c]isothiazole, tetrahydropyran, azetidine, pyrrolidine, piperidine, quinuclidine, azepane, and 8-azabicyclo[3.2.1]octane, any of which is optionally substituted with one or more substituents independently selected from:

[0663] Halogen, -OR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 )、-S(O)2R 17 、-S(O)2N(R 17 )2, =O and -CN;

[0664] C 1-6 Alkyl, C 2-6Alkenyl and C 2-6 alkynyl, each of which is optionally substituted with one or more substituents independently selected from:

[0665] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 , =O and -CN;

[0666] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 17 、-N(R 17 )2、-C(O)R 17 =O and -CN; and

[0667] C 3-10 carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0668] Halogen, -OR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 , =O and -CN;

[0669] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 , =O and -CN; and

[0670] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, C 1-6 The substituents are substituted with haloalkyl and -CN.

[0671] In some embodiments, for compounds or salts of Formula (I), (la), (II), or (III), B is selected from the group consisting of phenyl, naphthyl, cyclopropyl, cyclohexyl, bicyclo[2.2.2]octane, adamantane, thiazole, pyrazole, pyridine, indole, indazole, benzimidazole, indoline, 1,3-dihydrobenzo[c]isothiazole, tetrahydropyran, azetidine, pyrrolidine, piperidine, quinuclidine, azepane, and 8-azabicyclo[3.2.1]octane, any of which is optionally substituted with one or more substituents independently selected from:

[0672] Halogen, -OR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )S(O)2(R 17 )、-S(O)2R 17 and -CN;

[0673] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -SR 17 、C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl and C 1-6 haloalkyl; and

[0674] C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from: =O; -CN; C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen and -OR 17 ; and C 3-10 Carbon ring.

[0675] In some embodiments, for compounds or salts of Formula (I), (Ia), (II) or (III), B is selected from the group consisting of phenyl, naphthyl, cyclopropyl, cyclohexyl, bicyclo[2.2.2]octane, adamantane, thiazole, pyrazole, pyridine, indole, indazole, benzimidazole, indoline, 1,3-dihydrobenzo[c]isothiazole, tetrahydropyran, azetidine, pyrrolidine, piperidine, quinuclidine, azepane and 8-azabicyclo[3.2.1]octane, any of which is optionally substituted, any of which is optionally substituted with one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, OC 1-6Alkyl, -OC 1-6 Haloalkyl, =O, -CN, acetyl, difluoroacetyl,

[0676] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), B is selected from: C 3-7 Monocyclic carbocycle and 5- to 6-membered monocyclic heterocycle, any of which is optionally substituted with one or more substituents independently selected from:

[0677] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 )、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S and -CN;

[0678] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 alkynyl, each of which is optionally substituted with one or more substituents independently selected from:

[0679] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 )、-S(O)2R 17 、-S(O)2N(R 17 )2, =O and -CN;

[0680] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C1-6 Alkyl, C 1-6 Haloalkyl, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 )、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 and -CN; and C 3-10 carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0681] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 )、-S(O)2R 17 、-S(O)2N(R 17 )2, =O, =S and -CN;

[0682] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 )、-S(O)2N(R 17)2, =O and -CN; and

[0683] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 17 、-N(R 17 )2, substituted by =O and -CN substituents.

[0684] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), B is selected from: C 3-7 Monocyclic carbocycle and 5- to 6-membered monocyclic heterocycle, any of which is optionally substituted with one or more substituents independently selected from:

[0685] Halogen, -OR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 )、-S(O)2R 17 、-S(O)2N(R 17 )2, =O and -CN;

[0686] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 alkynyl, each of which is optionally substituted with one or more substituents independently selected from:

[0687] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 , =O and -CN;

[0688] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 17 、-N(R 17 )2、-C(O)R 17 =O and -CN; and

[0689] C 3-10 carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0690] Halogen, -OR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 , =O and -CN;

[0691] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 , =O and -CN; and

[0692] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, C 1-6 The substituents are substituted with haloalkyl and -CN.

[0693] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), B is selected from: C 3-7 Monocyclic carbocycle and 5- to 6-membered monocyclic heterocycle, any of which is optionally substituted with one or more substituents independently selected from:

[0694] Halogen, -OR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )S(O)2(R 17 )、-S(O)2R 17 and -CN;

[0695] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -SR 17 、C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from the group consisting of halogen, C1-6 Alkyl and C 1-6 haloalkyl; and

[0696] C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from: =O; -CN; C 1-6 Alkyl, which is optionally substituted by one or more independently selected from halogen and -OR 17 substituted with a substituent; and C 3-10 Carbon ring.

[0697] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), B is selected from: C 3-7 Monocyclic carbocycle and 5- to 6-membered monocyclic heterocycle, any of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, OC 1-6 Alkyl, -OC 1-6 Haloalkyl, =O, -CN, acetyl, difluoroacetyl,

[0698] In some embodiments, for compounds or salts of Formula (I), (la), (II), or (III), B is selected from the group consisting of phenyl, cyclopropyl, cyclohexyl, thiazole, pyrazole, pyridine, indole, indazole, tetrahydropyran, azetidine, pyrrolidine, piperidine, and azepane, any of which is optionally substituted with one or more substituents independently selected from:

[0699] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 )、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S and -CN;

[0700] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 alkynyl, each of which is optionally substituted with one or more substituents independently selected from:

[0701] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 )、-S(O)2R 17 、-S(O)2N(R 17 )2, =O and -CN;

[0702] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 )、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 and -CN; and

[0703] C 3-10 carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0704] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R17 )S(O)2(R 17 )、-S(O)2R 17 、-S(O)2N(R 17 )2, =O, =S and -CN;

[0705] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 )、-S(O)2N(R 17 )2, =O and -CN; and

[0706] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 17 、-N(R 17 )2, substituted by =O and -CN substituents.

[0707] In some embodiments, for compounds or salts of Formula (I), (la), (II), or (III), B is selected from the group consisting of phenyl, cyclopropyl, cyclohexyl, thiazole, pyrazole, pyridine, indole, indazole, tetrahydropyran, azetidine, pyrrolidine, piperidine, and azepane, any of which is optionally substituted with one or more substituents independently selected from:

[0708] Halogen, -OR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 )、-S(O)2R 17 、-S(O)2N(R 17 )2, =O and -CN;

[0709] C 1-6 Alkyl, C2-6 Alkenyl and C 2-6 alkynyl, each of which is optionally substituted with one or more substituents independently selected from:

[0710] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 , =O and -CN;

[0711] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 17 、-N(R 17 )2、-C(O)R 17 =O and -CN; and

[0712] C 3-10 carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0713] Halogen, -OR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 , =O and -CN;

[0714] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 , =O and -CN; and

[0715] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, C 1-6 The substituents are substituted with haloalkyl and -CN.

[0716] In some embodiments, for compounds or salts of Formula (I), (la), (II), or (III), B is selected from the group consisting of phenyl, cyclopropyl, cyclohexyl, thiazole, pyrazole, pyridine, indole, indazole, tetrahydropyran, azetidine, pyrrolidine, piperidine, and azepane, any of which is optionally substituted with one or more substituents independently selected from:

[0717] Halogen, -OR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )S(O)2(R 17 )、-S(O)2R 17 and -CN;

[0718] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -SR 17 、C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl and C 1-6 haloalkyl; and

[0719] C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from: =O; -CN; C 1-6 Alkyl, which is optionally substituted by one or more independently selected from halogen and -OR 17 substituted with a substituent; and C 3-10 Carbon ring.

[0720] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), B is selected from the group consisting of phenyl, cyclopropyl, cyclohexyl, thiazole, pyrazole, pyridine, indole, indazole, tetrahydropyran, azetidine, pyrrolidine, piperidine, and azepane, any of which is optionally substituted with one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, OC 1-6 Alkyl, -OC 1-6 Haloalkyl, =O, -CN, acetyl, difluoroacetyl,

[0721] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), B is selected from: C7-10 bicyclic carbocycle and 7- to 10-membered bicyclic heterocycle, any of which is optionally substituted with one or more substituents independently selected from:

[0722] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 )、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S and -CN;

[0723] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 alkynyl, each of which is optionally substituted with one or more substituents independently selected from:

[0724] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 )、-S(O)2R 17 、-S(O)2N(R 17 )2, =O and -CN;

[0725] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 )、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 and -CN; and

[0726] C 3-10 carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0727] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 )、-S(O)2R 17 、-S(O)2N(R 17 )2, =O, =S and -CN;

[0728] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 )、-S(O)2N(R 17 )2, =O and -CN; and

[0729] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR17 、

[0730] -N(R 17 )2, substituted by =O and -CN substituents.

[0731] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), B is selected from: C 7-10 bicyclic carbocycle and 7- to 10-membered bicyclic heterocycle, any of which is optionally substituted with one or more substituents independently selected from:

[0732] Halogen, -OR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 )、-S(O)2R 17 、-S(O)2N(R 17 )2, =O and -CN;

[0733] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 alkynyl, each of which is optionally substituted with one or more substituents independently selected from:

[0734] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 , =O and -CN;

[0735] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 17 、-N(R 17 )2、-C(O)R 17 =O and -CN; and

[0736] C 3-10 carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0737] Halogen, -OR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 , =O and -CN;

[0738] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 , =O and -CN; and

[0739] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, C 1-6 The substituents are substituted with haloalkyl and -CN.

[0740] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), B is selected from: C 7-10 bicyclic carbocycle and 7- to 10-membered bicyclic heterocycle, any of which is optionally substituted with one or more substituents independently selected from:

[0741] Halogen, -OR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )S(O)2(R 17 )、-S(O)2R 17 and -CN;

[0742] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -SR 17 、C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl and C 1-6 haloalkyl; and

[0743] C 3-10Carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from: =O; -CN; C 1-6 Alkyl, which is optionally substituted by one or more independently selected from halogen and -OR 17 substituted with a substituent; and C 3-10 Carbon ring.

[0744] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), B is selected from: C 7-10 bicyclic carbocycle and 7 to 10 membered bicyclic heterocycle, any of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, OC 1-6 Alkyl, -OC 1-6 Haloalkyl, =O, -CN, acetyl, difluoroacetyl,

[0745] In some embodiments, for compounds or salts of Formula (I), (la), (II), or (III), B is selected from the group consisting of: naphthyl, bicyclo[2.2.2]octane, adamantane, indole, indazole, benzimidazole, indoline, 1,3-dihydrobenzo[c]isothiazole, quinuclidine, and 8-azabicyclo[3.2.1]octane, any of which is optionally substituted with one or more substituents independently selected from:

[0746] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 )、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S and -CN;

[0747] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 alkynyl, each of which is optionally substituted with one or more substituents independently selected from:

[0748] Halogen, -OR 17 、-SR17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 )、-S(O)2R 17 、-S(O)2N(R 17 )2, =O and -CN;

[0749] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 )、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 and -CN; and

[0750] C 3-10 carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0751] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 )、-S(O)2R17 、-S(O)2N(R 17 )2, =O, =S and -CN;

[0752] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 )、-S(O)2N(R 17 )2, =O and -CN; and

[0753] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 17 、-N(R 17 )2, substituted by =O and -CN substituents.

[0754] In some embodiments, for compounds or salts of Formula (I), (la), (II), or (III), B is selected from the group consisting of: naphthyl, bicyclo[2.2.2]octane, adamantane, indole, indazole, benzimidazole, indoline, 1,3-dihydrobenzo[c]isothiazole, quinuclidine, and 8-azabicyclo[3.2.1]octane, any of which is optionally substituted with one or more substituents independently selected from:

[0755] Halogen, -OR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 )、-S(O)2R 17 、-S(O)2N(R 17 )2, =O and -CN;

[0756] C 1-6 Alkyl, C 2-6 Alkenyl and C2-6 alkynyl, each of which is optionally substituted with one or more substituents independently selected from:

[0757] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 , =O and -CN;

[0758] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 17 、-N(R 17 )2、-C(O)R 17 =O and -CN; and

[0759] C 3-10 carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0760] Halogen, -OR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 , =O and -CN;

[0761] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 , =O and -CN; and

[0762] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, C 1-6 The substituents are substituted with haloalkyl and -CN.

[0763] In some embodiments, for compounds or salts of Formula (I), (la), (II), or (III), B is selected from the group consisting of: naphthyl, bicyclo[2.2.2]octane, adamantane, indole, indazole, benzimidazole, indoline, 1,3-dihydrobenzo[c]isothiazole, quinuclidine, and 8-azabicyclo[3.2.1]octane, any of which is optionally substituted with one or more substituents independently selected from:

[0764] Halogen, -OR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )S(O)2(R 17 )、-S(O)2R 17 and -CN;

[0765] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -SR 17 、C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl and C 1-6 haloalkyl; and

[0766] C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from: =O; -CN; C 1-6 Alkyl, which is optionally substituted by one or more independently selected from halogen and -OR 17 substituted with a substituent; and C 3-10 Carbon ring.

[0767] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), B is selected from the group consisting of: naphthyl, bicyclo[2.2.2]octane, adamantane, indole, indazole, benzimidazole, indoline, 1,3-dihydrobenzo[c]isothiazole, quinuclidine, and 8-azabicyclo[3.2.1]octane, any of which is optionally substituted with one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, OC 1-6 Alkyl, -OC 1-6 Haloalkyl, =O, -CN, acetyl, difluoroacetyl,

[0768] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), B is selected from:

[0769] where X 1 Each independently is N or C(R 8 );

[0770] R 6 、R 6 '、R 7 and R 8 Each independently selected from:

[0771] Hydrogen; halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, -N3, -CN, and

[0772] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from:

[0773] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17)C(O)N(R 17 )2、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, -N3, -CN; and

[0774] C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, -N3 and -CN; and

[0775] C 3-10 carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0776] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17)C(O)N(R 17 )2、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, -N3 and -CN;

[0777] s is 0, 1, 2, or 3; and

[0778] r is 0, 1, or 2.

[0779] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), B is selected from:

[0780] where X 1 Each independently is N or C(R 8 );

[0781] R 6 and R 6 'Each independently selected from:

[0782] Hydrogen, halogen, -OR 17 、-SR 17 、-N(R 41 )2、-C(O)R 41 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, -N3, -CN and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 haloalkyl, -NH2, -NO2, =O, CN; and

[0783] R 7 and R 8 Each independently selected from:

[0784] Hydrogen; halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, -N3, -CN, and

[0785] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from:

[0786] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, -N3, -CN; and

[0787] C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, -N3 and -CN; and

[0788] C 3-10 carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0789] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, -N3 and -CN;

[0790] s is 0, 1, 2, or 3; and

[0791] r is 0, 1, or 2.

[0792] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), B is selected from:

[0793] where X 1 Each independently is N or C(R 8 );

[0794] R 6 、R 6 '、R 7 and R 8 Each independently selected from:

[0795] Hydrogen; halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, -N3, -CN, and

[0796] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from:

[0797] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, -N3, -CN; and

[0798] C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, -N3 and -CN; and

[0799] C 3-10 carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0800] Halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, -N3 and -CN; and

[0801] r is 0, 1, or 2.

[0802] In some embodiments, for the compound or salt of Formula (I), (la), (II), or (III), s is 0, 1, 2, or 3. In some embodiments, s is 0, 1, or 2. In some embodiments, s is 1, 2, or 3. In some embodiments, s is 0 or 1. In some embodiments, s is 1 or 2. In some embodiments, s is 2 or 3. In some embodiments, s is 0. In some embodiments, s is 1. In some embodiments, s is 2. In some embodiments, s is 3.

[0803] In some embodiments, for the compound or salt of Formula (I), (la), (II), or (III), r is 0, 1, or 2. In some embodiments, r is 0 or 1. In some embodiments, r is 1 or 2. In some embodiments, r is 0. In some embodiments, r is 1. In some embodiments, r is 2.

[0804] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), R 6 and R 6 ' are each independently selected from: hydrogen; halogen, -OR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 )、-S(O)2R 17 、-S(O)2N(R 17 )2, -CN and C1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from:

[0805] Halogen, -OR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 )、-S(O)2R 17 、-S(O)2N(R 17 )2, =O and -CN;

[0806] C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 )、-S(O)2R 17 、-S(O)2N(R 17 )2, =O and -CN.

[0807] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), R 6 and R 6 ' are each independently selected from: hydrogen, halogen, -OR 17 、-N(R 17 )2 and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 17 、-N(R 17 )2、C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 17 、-N(R 17)2, =O and -CN. In some embodiments, R 6 and R 6 ' are each independently selected from: hydrogen, halogen and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, C 3-10 carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from halogen, =0, and -CN. In some embodiments, R 6 and R 6 ' are each independently selected from: halogen and C 1-6 Alkyl, the C 1-6 Alkyl is optionally substituted with one or more substituents independently selected from halogen and a 3- to 10-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen.

[0808] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), R 6 and R 6 ' are each independently selected from: hydrogen, halogen, -OR 17 、-SR 17 、-N(R 41 )2、-C(O)R 41 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, -N3, -CN and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 In some embodiments, R 6 and R 6' are each independently selected from: hydrogen, halogen, -OR 17 、-SR 17 、-N(R 41 )2、-C(O)R 41 、-C(O)OR 17 、-OC(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -CN and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 In some embodiments, R 6 and R 6 ' are each independently selected from: hydrogen, halogen, -OR 17 、-SR 17 、-N(R 41 )2、-C(O)R 41 、-C(O)OR 17 、-OC(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 , -CN and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl and =0. In some embodiments, R 6 and R 6 ' are each independently selected from: hydrogen, halogen, -OR 17 、-SR 17 、-N(R 41 )2, -CN and C 1-6 Alkyl, the C 1-6 Alkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen and =0. In some embodiments, R 6 and R 6 ' are each independently selected from: hydrogen, halogen, -OR 17 、-N(R 41)2, -CN, C 1-6 Alkyl and C 1-6 In some embodiments, R 6 and R 6 ' are each independently selected from: hydrogen, halogen, C 1-6 Alkyl and C 1-6 In some embodiments, R 6 and R 6 ' are each independently selected from: halogen, C 1-6 Alkyl and C 1-6 In some embodiments, R 6 and R 6 ' are each independently selected from halogen. In some embodiments, R 6 and R 6 'Each is fluorine.

[0809] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), R 7 and R 8 Each independently selected from:

[0810] Hydrogen; halogen, -OR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 )、-S(O)2R 17 、-S(O)2N(R 17 )2 and -CN;

[0811] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from:

[0812] Halogen, -OR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 )、-S(O)2R17 、-S(O)2N(R 17 )2, =O and -CN;

[0813] C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 )、-S(O)2R 17 、-S(O)2N(R 17 )2, =O and -CN; and

[0814] C 3-10 carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0815] Halogen, -OR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, =O and -CN.

[0816] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), R 7 and R 8 Each independently selected from:

[0817] Hydrogen; halogen, -OR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 )、-S(O)2R 17 、-S(O)2N(R 17 )2 and -CN;

[0818] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from:

[0819] Halogen, -OR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 )、-S(O)2R 17 、-S(O)2N(R 17 )2, =O and -CN;

[0820] C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 17 、-SR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 )、-S(O)2R 17 、-S(O)2N(R 17 )2, =O and -CN; and

[0821] C 3-10 carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0822] Halogen, -OR 17 、-N(R17 )2、-C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )S(O)2(R 17 ),-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, =O and -CN.

[0823] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), R 7 and R 8 Each independently selected from:

[0824] Halogen, -OR 17 、-N(R 17 )2、-C(O)R 17 、-C(O)N(R 17 )2、-N(R 17 )S(O)2(R 17 )、-S(O)2R 17 and -CN;

[0825] C 1-6 Alkyl, which is optionally substituted by one or more substituents independently selected from the group consisting of halogen and a 3- to 10-membered heterocyclic ring, which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl and C 1-6 Substitution of the haloalkyl group by a substituent; and

[0826] C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl.

[0827] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), R 7 and R 8 Each independently selected from:

[0828] Halogen, -N(R 17 )2、-N(R 17 )S(O)2(R 17 ) and -CN;

[0829] C 1-6 Alkyl, which is optionally substituted with one or more substituents independently selected from halogen and 3 to 10 membered heterocyclic rings, which are optionally substituted with one or more substituents independently selected from halogen and C 1-6 Substitution of the alkyl group by a substituent; and

[0830] 3 to 10 membered heterocyclic ring, which is optionally substituted by one or more independently selected from C 1-6 Alkyl and C 1-6 The substituents of the haloalkyl group are substituted.

[0831] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), B is selected from:

[0832]

[0833]

[0834]

[0835] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), B is selected from:

[0836]

[0837]

[0838] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), B is selected from:

[0839]

[0840]

[0841] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), B is selected from:

[0842] In some embodiments, for compounds or salts of Formula (I), (Ia), (II) or (III), B is selected from the group consisting of: halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, OC 1-6 Alkyl, -OC 1-6 Haloalkyl, =O, -CN, acetyl, difluoroacetyl,

[0843] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), C is selected from C 5-10 Carbocyclic and 5- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0844] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 、-N(R 18 )C(O)OR 18 、-N(R 18 )C(O)N(R 18 )2、-N(R 18 )C(S)N(R 18 )2、-N(R 18 )S(O)2(R 18 ),-S(O)R 18 、-S(O)2R 18 、-S(O)2N(R 18 )2, -NO2, =O, =S, =NR 18 , -N3 and -CN;

[0845] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 alkynyl, each of which is optionally substituted with one or more substituents independently selected from:

[0846] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 、-N(R 18 )C(O)OR 18 、-N(R 18 )C(O)N(R 18 )2、-N(R 18 )C(S)N(R 18 )2、-N(R 18 )S(O)2(R 18 ),-S(O)R 18 、-S(O)2R 18 、-S(O)2N(R 18 )2, -NO2, =O, =S, =NR 18 、-N3、-CN、C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, wherein C 3-6 The carbocyclic and 3- to 6-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from the group consisting of halogen, C 1-4 Alkyl and C 1-4 haloalkyl; and

[0847] C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-NO2、=O、=S、=NR 18 , -N3 and -CN substituents.

[0848] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), C is C 5-10 A carbocyclic ring optionally substituted with one or more substituents independently selected from:

[0849] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18)2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 、-N(R 18 )C(O)OR 18 、-N(R 18 )C(O)N(R 18 )2、-N(R 18 )C(S)N(R 18 )2、-N(R 18 )S(O)2(R 18 ),-S(O)R 18 、-S(O)2R 18 、-S(O)2N(R 18 )2, -NO2, =O, =S, =NR 18 , -N3 and -CN;

[0850] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 alkynyl, each of which is optionally substituted with one or more substituents independently selected from:

[0851] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 、-N(R 18 )C(O)OR 18 、-N(R 18 )C(O)N(R 18 )2、-N(R 18 )C(S)N(R 18 )2、-N(R 18 )S(O)2(R 18 ),-S(O)R 18 、-S(O)2R 18 、-S(O)2N(R 18 )2, -NO2, =O, =S, =NR 18 、-N3、-CN、C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, wherein C 3-6 The carbocyclic and 3- to 6-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from the group consisting of halogen, C1-4 Alkyl and C 1-4 haloalkyl; and

[0852] C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-NO2、=O、=S、=NR 18 , -N3 and -CN substituents.

[0853] In some embodiments, for the compound or salt of Formula (I), (Ia), (II), or (III), C is a 5- to 10-membered heterocyclic ring, each of which is optionally substituted with one or more substituents independently selected from:

[0854] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 、-N(R 18 )C(O)OR 18 、-N(R 18 )C(O)N(R 18 )2、-N(R 18 )C(S)N(R 18 )2、-N(R 18 )S(O)2(R 18 ),-S(O)R 18 、-S(O)2R 18 、-S(O)2N(R 18 )2, -NO2, =O, =S, =NR 18 , -N3 and -CN;

[0855] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 alkynyl, each of which is optionally substituted with one or more substituents independently selected from:

[0856] Halogen, -OR 18、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 、-N(R 18 )C(O)OR 18 、-N(R 18 )C(O)N(R 18 )2、-N(R 18 )C(S)N(R 18 )2、-N(R 18 )S(O)2(R 18 ),-S(O)R 18 、-S(O)2R 18 、-S(O)2N(R 18 )2, -NO2, =O, =S, =NR 18 、-N3、-CN、C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, wherein C 3-6 The carbocyclic and 3- to 6-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from the group consisting of halogen, C 1-4 Alkyl and C 1-4 haloalkyl; and

[0857] C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 18 、-SR 18 、-N(R 18 )2.

[0858] -C(O)R 18 、-NO2、=O、=S、=NR 18 , -N3 and -CN substituents.

[0859] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), C is selected from C 5-10 Carbocyclic and 5- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0860] Halogen, -OR 18 、-SR 18 、-N(R18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 、-N(R 18 )S(O)2(R 18 ),-S(O)R 18 、-S(O)2R 18 、-S(O)2N(R 18 )2, -NO2, =O and -CN;

[0861] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 alkynyl, each of which is optionally substituted with one or more substituents independently selected from:

[0862] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 、-N(R 18 )S(O)2(R 18 ),-S(O)R 18 、-S(O)2R 18 、-S(O)2N(R 18 )2、-NO2、=O、-CN、C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, wherein C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings are optionally selected from one or more independently selected from:

[0863] Halogen, C 1-4 Alkyl and C 1-4 The substituent of haloalkyl is substituted; and C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 18 、-N(R 18 )2、-C(O)R 18 , -NO2, =O and -CN substituents.

[0864] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), C is selected from C 5-10 Carbocyclic and 5- to 10-membered heterocyclic rings

[0865] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-C(O)N(R 18 )2、-S(O)R 18 、-S(O)2R 18 , -NO2, =O, =S and -CN;

[0866] C 1-6 Alkyl and C 2-6 alkenyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 、-N(R 18 )C(O)OR 18 、-N(R 18 )C(O)N(R 18 )2、-N(R 18 )C(S)N(R 18 )2、-N(R 18 )S(O)2(R 18 )、-S(O)2N(R 18 )2, -NO2, =O, =S, -CN and 3 to 6 membered heterocyclic rings, said 3 to 6 membered heterocyclic rings being optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-4 Alkyl and C 1-4 haloalkyl; and

[0867] C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl and C 1-6 The substituents of the haloalkyl group are substituted.

[0868] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), C is selected from C 5-10 Carbocyclic and 5- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0869] Halogen, -OR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 、-N(R 18 )S(O)2(R 18 )、-S(O)2N(R 18 )2, =O and -CN;

[0870] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 alkynyl, each of which is optionally substituted with one or more substituents independently selected from:

[0871] Halogen, -OR 18 、-N(R 18 )2、-C(O)OR 18 、-OC(O)R 18 、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 、-N(R 18 )S(O)2(R 18 )、-S(O)2N(R 18 )2、=O、-CN、C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, wherein C 3-6 The carbocyclic and 3- to 6-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from the group consisting of halogen, C 1-4 Alkyl and C 1-4 haloalkyl; and

[0872] C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 18 、-N(R 18 )2、-C(O)R 18 , =O and -CN substituents.

[0873] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), C is selected from C 5-10 Carbocyclic and 5- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from:

[0874] Halogen, -OR 18 、-N(R 18 )2, =O and -CN;

[0875] C 1-6 Alkyl and C 2-6 alkenyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR 18 、-N(R 18 )2, =O, -CN and 3 to 6 membered heterocyclic rings, said 3 to 6 membered heterocyclic rings being optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-4 Alkyl and C 1-4 haloalkyl; and

[0876] C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl and C 1-6 The substituents of the haloalkyl group are substituted.

[0877] In some embodiments, for the compound or salt of Formula (I), (Ia), (II), or (III), C is selected from a 5- to 10-membered heterocycle, optionally substituted with one or more substituents independently selected from:

[0878] -OR 18 、-N(R 18 )2 and =0;

[0879] C 1-6 Alkyl and C 2-6 alkenyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR 18 、-N(R 18 ) 2 and 3 to 6 membered heterocyclic rings, said 3 to 6 membered heterocyclic rings being optionally substituted with one or more substituents independently selected from halogen; and

[0880] C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl and C 1-6 The substituents of the haloalkyl group are substituted.

[0881] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), R 18 independently selected at each occurrence from hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl and C 1-6 In some embodiments, R 18 independently selected at each occurrence from hydrogen, C 1-6 Alkyl and C 1-6 In some embodiments, R 18 independently selected at each occurrence from hydrogen and C 1-6 In some embodiments, R 18 In each occurrence, independently selected from C 1-6 In some embodiments, each R 18 For hydrogen.

[0882] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), C is selected from C 5-10 Carbocyclic and 5- to 10-membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, ═O, —N(CH 3 ) 2 , C 1-6 Alkyl, C 2-6 Alkenyl, C 1-6 Haloalkyl, -OC 1-6 Alkyl, -OC 1-6 Halogenated alkyl,

[0883] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), C is selected from C 3-6 In some embodiments, C is selected from phenyl, 5-6 membered monocyclic heterocycle and 7-10 membered bicyclic heterocycle, each of which is optionally substituted. In some embodiments, C is selected from phenyl, 5-6 membered monocyclic heterocycle and 7-10 membered bicyclic heterocycle, each of which is optionally substituted. In some embodiments, C is selected from phenyl, 5-6 membered monocyclic heterocycle and 7-10 membered bicyclic heterocycle, each of which is optionally substituted. 3-6 In some embodiments, C is selected from phenyl and 5-6 membered monocyclic heterocycles, each of which is optionally substituted. In some embodiments, C is selected from phenyl and 5-6 membered monocyclic heterocycles, each of which is optionally substituted. In some embodiments, C is selected from 7-10 membered bicyclic heterocycles, each of which is optionally substituted.

[0884] In some embodiments, for compounds or salts of Formula (I), (la), (II), or (III), C is selected from phenyl, pyridine, pyridin-2-one, pyrimidinone, pyrimidinedione, pyrazine, pyridazin-3-one, isoquinoline, naphthyridine, phthalazine, naphthyridin-2-one, 5,6,7,8-tetrahydronaphthyridin-2-one, triazolo[1,5-a]pyrazine, imidazo[1,2-a]pyrazine, pyrazolo[1,5-a]pyrazine, pyrido[4,3-d]pyrimidine-2,4-dione, pyrido[3,4-d]pyrimidine-2,4-dione, quinazoline-2,4-dione, quinolin-2-one, 3,4-dihydroquinolin-2-one, isoindolin-1-one, and 1,3-dihydrobenzo[d]imidazol-2-one, each of which is optionally substituted. In some embodiments, C is selected from phenyl, pyridine, pyridin-2-one, pyrimidinedione, pyrazine, pyridazin-3-one, isoquinoline, naphthyridine, phthalazine, naphthyridin-2-one, 5,6,7,8-tetrahydronaphthyridin-2-one, triazolo[1,5-a]pyrazine, imidazo[1,2-a]pyrazine, pyrazolo[1,5-a]pyrazine, pyrido[4,3-d]pyrimidine-2,4-dione, pyrido[3,4-d]pyrimidine-2,4-dione, quinazoline-2,4-dione, quinolin-2-one, 3,4-dihydroquinolin-2-one, isoindolin-1-one, and 1,3-dihydrobenzo[d]imidazol-2-one, each of which is optionally substituted. In some embodiments, C is selected from phenyl, pyridine, pyridin-2-one, pyrimidinedione, pyrazine, and pyridazin-3-one, each of which is optionally substituted. In some embodiments, C is selected from isoquinoline, naphthyridine, phthalazine, naphthyridine-2-one, 5,6,7,8-tetrahydronaphthyridine-2-one, triazolo[1,5-a]pyrazine, imidazo[1,2-a]pyrazine, pyrazolo[1,5-a]pyrazine, pyrido[4,3-d]pyrimidine-2,4-dione, pyrido[3,4-d]pyrimidine-2,4-dione, quinazoline-2,4-dione, quinolin-2-one, 3,4-dihydroquinolin-2-one, isoindolin-1-one, and 1,3-dihydrobenzo[d]imidazol-2-one, each of which is optionally substituted.

[0885] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), the optional substituents on C are independently selected at each occurrence from:

[0886] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18)2、-N(R 18 )C(O)R 18 、-N(R 18 )C(O)OR 18 、-N(R 18 )C(O)N(R 18 )2、-N(R 18 )C(S)N(R 18 )2、-N(R 18 )S(O)2(R 18 ),-S(O)R 18 、-S(O)2R 18 、-S(O)2N(R 18 )2, -NO2, =O, =S, =NR 18 , -N3 and -CN;

[0887] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 alkynyl, each of which is optionally substituted with one or more substituents independently selected from:

[0888] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 、-N(R 18 )C(O)OR 18 、-N(R 18 )C(O)N(R 18 )2、-N(R 18 )C(S)N(R 18 )2、-N(R 18 )S(O)2(R 18 ),-S(O)R 18 、-S(O)2R 18 、-S(O)2N(R 18 )2, -NO2, =O, =S, =NR 18 、-N3、-CN、C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, wherein C 3-6 The carbocyclic and 3- to 6-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from the group consisting of halogen, C 1-4 Alkyl and C1-4 haloalkyl; and

[0889] C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-NO2、=O、=S、=NR 18 , -N3 and -CN substituents.

[0890] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), the optional substituents on C are independently selected at each occurrence from:

[0891] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-C(O)N(R 18 )2、-S(O)R 18 、-S(O)2R 18 , -NO2, =O, =S and -CN;

[0892] C 1-6 Alkyl and C 2-6 alkenyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 、-N(R 18 )C(O)OR 18 、-N(R 18 )C(O)N(R 18 )2、-N(R 18 )C(S)N(R 18 )2、-N(R 18 )S(O)2(R 18 )、-S(O)2N(R 18)2, -NO2, =O, =S, -CN and 3 to 6 membered heterocyclic rings, the 3 to 6 membered heterocyclic rings are optionally substituted by one or more independently selected from halogen, C 1-4 Alkyl and C 1-4 Substitution of the haloalkyl group by a substituent; and

[0893] C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl and C 1-6 The substituents of the haloalkyl group are substituted.

[0894] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), the optional substituents on C are independently selected at each occurrence from:

[0895] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 、-N(R 18 )S(O)2(R 18 ),-S(O)R 18 、-S(O)2R 18 、-S(O)2N(R 18 )2, -NO2, =O and -CN;

[0896] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 alkynyl, each of which is optionally substituted with one or more substituents independently selected from:

[0897] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 、-N(R 18 )S(O)2(R 18 ),-S(O)R 18 、-S(O)2R18 、-S(O)2N(R 18 )2、-NO2、=O、-CN、C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, wherein C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings are optionally selected from one or more independently selected from:

[0898] Halogen, C 1-4 Alkyl and C 1-4 The substituent of haloalkyl is substituted; and C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 18 、-N(R 18 )2、-C(O)R 18 , -NO2, =O and -CN substituents.

[0899] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), the optional substituents on C are independently selected at each occurrence from:

[0900] Halogen, -OR 18 、-N(R 18 )2, =O and -CN;

[0901] C 1-6 Alkyl and C 2-6 alkenyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR 18 、-N(R 18 )2, =O, -CN and 3 to 6 membered heterocyclic rings, said 3 to 6 membered heterocyclic rings being optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-4 Alkyl and C 1-4 haloalkyl; and

[0902] C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl and C 1-6 The substituents of the haloalkyl group are substituted.

[0903] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), the optional substituents on C are independently selected at each occurrence from:

[0904] -OR 18 、-N(R 18 )2 and =0;

[0905] C 1-6 Alkyl and C 2-6 alkenyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR 18 、-N(R 18 ) 2 and 3 to 6 membered heterocyclic rings, said 3 to 6 membered heterocyclic rings being optionally substituted with one or more substituents independently selected from halogen; and

[0906] C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl and C 1-6 The substituents of the haloalkyl group are substituted.

[0907] In some embodiments, for compounds or salts of Formula (I), (Ia), (II) or (III), the optional substituents on C are independently selected at each occurrence from the group consisting of: halogen, =O, -N(CH3)2, C 1-6 Alkyl, C 2-6 Alkenyl, C 1-6 Haloalkyl, -OC 1-6 Alkyl, -OC 1-6 Halogenated alkyl,

[0908] In some embodiments, for compounds or salts of Formula (I), (la), (II), or (III), C is selected from phenyl, pyridine, pyridin-2-one, pyrimidinedione, pyrazine, pyridazin-3-one, isoquinoline, naphthyridine, phthalazine, naphthyridin-2-one, 5,6,7,8-tetrahydronaphthyridin-2-one, triazolo[1,5-a]pyrazine, imidazo[1,2-a]pyrazine, pyrazolo[1,5-a]pyrazine, pyrido[4,3-d]pyrimidine-2,4-dione, pyrido[3,4-d]pyrimidine-2,4-dione, quinazoline-2,4-dione, quinolin-2-one, 3,4-dihydroquinolin-2-one, isoindolin-1-one, and 1,3-dihydrobenzo[d]imidazol-2-one, each of which is optionally substituted with one or more substituents independently selected from:

[0909] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18、-N(R 18 )C(O)OR 18 、-N(R 18 )C(O)N(R 18 )2、-N(R 18 )C(S)N(R 18 )2、-N(R 18 )S(O)2(R 18 ),-S(O)R 18 、-S(O)2R 18 、-S(O)2N(R 18 )2, -NO2, =O, =S, =NR 18 , -N3 and -CN;

[0910] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 alkynyl, each of which is optionally substituted with one or more substituents independently selected from:

[0911] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 、-N(R 18 )C(O)OR 18 、-N(R 18 )C(O)N(R 18 )2、-N(R 18 )C(S)N(R 18 )2、-N(R 18 )S(O)2(R 18 ),-S(O)R 18 、-S(O)2R 18 、-S(O)2N(R 18 )2, -NO2, =O, =S, =NR 18 、-N3、-CN、C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings,

[0912] Among them C 3-6 The carbocyclic and 3- to 6-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from the group consisting of halogen, C 1-4 Alkyl and C 1-4 haloalkyl; and

[0913] C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 18 、-SR 18 、-N(R 18 )2.

[0914] -C(O)R 18 、-NO2、=O、=S、=NR 18 , -N3 and -CN substituents.

[0915] In some embodiments, for compounds or salts of Formula (I), (la), (II), or (III), C is selected from phenyl, pyridine, pyridin-2-one, pyrimidinedione, pyrazine, pyridazin-3-one, isoquinoline, naphthyridine, phthalazine, naphthyridin-2-one, 5,6,7,8-tetrahydronaphthyridin-2-one, triazolo[1,5-a]pyrazine, imidazo[1,2-a]pyrazine, pyrazolo[1,5-a]pyrazine, pyrido[4,3-d]pyrimidine-2,4-dione, pyrido[3,4-d]pyrimidine-2,4-dione, quinazoline-2,4-dione, quinolin-2-one, 3,4-dihydroquinolin-2-one, isoindolin-1-one, and 1,3-dihydrobenzo[d]imidazol-2-one, each of which is optionally substituted with one or more substituents independently selected from:

[0916] Halogen, -OR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 、-N(R 18 )S(O)2(R 18 )、-S(O)2N(R 18 )2, =O and -CN;

[0917] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 alkynyl, each of which is optionally substituted with one or more substituents independently selected from:

[0918] Halogen, -OR 18 、-N(R 18 )2、-C(O)OR 18 、-OC(O)R18 、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 、-N(R 18 )S(O)2(R 18 )、-S(O)2N(R 18 )2、=O、-CN、C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, wherein C 3-6 The carbocyclic and 3- to 6-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from the group consisting of halogen, C 1-4 Alkyl and C 1-4 haloalkyl; and

[0919] C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 18 、-N(R 18 )2.

[0920] -C(O)R 18 , =O and -CN substituents.

[0921] In some embodiments, for compounds or salts of Formula (I), (la), (II), or (III), C is selected from phenyl, pyridine, pyridin-2-one, pyrimidinedione, pyrazine, pyridazin-3-one, isoquinoline, naphthyridine, phthalazine, naphthyridin-2-one, 5,6,7,8-tetrahydronaphthyridin-2-one, triazolo[1,5-a]pyrazine, imidazo[1,2-a]pyrazine, pyrazolo[1,5-a]pyrazine, pyrido[4,3-d]pyrimidine-2,4-dione, pyrido[3,4-d]pyrimidine-2,4-dione, quinazoline-2,4-dione, quinolin-2-one, 3,4-dihydroquinolin-2-one, isoindolin-1-one, and 1,3-dihydrobenzo[d]imidazol-2-one, each of which is optionally substituted with one or more substituents independently selected from:

[0922] -OR 18 、-N(R 18 )2 and =0;

[0923] C 1-6 Alkyl and C 2-6 alkenyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR 18 、-N(R 18 ) 2 and 3 to 6 membered heterocyclic rings, said 3 to 6 membered heterocyclic rings being optionally substituted with one or more substituents independently selected from halogen; and

[0924] C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl and C 1-6 The substituents of the haloalkyl group are substituted.

[0925] In some embodiments, for compounds or salts of Formula (I), (Ia), (II) or (III), C is selected from phenyl, pyridine, pyridin-2-one, pyrimidinedione, pyrazine, pyridazin-3-one, isoquinoline, naphthyridine, phthalazine, naphthyridine-2-one, 5,6,7,8-tetrahydronaphthyridin-2-one, triazolo[1,5-a]pyrazine, imidazo[1,2-a]pyrazine, pyrazolo[1,5-a]pyrazine , pyrido[4,3-d]pyrimidine-2,4-dione, pyrido[3,4-d]pyrimidine-2,4-dione, quinazoline-2,4-dione, quinolin-2-one, 3,4-dihydroquinolin-2-one, isoindolin-1-one and 1,3-dihydrobenzo[d]imidazol-2-one, each of which is optionally substituted with one or more substituents independently selected from the group consisting of halogen, =O, -N(CH3)2, C 1-6 Alkyl, C 2-6 Alkenyl, C 1-6 Haloalkyl, -OC 1-6 Alkyl, -OC 1-6 Halogenated alkyl,

[0926] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), C is selected from C 3-6 Monocyclic carbocycle and 5-6 membered monocyclic heterocycle, each of which is optionally substituted with one or more substituents independently selected from:

[0927] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 、-N(R 18 )C(O)OR 18 、-N(R 18 )C(O)N(R 18 )2、-N(R 18 )C(S)N(R 18)2、-N(R 18 )S(O)2(R 18 ),-S(O)R 18 、-S(O)2R 18 、-S(O)2N(R 18 )2, -NO2, =O, =S, =NR 18 , -N3 and -CN;

[0928] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 alkynyl, each of which is optionally substituted with one or more substituents independently selected from:

[0929] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 、-N(R 18 )C(O)OR 18 、-N(R 18 )C(O)N(R 18 )2、-N(R 18 )C(S)N(R 18 )2、-N(R 18 )S(O)2(R 18 ),-S(O)R 18 、-S(O)2R 18 、-S(O)2N(R 18 )2, -NO2, =O, =S, =NR 18 、-N3、-CN、C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings,

[0930] Among them C 3-6 The carbocyclic and 3- to 6-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from the group consisting of halogen, C 1-4 Alkyl and C 1-4 haloalkyl; and

[0931] C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 18、-SR 18 、-N(R 18 )2、-C(O)R 18 、-NO2、=O、=S、=NR 18 , -N3 and -CN substituents.

[0932] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), C is selected from C 3-6 Monocyclic carbocycle and 5-6 membered monocyclic heterocycle, each of which is optionally substituted with one or more substituents independently selected from:

[0933] Halogen, -OR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 、-N(R 18 )S(O)2(R 18 )、-S(O)2N(R 18 )2, =O and -CN;

[0934] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 alkynyl, each of which is optionally substituted with one or more substituents independently selected from:

[0935] Halogen, -OR 18 、-N(R 18 )2、-C(O)OR 18 、-OC(O)R 18 、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 、-N(R 18 )S(O)2(R 18 )、-S(O)2N(R 18 )2、=O、-CN、C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, wherein C 3-6 The carbocyclic and 3- to 6-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from the group consisting of halogen, C 1-4 Alkyl and C 1-4 haloalkyl; and

[0936] C 3-6Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 18 、-N(R 18 )2、-C(O)R 18 , =O and -CN substituents.

[0937] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), C is selected from C 3-6 Monocyclic carbocycle and 5-6 membered monocyclic heterocycle, each of which is optionally substituted with one or more substituents independently selected from:

[0938] -OR 18 、-N(R 18 )2 and =0;

[0939] C 1-6 Alkyl and C 2-6 alkenyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR 18 、-N(R 18 ) 2 and 3 to 6 membered heterocyclic rings, said 3 to 6 membered heterocyclic rings being optionally substituted with one or more substituents independently selected from halogen; and

[0940] C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl and C 1-6 The substituents of the haloalkyl group are substituted.

[0941] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), C is selected from C 3-6 Monocyclic carbocyclic ring and 5-6 membered monocyclic heterocyclic ring, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, =O, -N(CH3)2, C 1-6 Alkyl, C 2-6 Alkenyl, C 1-6 Haloalkyl, -OC 1-6 Alkyl, -OC 1-6 Halogenated alkyl,

[0942] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), C is selected from phenyl, pyridine, pyridin-2-one, pyrimidinedione, pyrazine, and pyridazin-3-one, each of which is optionally substituted with one or more substituents independently selected from:

[0943] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 、-N(R 18 )C(O)OR 18 、-N(R 18 )C(O)N(R 18 )2、-N(R 18 )C(S)N(R 18 )2、-N(R 18 )S(O)2(R 18 ),-S(O)R 18 、-S(O)2R 18 、-S(O)2N(R 18 )2, -NO2, =O, =S, =NR 18 , -N3 and -CN;

[0944] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 alkynyl, each of which is optionally substituted with one or more substituents independently selected from:

[0945] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 、-N(R 18 )C(O)OR 18 、-N(R 18 )C(O)N(R 18 )2、-N(R 18 )C(S)N(R 18 )2、-N(R 18 )S(O)2(R 18 ),-S(O)R 18 、-S(O)2R18 、-S(O)2N(R 18 )2, -NO2, =O, =S, =NR 18 、-N3、-CN、C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings,

[0946] Among them C 3-6 The carbocyclic and 3- to 6-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from the group consisting of halogen, C 1-4 Alkyl and C 1-4 haloalkyl; and

[0947] C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-NO2、=O、=S、=NR 18 , -N3 and -CN substituents.

[0948] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), C is selected from phenyl, pyridine, pyridin-2-one, pyrimidinedione, pyrazine, and pyridazin-3-one, each of which is optionally substituted with one or more substituents independently selected from:

[0949] Halogen, -OR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 、-N(R 18 )S(O)2(R 18 )、-S(O)2N(R 18 )2, =O and -CN;

[0950] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 alkynyl, each of which is optionally substituted with one or more substituents independently selected from:

[0951] Halogen, -OR 18 、-N(R 18 )2、-C(O)OR18 、-OC(O)R 18 、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 、-N(R 18 )S(O)2(R 18 )、-S(O)2N(R 18 )2、=O、-CN、C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings,

[0952] Among them C 3-6 The carbocyclic and 3- to 6-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from the group consisting of halogen, C 1-4 Alkyl and C 1-4 haloalkyl; and

[0953] C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 18 、-N(R 18 )2、-C(O)R 18 , =O and -CN substituents.

[0954] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), C is selected from phenyl, pyridine, pyridin-2-one, pyrimidinedione, pyrazine, and pyridazin-3-one, each of which is optionally substituted with one or more substituents independently selected from:

[0955] -OR 18 、-N(R 18 )2 and =0;

[0956] C 1-6 Alkyl and C 2-6 alkenyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR 18 、-N(R 18 ) 2 and 3 to 6 membered heterocyclic rings, said 3 to 6 membered heterocyclic rings being optionally substituted with one or more substituents independently selected from halogen; and

[0957] C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl and C 1-6 The substituents of the haloalkyl group are substituted.

[0958] In some embodiments, for compounds or salts of Formula (I), (Ia), (II) or (III), C is selected from phenyl, pyridine, pyridin-2-one, pyrimidinedione, pyrazine and pyridazin-3-one, each of which is optionally substituted with one or more substituents independently selected from halogen, =O, -N(CH3)2, C 1-6 Alkyl, C 2-6 Alkenyl, C 1-6 Haloalkyl, -OC 1-6 Alkyl, -OC 1-6 Halogenated alkyl,

[0959] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), C is selected from a 7-10 membered bicyclic heterocycle, each of which is optionally substituted with one or more substituents independently selected from:

[0960] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 、-N(R 18 )C(O)OR 18 、-N(R 18 )C(O)N(R 18 )2、-N(R 18 )C(S)N(R 18 )2、-N(R 18 )S(O)2(R 18 ),-S(O)R 18 、-S(O)2R 18 、-S(O)2N(R 18 )2, -NO2, =O, =S, =NR 18 , -N3 and -CN;

[0961] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 alkynyl, each of which is optionally substituted with one or more substituents independently selected from:

[0962] Halogen, -OR 18 、-SR 18 、-N(R18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 、-N(R 18 )C(O)OR 18 、-N(R 18 )C(O)N(R 18 )2、-N(R 18 )C(S)N(R 18 )2、-N(R 18 )S(O)2(R 18 ),-S(O)R 18 、-S(O)2R 18 、-S(O)2N(R 18 )2, -NO2, =O, =S, =NR 18 、-N3、-CN、C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings,

[0963] Among them C 3-6 The carbocyclic and 3- to 6-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from the group consisting of halogen, C 1-4 Alkyl and C 1-4 haloalkyl; and

[0964] C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-NO2、=O、=S、=NR 18 , -N3 and -CN substituents.

[0965] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), C is selected from a 7-10 membered bicyclic heterocycle, each of which is optionally substituted with one or more substituents independently selected from:

[0966] Halogen, -OR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18、-OC(O)R 18 、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 、-N(R 18 )S(O)2(R 18 )、-S(O)2N(R 18 )2, =O and -CN;

[0967] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 alkynyl, each of which is optionally substituted with one or more substituents independently selected from:

[0968] Halogen, -OR 18 、-N(R 18 )2、-C(O)OR 18 、-OC(O)R 18 、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 、-N(R 18 )S(O)2(R 18 )、-S(O)2N(R 18 )2、=O、-CN、C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings,

[0969] Among them C 3-6 The carbocyclic and 3- to 6-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from the group consisting of halogen, C 1-4 Alkyl and C 1-4 haloalkyl; and

[0970] C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 18 、-N(R 18 )2、-C(O)R 18 , =O and -CN substituents.

[0971] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), C is selected from a 7-10 membered bicyclic heterocycle, each of which is optionally substituted with one or more substituents independently selected from:

[0972] -OR 18 、-N(R 18 )2 and =0;

[0973] C 1-6 Alkyl and C 2-6 alkenyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR 18 、-N(R 18 ) 2 and 3 to 6 membered heterocyclic rings, said 3 to 6 membered heterocyclic rings being optionally substituted with one or more substituents independently selected from halogen; and

[0974] C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl and C 1-6 The substituents of the haloalkyl group are substituted.

[0975] In some embodiments, for compounds or salts of Formula (I), (Ia), (II) or (III), C is selected from a 7-10 membered bicyclic heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, =O, -N(CH3)2, C 1-6 Alkyl, C 2-6 Alkenyl, C 1-6 Haloalkyl, -OC 1-6 Alkyl, -OC 1-6 Halogenated alkyl,

[0976] In some embodiments, for compounds or salts of Formula (I), (la), (II), or (III), C is selected from isoquinoline, naphthyridine, phthalazine, naphthyridin-2-one, 5,6,7,8-tetrahydronaphthyridin-2-one, triazolo[1,5-a]pyrazine, imidazo[1,2-a]pyrazine, pyrazolo[1,5-a]pyrazine, pyrido[4,3-d]pyrimidine-2,4-dione, pyrido[3,4-d]pyrimidine-2,4-dione, quinazoline-2,4-dione, quinolin-2-one, 3,4-dihydroquinolin-2-one, isoindolin-1-one, and 1,3-dihydrobenzo[d]imidazol-2-one, each of which is optionally substituted with one or more substituents independently selected from:

[0977] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18、-N(R 18 )C(O)OR 18 、-N(R 18 )C(O)N(R 18 )2、-N(R 18 )C(S)N(R 18 )2、-N(R 18 )S(O)2(R 18 ),-S(O)R 18 、-S(O)2R 18 、-S(O)2N(R 18 )2, -NO2, =O, =S, =NR 18 , -N3 and -CN;

[0978] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 alkynyl, each of which is optionally substituted with one or more substituents independently selected from:

[0979] Halogen, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 、-N(R 18 )C(O)OR 18 、-N(R 18 )C(O)N(R 18 )2、-N(R 18 )C(S)N(R 18 )2、-N(R 18 )S(O)2(R 18 ),-S(O)R 18 、-S(O)2R 18 、-S(O)2N(R 18 )2, -NO2, =O, =S, =NR 18 、-N3、-CN、C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings,

[0980] Among them C 3-6 The carbocyclic and 3- to 6-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from the group consisting of halogen, C 1-4 Alkyl and C 1-4 haloalkyl; and

[0981] C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 18 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-NO2、=O、=S、=NR 18 , -N3 and -CN substituents.

[0982] In some embodiments, for compounds or salts of Formula (I), (la), (II), or (III), C is selected from isoquinoline, naphthyridine, phthalazine, naphthyridin-2-one, 5,6,7,8-tetrahydronaphthyridin-2-one, triazolo[1,5-a]pyrazine, imidazo[1,2-a]pyrazine, pyrazolo[1,5-a]pyrazine, pyrido[4,3-d]pyrimidine-2,4-dione, pyrido[3,4-d]pyrimidine-2,4-dione, quinazoline-2,4-dione, quinolin-2-one, 3,4-dihydroquinolin-2-one, isoindolin-1-one, and 1,3-dihydrobenzo[d]imidazol-2-one, each of which is optionally substituted with one or more substituents independently selected from:

[0983] Halogen, -OR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 、-N(R 18 )S(O)2(R 18 )、-S(O)2N(R 18 )2, =O and -CN;

[0984] C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 alkynyl, each of which is optionally substituted with one or more substituents independently selected from:

[0985] Halogen, -OR 18 、-N(R 18 )2、-C(O)OR 18 、-OC(O)R 18 、-C(O)N(R 18 )2、-N(R 18)C(O)R 18 、-N(R 18 )S(O)2(R 18 )、-S(O)2N(R 18 )2、=O、-CN、C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings,

[0986] Among them C 3-6 The carbocyclic and 3- to 6-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from the group consisting of halogen, C 1-4 Alkyl and C 1-4 haloalkyl; and

[0987] C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 18 、-N(R 18 )2、-C(O)R 18 , =O and -CN substituents.

[0988] In some embodiments, for compounds or salts of Formula (I), (la), (II), or (III), C is selected from isoquinoline, naphthyridine, phthalazine, naphthyridin-2-one, 5,6,7,8-tetrahydronaphthyridin-2-one, triazolo[1,5-a]pyrazine, imidazo[1,2-a]pyrazine, pyrazolo[1,5-a]pyrazine, pyrido[4,3-d]pyrimidine-2,4-dione, pyrido[3,4-d]pyrimidine-2,4-dione, quinazoline-2,4-dione, quinolin-2-one, 3,4-dihydroquinolin-2-one, isoindolin-1-one, and 1,3-dihydrobenzo[d]imidazol-2-one, each of which is optionally substituted with one or more substituents independently selected from:

[0989] -OR 18 、-N(R 18 )2 and =0;

[0990] C 1-6 Alkyl and C 2-6 alkenyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR 18 、-N(R 18 ) 2 and 3 to 6 membered heterocyclic rings, said 3 to 6 membered heterocyclic rings being optionally substituted with one or more substituents independently selected from halogen; and

[0991] C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl and C1-6 The substituents of the haloalkyl group are substituted.

[0992] In some embodiments, for compounds or salts of Formula (I), (Ia), (II), or (III), C is selected from isoquinoline, naphthyridin...

Claims

1. Compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein: A is selected from: X 1 , X 2 , X 3 and X 4 Each independently selected from N and C(R 2 ), where X 1 , X 2 and X 3 At least one of them is C(R 2 ); represents a single bond or a double bond; m is 0, 1, 2 or 3; n is 0, 1 or 2; p is 0, 1, 2 or 3; R 1 Each independently selected from: Halogen, -OR 11 、-SR 11 、-N(R 11 )2、-C(O)R 11 、-C(O)OR 11 、-OC(O)R 11 、-OC(O)N(R 11 )2、-C(O)N(R 11 )2、-N(R 11 )C(O)R 11 、-N(R 11 )C(O)OR 11 、-N(R 11 )C(O)N(R 11 )2、-N(R 11 )C(S)N(R 11 )2、-N(R 11 )S(O)2(R 11 )、-S(O)R 11 、-S(O)2R 11 、-S(O)2N(R 11 )2、-NO2 and -CN; C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 alkynyl, each of which is optionally substituted by one or more independently selected from halogen, -OR 11 、-SR 11 、-N(R 11 )2, substituted by =O, =S and -CN; C 3-6 carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-4 Alkyl, C 1-4 Haloalkyl, -OR 11 、-SR 11 、-N(R 11 )2, substituted by =O, =S and -CN; R2 is each independently selected from: Hydrogen, halogen, -OR 12 , -SR 12 , -N(R 12 )2, -C(O)R 12 , -C(O)OR 12 , -OC(O)R 12 , -OC(O)N(R 12 )2, -C(O)N(R 12 )2, -N(R 12 )C(O)R 12 , -N(R 12 )C(O)OR 12 , -N(R 12 )C(O)N(R 12 )2, -N(R 12 )C(S)N(R 12 )2, -N(R 12 )S(O)2(R 12 , -S(O)R 12 , -S(O)2R 12 , -S(O)2N(R 12 )2, -NO2, and -CN; C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 alkynyl, each of which is optionally substituted by one or more independently selected from halogen, -OR 12 、-SR 12 、-N(R 12 )2, =O, =S and -CN substituents; and C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from: halogen, C 1-4 Alkyl, C 1-4 Haloalkyl, -OR 12 、-SR 12 、-N(R 12 )2, substituted by =O, =S and -CN; R 3 is hydrogen or C 1-6 alkyl; R 4a and R 4b Each independently selected from: Hydrogen, halogen, -OR 13 、-SR 13 、-N(R 13 )2. -C(O)R 13 , -NO2, -CN and C 1-6 Alkyl, the C 1-6 Alkyl is optionally substituted by one or more independently selected from halogen, -OR 13 、-SR 13 、-N(R 13 )2. -C(O)R 13 , -NO2 and -CN substituents; R 5 is hydrogen or C 1-6 alkyl; Y is a bond, -O-, -N(R 14 )-or-C(R 14a )(R 14b )-; Z is selected from: a bond, -C(O)-, -C(R 15 )2-, -C(O)C(R 15 )2-, -C(O)[C(R 15 )2] q S-, -C(=N-CN)-, -C(O)O-, -C(O)N(R 16 )-, -C(S)-, -C(S)N(R 16 )-, -S(O)- and -S(O)2-; wherein q is selected from 1, 2 and 3; B is selected from C 3-12 Carbocyclic and 3 to 12 membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OR 17 , -SR 17 , -N(R 17 )2, -C(O)R 17 , -C(O)OR 17 , -OC(O)R 17 , -OC(O)N(R 17 )2, -C(O)N(R 17 )2, -N(R 17 )C(O)R 17 , -N(R 17 )C(O)OR 17 , -N(R 17 )C(O)N(R 17 )2, -N(R 17 )C(S)N(R 17 )2, -N(R 17 )S(O)2(R 17 , -S(O)R 17 , -S(O)2R 17 , -S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN; C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OR 17 , -SR 17 , -N(R 17 )2, -C(O)R 17 , -C(O)OR 17 , -OC(O)R 17 , -OC(O)N(R 17 )2, -C(O)N(R 17 )2, -N(R 17 )C(O)R 17 , -N(R 17 )C(O)OR 17 , -N(R 17 )C(O)N(R 17 )2, -N(R 17 )C(S)N(R 17 )2, -N(R 17 )S(O)2(R 17 , -S(O)R 17 , -S(O)2R 17 , -S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN; C 3-10 carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 17 、-SR 17 、-N(R 17 )2. -C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )C(S)N(R 17 )2、-N(R 17 )S(O)2(R 17 )、-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN; and C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OR 17 , -SR 17 , -N(R 17 )2, -C(O)R 17 , -C(O)OR 17 , -OC(O)R 17 , -OC(O)N(R 17 )2, -C(O)N(R 17 )2, -N(R 17 )C(O)R 17 , -N(R 17 )C(O)OR 17 , -N(R 17 )C(O)N(R 17 )2, -N(R 17 )C(S)N(R 17 )2, -N(R 17 )S(O)2(R 17 , -S(O)R 17 , -S(O)2R 17 , -S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN; C 1-6 Alkyl, optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 17 、-SR 17 、-N(R 17 )2. -C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )C(S)N(R 17 )2、-N(R 17 )S(O)2(R 17 )、-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN; and C 3-10 carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 17 、-SR 17 、-N(R 17 )2. -C(O)R 17 、-NO2、=O、=S、=NR 17 , -N3 and -CN substituents; C is selected from C 3-12 Carbocyclic and 3 to 12 membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OR 18 、-OR 18A 、-SR 18 、-N(R 18 )2、-C(O)R 18 、-C(O)R 18A 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 、-N(R 18 )C(O)OR 18 、-N(R 18 )C(O)N(R 18 )2、-N(R 18 )C(S)N(R 18 )2、-N(R 18 )S(O)2(R 18 )、-S(O)R 18 、-S(O)2R 18 、-S(O)2N(R 18 )2、-NO2、=O、=S、=NR 18 、-N3 and -CN; C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OR 18 , -SR 18 , -N(R 18 )2, -C(O)R 18 , -C(O)OR 18 , -OC(O)R 18 , -OC(O)N(R 18 )2, -C(O)N(R 18 )2, -N(R 18 )C(O)R 18 , -N(R 18 )C(O)OR 18 , -N(R 18 )C(O)N(R 18 )2, -N(R 18 )C(S)N(R 18 )2, -N(R 18 )S(O)2(R 18 , -S(O)R 18 , -S(O)2R 18 , -S(O)2N(R 18 )2, -NO2, =O, =S, =NR 18 , -N3 and -CN; and C 3-12 carbocyclic and 3 to 12 membered heterocyclic rings, any of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2. -C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-N(R 18A )C(O)OR 18A 、-N(R 18A )C(O)N(R 18A )2、-N(R 18A )C(S)N(R 18A )2、-N(R 18A )S(O)2(R 18A )、-S(O)R 18A 、-S(O)2R 18A 、-S(O)2N(R 18A )2, -NO2, =O, =S, =NR 18A 、-N3、-CN、C 1-10 Alkyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-10 Alkyl, C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2. -C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-N(R 18A )C(O)OR 18A 、-N(R 18A )C(O)N(R 18A )2、-N(R 18A )C(S)N(R 18A )2、-N(R 18A )S(O)2(R 18A )、-S(O)R 18A 、-S(O)2R 18A 、-S(O)2N(R 18A )2, -NO2, =O, =S, =NR 18A 、-N3、-CN、C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Carbon ring, -C 3-6 Carbon ring-(C 1-6 haloalkyl) and a 3- to 6-membered heterocyclic ring; and C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18 、-SR 18 、-N(R 18 )2. -C(O)R 18 、-NO2、=O、=S、=NR 18 , -N3, -CN; and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2. -C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-N(R 18A )C(O)OR 18A 、-N(R 18A )C(O)N(R 18A )2、-N(R 18A )C(S)N(R 18A )2、-N(R 18A )S(O)2(R 18A )、-S(O)R 18A 、-S(O)2R 18A 、-S(O)2N(R 18A )2, -NO2, =O, =S, =NR 18A 、-N3、-CN、C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, wherein C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2. -C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-N(R 18A )C(O)OR 18A , -N(R 18A )C(O)N(R 18A )2, -N(R 18A )C(S)N(R 18A )2, -N(R 18A )S(O)2(R 18A ), -S(O)R 18A ), -S(O)2R 18A ), -S(O)2N(R 18A )2, -NO2, =O, =S, =NR 18A ), -N3 and -CN; R 11 and R 12 is independently selected at each occurrence from hydrogen and C 1-6 Alkyl, where C 1-6 The alkyl group is optionally substituted by one or more independently selected from: halogen, -OH, -NH2, -OC 1-6 Alkyl, -OC 1-6 Substitution with haloalkyl, =O and CN substituents; R 14 Selected from hydrogen, C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 The carbocyclic rings are each optionally substituted by one or more independently selected from halogen, -OH, -NH2, -OC 1-6 Alkyl, -OC 1-6 Substitution with haloalkyl, =O and -CN substituents; R 13 is independently selected at each occurrence from hydrogen and C 1-6 alkyl; R 14a and R 14b Each independently selected from: Hydrogen, C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 The carbocyclic rings are each optionally substituted by one or more independently selected from halogen, -OH, -NH2, -OC 1-6 Alkyl, -OC 1-6 or R 14a and R 14b Together they form C 3-6 carbocyclic or 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, -OH, -NH2, C 1-6 Alkyl, -C 1-6 Haloalkyl, -OC 1-6 Alkyl, -OC 1-6 Substitution with haloalkyl, =O and -CN substituents; R 15 is independently selected at each occurrence from hydrogen, halogen, =O, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 carbocyclic ring and 3 to 6 membered heterocyclic ring; or two R 15 Together they form C 3-6 Carbon ring; R 16 At each occurrence selected from hydrogen and C 1-6 alkyl; R 17 Independently selected at each occurrence from: hydrogen; C 1-6 Alkyl, optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 21 、-SR 21 、-N(R 21 )2. -C(O)R 21 、-C(O)OR 21 、-OC(O)R 21 、-OC(O)N(R 21 )2、-C(O)N(R 21 )2、-N(R 21 )C(O)R 21 、-NO2、=O、=S、=NR 21 and -CN; and C 3-10 carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 21 、-SR 21 、-N(R 21 )2. -C(O)R 21 、-C(O)OR 21 、-OC(O)R 21 、-OC(O)N(R 21 )2、-C(O)N(R 21 )2、-N(R 21 )C(O)R 21 、-N(R 21 )C(O)OR 21 、-N(R 21 )C(O)N(R 21 )2、-N(R 21 )C(S)N(R 21 )2、-N(R 21 )S(O)2(R 21 )、-S(O)R 21 、-S(O)2R 21 、-S(O)2N(R 21 )2, -NO2, =O, =S, =NR 17 、-CN、C 3-6 Carbocyclic rings and 3 to 6 membered heterocyclic rings; and R 18 and R 21 are independently selected at each occurrence from hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl and C 1-6 aminoalkyl; and R 18A At each occurrence, select from: hydrogen; C 1-6 Alkyl, optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are each optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OH, C 1-6 Alkyl, C 1-6 Haloalkyl, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O and -CN; and C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, which are optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OH, C 1-6 Alkyl, C 1-6 Haloalkyl, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings.

2. The compound or salt according to claim 1, wherein B is a 3- to 12-membered heterocyclic ring, which is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 17 , -SR 17 , -N(R 17 )2, -C(O)R 17 , -C(O)OR 17 , -OC(O)R 17 , -OC(O)N(R 17 )2, -C(O)N(R 17 )2, -N(R 17 )C(O)R 17 , -N(R 17 )C(O)OR 17 , -N(R 17 )C(O)N(R 17 )2, -N(R 17 )C(S)N(R 17 )2, -N(R 17 )S(O)2(R 17 , -S(O)R 17 , -S(O)2R 17 , -S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN; C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OR 17 , -SR 17 , -N(R 17 )2, -C(O)R 17 , -C(O)OR 17 , -OC(O)R 17 , -OC(O)N(R 17 )2, -C(O)N(R 17 )2, -N(R 17 )C(O)R 17 , -N(R 17 )C(O)OR 17 , -N(R 17 )C(O)N(R 17 )2, -N(R 17 )C(S)N(R 17 )2, -N(R 17 )S(O)2(R 17 , -S(O)R 17 , -S(O)2R 17 , -S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN; C 3-10 carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 17 、-SR 17 、-N(R 17 )2. -C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 , -N(R 17 )C(O)N(R 17 )2、-N(R 17 )C(S)N(R 17 )2、-N(R 17 )S(O)2(R 17 )、-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN; and C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OR 17 , -SR 17 , -N(R 17 )2, -C(O)R 17 , -C(O)OR 17 , -OC(O)R 17 , -OC(O)N(R 17 )2, -C(O)N(R 17 )2, -N(R 17 )C(O)R 17 , -N(R 17 )C(O)OR 17 , -N(R 17 )C(O)N(R 17 )2, -N(R 17 )C(S)N(R 17 )2, -N(R 17 )S(O)2(R 17 , -S(O)R 17 , -S(O)2R 17 , -S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN; C 1-6 Alkyl, optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 17 、-SR 17 、-N(R 17 )2. -C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )C(S)N(R 17 )2、-N(R 17 )S(O)2(R 17 )、-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN; and C 3-10 carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 17 、-SR 17 、-N(R 17 )2. -C(O)R 17 、-NO2、=O、=S、=NR 17 , -N3 and -CN.

3. The compound or salt according to claim 2, wherein B is selected from a 3- to 12-membered heterocycle, which is optionally substituted with one or more substituents independently selected from the following: Halogen, -OR 17 、-SR 17 、-N(R 17 )2. -C(O)R 17 、-C(O)OR 17 , -NO2, -CN; C 1-6 Alkyl, optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 17 、-SR 17 、-N(R 17 )2. -C(O)R 17 、-C(O)OR 17 、-NO2、-CN、C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 17 、-SR 17 、-N(R 17 )2. -C(O)R 17 、-C(O)OR 17 , -NO2, -CN; and C 3-10 carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 17 、-SR 17 、-N(R 17 )2. -C(O)R 17 、-C(O)OR 17 , -NO2, -CN; and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 17 、-SR 17 、-N(R 17 )2. -C(O)R 17 、-C(O)OR 17 , -NO2 and -CN.

4. The compound or salt of claim 3, wherein B is a 6- to 12-membered bicyclic heterocycle selected from a 6- to 12-membered fused heterocycle, a 6- to 12-membered spirocyclic heterocycle, and a 6- to 12-membered bridged heterocycle, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 17 、-SR 17 、-N(R 17 )2. -C(O)R 17 、-C(O)OR 17 , -NO2, -CN; and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 17 、-SR 17 、-N(R 17 )2. -C(O)R 17 、-C(O)OR 17 , -NO2 and -CN.

5. The compound or salt according to claim 4, wherein B is a 6- to 12-membered spirocyclic heterocycle, which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 17 、-SR 17 、-N(R 17 )2. -C(O)R 17 、-C(O)OR 17 , -NO2, -CN; and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 17 、-SR 17 、-N(R 17 )2. -C(O)R 17 、-C(O)OR 17 , -NO2 and -CN.

6. The compound or salt according to claim 5, wherein B is 7. The compound or salt according to any one of claims 1 to 6, wherein C is selected from C 3-10 Carbocyclic and 3 to 10 membered heterocyclic rings, which are optionally substituted with -OR 18A or -C(O)R 18A Replace; and R 18A Selected from: hydrogen; C 1-6 Alkyl, optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are each optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OH, C 1-6 Alkyl, C 1-6 Haloalkyl, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O and -CN; and C 3-6 Carbocyclic and 3 to 6 membered heterocyclic rings, which are optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OH, C 1-6 Alkyl, C 1-6 Haloalkyl, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings.

8. The compound or salt according to claim 7, wherein C is selected from 9. The compound or salt according to any one of claims 1 to 6, wherein C is C 3-12 A carbocyclic ring optionally substituted with one or more substituents independently selected from: halogen, -OR 18 , -SR 18 , -N(R 18 )2, -C(O)R 18 , -C(O)OR 18 , -OC(O)R 18 , -OC(O)N(R 18 )2, -C(O)N(R 18 )2, -N(R 18 )C(O)R 18 , -N(R 18 )C(O)OR 18 , -N(R 18 )C(O)N(R 18 )2, -N(R 18 )C(S)N(R 18 )2, -N(R 18 )S(O)2(R 18 , -S(O)R 18 , -S(O)2R 18 , -S(O)2N(R 18 )2, -NO2, =O, =S, =NR 18 , -N3 and -CN; C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OR 18 , -SR 18 , -N(R 18 )2, -C(O)R 18 , -C(O)OR 18 , -OC(O)R 18 , -OC(O)N(R 18 )2, -C(O)N(R 18 )2, -N(R 18 )C(O)R 18 , -N(R 18 )C(O)OR 18 , -N(R 18 )C(O)N(R 18 )2, -N(R 18 )C(S)N(R 18 )2, -N(R 18 )S(O)2(R 18 , -S(O)R 18 , -S(O)2R 18 , -S(O)2N(R 18 )2, -NO2, =O, =S, =NR 18 , -N3 and -CN; and C 3-12 carbocyclic and 3 to 12 membered heterocyclic rings, any of which is optionally substituted with one or more substituents independently selected from: Halogen, -OR 18A 、-SR 18A 、-N(R 18A )2. -C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-N(R 18A )C(O)OR 18A 、-N(R 18A )C(O)N(R 18A )2、-N(R 18A )C(S)N(R 18A )2、-N(R 18A )S(O)2(R 18A )、-S(O)R 18A 、-S(O)2R 18A 、-S(O)2N(R 18A )2, -NO2, =O, =S, =NR 18A 、-N3、-CN、C 1-10 Alkyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-10 Alkyl, C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2. -C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-N(R 18A )C(O)OR 18A 、-N(R 18A )C(O)N(R 18A )2、-N(R 18A )C(S)N(R 18A )2、-N(R 18A )S(O)2(R 18A )、-S(O)R 18A 、-S(O)2R 18A 、-S(O)2N(R 18A )2, -NO2, =O, =S, =NR 18A 、-N3、-CN、C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Carbon ring, -C 3-6 Carbon ring-(C 1-6 haloalkyl) and a 3- to 6-membered heterocyclic ring; and C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from: Halogen, -OR 18 、-SR 18 、-N(R 18 )2. -C(O)R 18 、-NO2、=O、=S、=NR 18 , -N3, -CN; and C 1-6 Alkyl, optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2. -C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-N(R 18A )C(O)OR 18A 、-N(R 18A )C(O)N(R 18A )2、-N(R 18A )C(S)N(R 18A )2、-N(R 18A )S(O)2(R 18A )、-S(O)R 18A 、-S(O)2R 18A 、-S(O)2N(R 18A )2, -NO2, =O, =S, =NR 18A 、-N3、-CN、C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, wherein C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2. -C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-N(R 18A )C(O)OR 18A 、-N(R 18A )C(O)N(R 18A )2、-N(R 18A )C(S)N(R 18A )2、-N(R 18A )S(O)2(R 18A )、-S(O)R 18A 、-S(O)2R 18A 、-S(O)2N(R 18A )2, -NO2, =O, =S, =NR 18A , -N3 and -CN.

10. The compound or salt according to claim 9, wherein C is C 3-10 A carbocyclic ring optionally substituted with one or more substituents independently selected from: halogen, -OR 18 , -SR 18 , -N(R 18 )2, -C(O)R 18 , -C(O)OR 18 , -OC(O)R 18 , -OC(O)N(R 18 )2, -C(O)N(R 18 )2, -N(R 18 )C(O)R 18 , -NO2 and -CN; C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from: Halogen, -OR 18 、-SR 18 、-N(R 18 )2. -C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 , -NO2 and -CN; and C 3-12 carbocyclic and 3 to 12 membered heterocyclic rings, any of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2. -C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-NO2、-CN、C 1-6 Alkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2. -C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-NO2、-CN、C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Carbon ring, -C 3-6 Carbon ring-(C 1-6 haloalkyl) and a 3- to 6-membered heterocyclic ring; and C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from: Halogen, -OR 18 、-SR 18 、-N(R 18 )2. -C(O)R 18 , -NO2 and -CN; and C 1-6 Alkyl, optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2. -C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-NO2、-CN、C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, wherein C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2. -C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A , -NO2, -CN.

11. The compound or salt according to claim 10, wherein C is phenyl, which is optionally substituted with one or more substituents independently selected from the following: Halogen, -OR 18 、-SR 18 、-N(R 18 )2. -C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 , -NO2 and -CN; and C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from: Halogen, -OR 18 、-SR 18 、-N(R 18 )2. -C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 , -NO2 and -CN; and C 3-12 carbocyclic and 3 to 12 membered heterocyclic rings, any of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2. -C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-NO2、-CN、C 1-6 Alkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2. -C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-NO2、-CN、C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Carbon ring, -C 3-6 Carbon ring-(C 1-6 haloalkyl) and 3 to 6 membered heterocyclic rings.

12. The compound or salt according to claim 11, wherein C is phenyl, which is optionally substituted with one or more substituents independently selected from the following: Halogen, -OR 18 、-N(R 18 )2, -NO2 and -CN; and C 1-6 Alkyl, optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18 、-N(R 18 )2, -NO2, and -CN; and a 3- to 12-membered saturated heterocyclic ring, which is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 18A 、-NO2、-CN、C 1-6 Alkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-N(R 18A )2, -NO2, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Carbon ring, -C 3-6 Carbon ring-(C 1-6 haloalkyl) and 3 to 6 membered heterocyclic rings.

13. The compound or salt according to claim 12, wherein C is phenyl, which is optionally substituted with one or more substituents independently selected from the following: Halogen, -OR 18 、-N(R 18 )2, -NO2 and -CN; and C 1-6 Alkyl, optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18 、-N(R 18 )2, -NO2, and -CN; and 3 to 7 membered heterocycloalkyl, optionally substituted by one or more substituents independently selected from the following: halogen, -OR 18A 、-NO2、-CN、C 1-6 Alkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-N(R 18A )2, -NO2, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Carbon ring, -C 3-6 Carbon ring-(C 1-6 haloalkyl) and 3 to 6 membered heterocyclic rings.

14. The compound or salt according to claim 13, wherein C is phenyl, which is optionally substituted with one or more substituents independently selected from the following: Halogen, -OR 18 、-N(R 18 )2, -NO2 and -CN; and C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from: Halogen, -OR 18 、-N(R 18 )2, -NO2, -CN; and azetidinyl, piperidinyl, piperazinyl and azepanyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR 18A 、-NO2、-CN、C 1-6 Alkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-N(R 18A )2, -NO2, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Carbon ring, -C 3-6 Carbon ring-(C 1-6 haloalkyl) and a 3 to 6 membered heterocyclic ring; and R 18 and R 18A is independently selected at each occurrence from hydrogen, halogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl.

15. The compound or salt according to claim 14, wherein C is selected from:

16. The compound or salt of claim 12, wherein C is phenyl, optionally substituted with one or more substituents independently selected from: Halogen, -OR 18 、-N(R 18 )2, -NO2 and -CN; and C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from: Halogen, -OR 18 、-N(R 18 )2, -NO2 and -CN; and 8 to 12 membered spirocyclic saturated heterocyclic ring, which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-NO2、-CN、C 1-6 Alkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-N(R 18A )2, -NO2, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings.

17. The compound or salt of claim 16, wherein C is phenyl, optionally substituted with one or more substituents independently selected from: Halogen, -OR 18 、-N(R 18 )2, -NO2 and -CN; and C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from: Halogen, -OR 18 、-N(R 18 )2, -NO2 and -CN; and 6-azaspiro[2.5]octyl, 2-oxa-8-azaspiro[4.5]decyl, 3-azaspiro[5.5]undecyl and 2,9-diazaspiro[5.5]undecyl, each of which is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-NO2、-CN、C 1-6 Alkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-N(R 18A )2, -NO2, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 carbocyclic ring and 3 to 6 membered heterocyclic ring; and R 18 and R 18A is independently selected at each occurrence from hydrogen, halogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl.

18. The compound or salt according to claim 17, wherein C is selected from:

19. The compound or salt of claim 12, wherein C is phenyl, optionally substituted with one or more substituents independently selected from: Halogen, -OR 18 、-N(R 18 )2, -NO2 and -CN; and C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from: Halogen, -OR 18 、-N(R 18 )2, -NO2 and -CN; and 8 to 10 membered bridged saturated heterocyclic ring, optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-NO2、-CN、C 1-6 Alkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-N(R 18A )2, -NO2, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings.

20. The compound or salt of claim 16, wherein C is phenyl, optionally substituted with one or more substituents independently selected from: Halogen, -OR 18 、-N(R 18 )2, -NO2 and -CN; and C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from: Halogen, -OR 18 、-N(R 18 )2, -NO2 and -CN; and 8-oxa-3-azabicyclo[3.2.1]octyl, optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-NO2、-CN、C 1-6 Alkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-N(R 18A )2, -NO2, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 carbocyclic ring and 3 to 6 membered heterocyclic ring; and R 18 and R 18A is independently selected at each occurrence from hydrogen, halogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl.

21. The compound or salt according to claim 20, wherein C is selected from:

22. The compound or salt of claim 12, wherein C is phenyl, optionally substituted with one or more substituents independently selected from: Halogen, -OR 18 、-N(R 18 )2, -NO2 and -CN; and C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from: Halogen, -OR 18 、-N(R 18 )2, -NO2 and -CN; and 6 to 10 membered fused saturated heterocyclic ring, optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-NO2、-CN、C 1-6 Alkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-N(R 18A )2, -NO2, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings.

23. The compound or salt of claim 16, wherein C is phenyl, optionally substituted with one or more substituents independently selected from: Halogen, -OR 18 、-N(R 18 )2, -NO2 and -CN; and C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from: Halogen, -OR 18 、-N(R 18 )2, -NO2 and -CN; and Octahydro-1H-isoindolyl, optionally substituted with one or more substituents independently selected from halogen, -OR 18A 、-NO2、-CN、C 1-6 Alkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-N(R 18A )2, -NO2, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 carbocyclic ring and 3 to 6 membered heterocyclic ring; and R 18 and R 18A is independently selected at each occurrence from hydrogen, halogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl.

24. The compound or salt according to claim 23, wherein C is 25. The compound or salt according to claim 9, wherein C is C 6-12 A carbocyclic ring, which is optionally substituted by one or more substituents independently selected from the group consisting of: 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from: Halogen, -OR 18 、-SR 18 、-N(R 18 )2. -C(O)R 18 、-NO2、=O、=S、=NR 18 , -N3, -CN; and C 1-6 Alkyl, optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2. -C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-N(R 18A )C(O)OR 18A 、-N(R 18A )C(O)N(R 18A )2、-N(R 18A )C(S)N(R 18A )2、-N(R 18A )S(O)2(R 18A )、-S(O)R 18A 、-S(O)2R 18A 、-S(O)2N(R 18A )2, -NO2, =O, =S, =NR 18A 、-N3、-CN、C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, wherein C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2. -C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-N(R 18A )C(O)OR 18A 、-N(R 18A )C(O)N(R 18A )2、-N(R 18A )C(S)N(R 18A )2、-N(R 18A )S(O)2(R 18A )、-S(O)R 18A 、-S(O)2R 18A 、-S(O)2N(R 18A )2, -NO2, =O, =S, =NR 18A , -N3 and -CN.

26. The compound or salt according to claim 25, wherein C is C 8-12 A fused carbocyclic ring optionally substituted with one or more substituents independently selected from 5- to 6-membered heteroaryl optionally substituted with one or more substituents independently selected from: Halogen, -OR 18 、-SR 18 、-N(R 18 )2, -NO2, -CN; and C 1-6 Alkyl, which is optionally substituted by one or more independently selected from halogen, -OR 18A 、-N(R 18A )2, -NO2, -CN, C 3-6 The substituents of carbocyclic and 3- to 6-membered heterocyclic rings are substituted, wherein C 3-6 The carbocyclic ring and the 3 to 6 membered heterocyclic ring are each optionally substituted by one or more independently selected from halogen, -OR 18A 、-N(R 18A )2, -NO2, -CN; and R 18 and R 18A is independently selected at each occurrence from hydrogen, halogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl.

27. The compound or salt according to claim 26, wherein C is 28. A compound or salt according to any one of claims 1 to 6, wherein C is a 3 to 12 membered heterocyclic ring optionally substituted with one or more substituents independently selected from: halogen, -OR 18 , -SR 18 , -N(R 18 )2, -C(O)R 18 , -C(O)OR 18 , -OC(O)R 18 , -OC(O)N(R 18 )2, -C(O)N(R 18 )2, -N(R 18 )C(O)R 18 , -N(R 18 )C(O)OR 18 , -N(R 18 )C(O)N(R 18 )2, -N(R 18 )C(S)N(R 18 )2, -N(R 18 )S(O)2(R 18 , -S(O)R 18 , -S(O)2R 18 , -S(O)2N(R 18 )2, -NO2, =O, =S, =NR 18 , -N3 and -CN; C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OR 18 , -SR 18 , -N(R 18 )2, -C(O)R 18 , -C(O)OR 18 , -OC(O)R 18 , -OC(O)N(R 18 )2, -C(O)N(R 18 )2, -N(R 18 )C(O)R 18 , -N(R 18 )C(O)OR 18 , -N(R 18 )C(O)N(R 18 )2, -N(R 18 )C(S)N(R 18 )2, -N(R 18 )S(O)2(R 18 , -S(O)R 18 , -S(O)2R 18 , -S(O)2N(R 18 )2, -NO2, =O, =S, =NR 18 , -N3 and -CN; and C 3-12 carbocyclic and 3 to 12 membered heterocyclic rings, any of which is optionally substituted with one or more substituents independently selected from: Halogen, -OR 18A 、-SR 18A 、-N(R 18A )2. -C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-N(R 18A )C(O)OR 18A 、-N(R 18A )C(O)N(R 18A )2、-N(R 18A )C(S)N(R 18A )2、-N(R 18A )S(O)2(R 18A )、-S(O)R 18A 、-S(O)2R 18A 、-S(O)2N(R 18A )2, -NO2, =O, =S, =NR 18A 、-N3、-CN、C 1-10 Alkyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein C 1-10 Alkyl, C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2. -C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-N(R 18A )C(O)OR 18A 、-N(R 18A )C(O)N(R 18A )2、-N(R 18A )C(S)N(R 18A )2、-N(R 18A )S(O)2(R 18A )、-S(O)R 18A 、-S(O)2R 18A 、-S(O)2N(R 18A )2, -NO2, =O, =S, =NR 18A 、-N3、-CN、C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Carbon ring, -C 3-6 Carbon ring-(C 1-6 haloalkyl) and a 3- to 6-membered heterocyclic ring; and C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from: Halogen, -OR 18 、-SR 18 、-N(R 18 )2. -C(O)R 18 、-NO2、=O、=S、=NR 18 , -N3, -CN; and C 1-6 Alkyl, optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2. -C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-N(R 18A )C(O)OR 18A 、-N(R 18A )C(O)N(R 18A )2、-N(R 18A )C(S)N(R 18A )2、-N(R 18A )S(O)2(R 18A )、-S(O)R 18A 、-S(O)2R 18A 、-S(O)2N(R 18A )2, -NO2, =O, =S, =NR 18A 、-N3、-CN、C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, wherein C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2. -C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-N(R 18A )C(O)OR 18A 、-N(R 18A )C(O)N(R 18A )2、-N(R 18A )C(S)N(R 18A )2、-N(R 18A )S(O)2(R 18A )、-S(O)R 18A 、-S(O)2R 18A 、-S(O)2N(R 18A )2, -NO2, =O, =S, =NR 18A , -N3 and -CN.

29. The compound or salt of claim 28, wherein C is pyridyl, optionally substituted with one or more substituents independently selected from: Halogen, -OR 18 、-N(R 18 )2. -C(O)R 18 , -NO2 and -CN; C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from: Halogen, -OR 18 、-N(R 18 )2. -C(O)R 18 , -NO2 and -CN; and C 3-12 carbocyclic and 3 to 12 membered heterocyclic rings, any of which is optionally substituted with one or more substituents independently selected from: Halogen, -OR 18A 、-N(R 18A )2. -C(O)R 18A 、-NO2、-CN、C 1-6 Alkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-N(R 18A )2. -C(O)R 18A 、-NO2、-CN、C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Carbon ring, -C 3-6 Carbon ring-(C 1-6 haloalkyl) and a 3 to 6 membered heterocyclic ring; and R 18 and R 18A is independently selected at each occurrence from hydrogen, halogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl.

30. The compound or salt according to claim 29, wherein C is selected from:

31. The compound or salt of claim 28, wherein C is selected from an 8- to 12-membered bicyclic heterocycle, optionally substituted with one or more substituents independently selected from: halogen, -OR 18 , -SR 18 , -N(R 18 )2, -C(O)R 18 , -C(O)OR 18 , -OC(O)R 18 , -OC(O)N(R 18 )2, -C(O)N(R 18 )2, -N(R 18 )C(O)R 18 , =O, -NO2 and -CN; C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from: Halogen, -OR 18 、-SR 18 、-N(R 18 )2. -C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 , -NO2 and -CN; and C 3-12 carbocyclic and 3 to 12 membered heterocyclic rings, any of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2. -C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-NO2、-CN、C 1-6 Alkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2. -C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-NO2、-CN、C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Carbon ring, -C 3-6 Carbon ring-(C 1-6 haloalkyl) and a 3- to 6-membered heterocyclic ring; and C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from: Halogen, -OR 18 、-SR 18 、-N(R 18 )2. -C(O)R 18 , -NO2 and -CN; and C 1-6 Alkyl, optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2. -C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-NO2、-CN、C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, wherein C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2. -C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A , -NO2, -CN.

32. The compound or salt of claim 31, wherein C is an 8- to 12-membered bicyclic heterocycle optionally substituted with one or more substituents independently selected from: Halogen, -OR 18 、-SR 18 、-N(R 18 )2. -C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 , -NO2 and -CN; and C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from: Halogen, -OR 18 、-SR 18 、-N(R 18 )2. -C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 , =O, -NO2 and -CN; and C 3-12 carbocyclic and 3 to 12 membered heterocyclic rings, any of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2. -C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-NO2、-CN、C 1-6 Alkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2. -C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-NO2、-CN、C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Carbon ring, -C 3-6 Carbon ring-(C 1-6 haloalkyl) and 3 to 6 membered heterocyclic rings.

33. The compound or salt of claim 32, wherein C is an 8- to 12-membered bicyclic heterocycle optionally substituted with one or more substituents independently selected from: Halogen, -OR 18 、-SR 18 、-N(R 18 )2. -C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 , =O, -NO2 and -CN; and C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from: Halogen, -OR 18 、-SR 18 、-N(R 18 )2. -C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 , -NO2 and -CN; and 3 to 8 membered monocyclic heterocycloalkyl, optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2. -C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-NO2、-CN、C 1-6 Alkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2. -C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-NO2、-CN、C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Carbon ring, -C 3-6 Carbon ring-(C 1-6 haloalkyl) and 3 to 6 membered heterocyclic rings.

34. The compound or salt of claim 32, wherein C is an 8- to 12-membered bicyclic heterocycle optionally substituted with one or more substituents independently selected from: Halogen, -OR 18 、-N(R 18 )2. -C(O)R 18 , =O, -NO2 and -CN; and C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from: Halogen, -OR 18 、-N(R 18 )2. -C(O)R 18 , -NO2 and -CN; and 3 to 8 membered monocyclic heterocycloalkyl, optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-N(R 18A )2. -C(O)R 18A 、-NO2、-CN、C 1-6 Alkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings.

35. The compound or salt according to claim 34, wherein C is selected from 36. The compound or salt of claim 32, wherein C is an 8- to 12-membered bicyclic heterocycle optionally substituted with one or more substituents independently selected from: Halogen, -OR 18 、-SR 18 、-N(R 18 )2. -C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 , =O, -NO2 and -CN; and C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from: Halogen, -OR 18 、-SR 18 、-N(R 18 )2. -C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 , -NO2 and -CN; and 3 to 12 membered bicyclic heterocyclic ring, which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2. -C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-NO2、-CN、C 1-6 Alkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2. -C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-NO2、-CN、C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Carbon ring, -C 3-6 Carbon ring-(C 1-6 haloalkyl) and 3 to 6 membered heterocyclic rings.

37. The compound or salt of claim 36, wherein C is an 8- to 12-membered bicyclic heterocycle optionally substituted with one or more substituents independently selected from: Halogen, -OR 18 、-SR 18 、-N(R 18 )2. -C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 , =O, -NO2 and -CN; and C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from: Halogen, -OR 18 、-SR 18 、-N(R 18 )2. -C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 , -NO2 and -CN; and 6 to 12 membered spirocyclic heterocyclic ring, which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2. -C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-NO2、-CN、C 1-6 Alkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2. -C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-NO2、-CN、C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Carbon ring, -C 3-6 Carbon ring-(C 1-6 haloalkyl) and 3 to 6 membered heterocyclic rings.

38. The compound or salt of claim 37, wherein C is an 8- to 12-membered bicyclic heterocycle optionally substituted with one or more substituents independently selected from: Halogen, -OR 18 、-N(R 18 )2. -C(O)R 18 , =O, -NO2 and -CN; and C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from: Halogen, -OR 18 、-N(R 18 )2. -C(O)R 18 , -NO2 and -CN; and 6 to 12 membered spirocyclic heterocyclic ring, which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-N(R 18A )2. -C(O)R 18A 、-NO2、-CN、C 1-6 Alkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings.

39. The compound or salt according to claim 38, wherein C is selected from 40. The compound or salt of claim 36, wherein C is an 8- to 12-membered bicyclic heterocycle optionally substituted with one or more substituents independently selected from: Halogen, -OR 18 、-SR 18 、-N(R 18 )2. -C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 , =O, -NO2 and -CN; and C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from: Halogen, -OR 18 、-SR 18 、-N(R 18 )2. -C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 , -NO2 and -CN; and 6 to 12 membered bridged heterocyclic ring, optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2. -C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-NO2、-CN、C 1-6 Alkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, wherein C 1-6 Alkyl, C 3-6 The carbocyclic ring and the 3- to 6-membered heterocyclic ring are each optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-SR 18A 、-N(R 18A )2. -C(O)R 18A 、-C(O)OR 18A 、-OC(O)R 18A 、-OC(O)N(R 18A )2、-C(O)N(R 18A )2、-N(R 18A )C(O)R 18A 、-NO2、-CN、C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Carbon ring, -C 3-6 Carbon ring-(C 1-6 haloalkyl) and 3 to 6 membered heterocyclic rings.

41. The compound or salt of claim 39, wherein C is an 8- to 12-membered bicyclic heterocycle optionally substituted with one or more substituents independently selected from: Halogen, -OR 18 、-N(R 18 )2. -C(O)R 18 , =O, -NO2 and -CN; and C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from: Halogen, -OR 18 、-N(R 18 )2. -C(O)R 18 , -NO2 and -CN; and 6 to 12 membered bridged heterocyclic ring, optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 18A 、-N(R 18A )2. -C(O)R 18A 、-NO2、-CN、C 1-6 Alkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings.

42. The compound or salt according to claim 41, wherein C is selected from 43. The compound or salt of claim 1, wherein Formula (I) is represented by the structure of Formula (Ia): or a pharmaceutically acceptable salt thereof, wherein: A is selected from: X 1 , X 2 , X 3 and X 4 Each independently selected from N and C(R 2 ), where X 1 , X 2 and X 3 At least one of them is C(R 2 ); represents a single bond or a double bond; m is 0, 1, 2 or 3; n is 0, 1 or 2; p is 0, 1, 2 or 3; R 1 Each independently selected from: halogen, -OR 11 , -SR 11 , -N(R 11 )2, -C(O)R 11 , -C(O)OR 11 , -OC(O)R 11 , -OC(O)N(R 11 )2, -C(O)N(R 11 )2, -N(R 11 )C(O)R 11 , -N(R 11 )C(O)OR 11 , -N(R 11 )C(O)N(R 11 )2, -N(R 11 )C(S)N(R 11 )2, -N(R 11 )S(O)2(R 11 , -S(O)R 11 , -S(O)2R 11 , -S(O)2N(R 11 )2, -NO2, and -CN; C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 alkynyl, each of which is optionally substituted by one or more independently selected from halogen, -OR 11 、-SR 11 、-N(R 11 )2, substituted by =O, =S and -CN; C 3-6 carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-4 Alkyl, C 1-4 Haloalkyl, -OR 11 、-SR 11 、-N(R 11 )2, substituted by =O, =S and -CN; R2 is each independently selected from: Hydrogen, halogen, -OR 12 , -SR 12 , -N(R 12 )2, -C(O)R 12 , -C(O)OR 12 , -OC(O)R 12 , -OC(O)N(R 12 )2, -C(O)N(R 12 )2, -N(R 12 )C(O)R 12 , -N(R 12 )C(O)OR 12 , -N(R 12 )C(O)N(R 12 )2, -N(R 12 )C(S)N(R 12 )2, -N(R 12 )S(O)2(R 12 , -S(O)R 12 , -S(O)2R 12 , -S(O)2N(R 12 )2, -NO2, and -CN; C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 alkynyl, each of which is optionally substituted by one or more independently selected from halogen, -OR 12 、-SR 12 、-N(R 12 )2, =O, =S and -CN substituents; and C 3-6 carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-4 Alkyl, C 1-4 Haloalkyl, -OR 12 、-SR 12 、-N(R 12 )2, =O, =S and -CN; R 3 is hydrogen or C 1-6 alkyl; R 4a and R 4b Each independently selected from: Hydrogen, halogen, -OR 13 、-SR 13 、-N(R 13 )2. -C(O)R 13 , -NO2, -CN and C 1-6 Alkyl, the C 1-6 Alkyl is optionally substituted by one or more independently selected from halogen, -OR 13 、-SR 13 、-N(R 13 )2. -C(O)R 13 , -NO2 and -CN substituents; R 5 is hydrogen or C 1-6 alkyl; Y is a bond, -O-, -N(R 14 )-or-C(R 14a )(R 14b )-; Z is selected from: a bond, -C(O)-, -C(R 15 )2-, -C(O)C(R 15 )2-, -C(O)[C(R 15 )2] q S-, -C(=N-CN)-, -C(O)O-, -C(O)N(R 16 )-, -C(S)-, -C(S)N(R 16 )-, -S(O)- and -S(O)2-; wherein q is selected from 1, 2 and 3; B is selected from C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OR 17 , -SR 17 , -N(R 17 )2, -C(O)R 17 , -C(O)OR 17 , -OC(O)R 17 , -OC(O)N(R 17 )2, -C(O)N(R 17 )2, -N(R 17 )C(O)R 17 , -N(R 17 )C(O)OR 17 , -N(R 17 )C(O)N(R 17 )2, -N(R 17 )C(S)N(R 17 )2, -N(R 17 )S(O)2(R 17 , -S(O)R 17 , -S(O)2R 17 , -S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN; C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OR 17 , -SR 17 , -N(R 17 )2, -C(O)R 17 , -C(O)OR 17 , -OC(O)R 17 , -OC(O)N(R 17 )2, -C(O)N(R 17 )2, -N(R 17 )C(O)R 17 , -N(R 17 )C(O)OR 17 , -N(R 17 )C(O)N(R 17 )2, -N(R 17 )C(S)N(R 17 )2, -N(R 17 )S(O)2(R 17 , -S(O)R 17 , -S(O)2R 17 , -S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN; C 3-10 carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 17 、-SR 17 、-N(R 17 )2. -C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 , -N(R 17 )C(O)N(R 17 )2、-N(R 17 )C(S)N(R 17 )2、-N(R 17 )S(O)2(R 17 )、-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN; and C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OR 17 , -SR 17 , -N(R 17 )2, -C(O)R 17 , -C(O)OR 17 , -OC(O)R 17 , -OC(O)N(R 17 )2, -C(O)N(R 17 )2, -N(R 17 )C(O)R 17 , -N(R 17 )C(O)OR 17 , -N(R 17 )C(O)N(R 17 )2, -N(R 17 )C(S)N(R 17 )2, -N(R 17 )S(O)2(R 17 , -S(O)R 17 , -S(O)2R 17 , -S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN; C 1-6 Alkyl, optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 17 、-SR 17 、-N(R 17 )2. -C(O)R 17 、-C(O)OR 17 、-OC(O)R 17 、-OC(O)N(R 17 )2、-C(O)N(R 17 )2、-N(R 17 )C(O)R 17 、-N(R 17 )C(O)OR 17 、-N(R 17 )C(O)N(R 17 )2、-N(R 17 )C(S)N(R 17 )2、-N(R 17 )S(O)2(R 17 )、-S(O)R 17 、-S(O)2R 17 、-S(O)2N(R 17 )2, -NO2, =O, =S, =NR 17 , -N3 and -CN; and C 3-10 carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 17 、-SR 17 、-N(R 17 )2. -C(O)R 17 、-NO2、=O、=S、=NR 17 , -N3 and -CN; C is selected from C 5-10 Carbocyclic and 5- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OR 18 , -SR 18 , -N(R 18 )2, -C(O)R 18 , -C(O)OR 18 , -OC(O)R 18 , -OC(O)N(R 18 )2, -C(O)N(R 18 )2, -N(R 18 )C(O)R 18 , -N(R 18 )C(O)OR 18 , -N(R 18 )C(O)N(R 18 )2, -N(R 18 )C(S)N(R 18 )2, -N(R 18 )S(O)2(R 18 , -S(O)R 18 , -S(O)2R 18 , -S(O)2N(R 18 )2, -NO2, =O, =S, =NR 18 , -N3 and -CN; C 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OR 18 , -SR 18 , -N(R 18 )2, -C(O)R 18 , -C(O)OR 18 , -OC(O)R 18 , -OC(O)N(R 18 )2, -C(O)N(R 18 )2, -N(R 18 )C(O)R 18 , -N(R 18 )C(O)OR 18 , -N(R 18 )C(O)N(R 18 )2, -N(R 18 )C(S)N(R 18 )2, -N(R 18 )S(O)2(R 18 , -S(O)R 18 , -S(O)2R 18 , -S(O)2N(R 18 )2, -NO2, =O, =S, =NR 18 , -N3 and -CN; and C 3-6 carbocyclic and 3 to 6 membered heterocyclic rings, any of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-4 Alkyl and C 1-4 haloalkyl; and C 3-6 carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 18 、-SR 18 、-N(R 18 )2. -C(O)R 18 、-NO2、=O、=S、=NR 18 , -N3 and -CN; R 11 and R 12 is independently selected at each occurrence from hydrogen and C 1-6 Alkyl, where C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -NH2, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, =O and CN; R 14 Selected from hydrogen, C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 The carbocyclic rings are each optionally substituted by one or more independently selected from halogen, -OH, -NH2, -OC 1-6 Alkyl, -OC 1-6 Substitution with haloalkyl, =O and -CN substituents; R 13 is independently selected at each occurrence from hydrogen and C 1-6 alkyl; R 14a and R 14b Each independently selected from: Hydrogen, C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 The carbocyclic rings are each optionally substituted by one or more independently selected from halogen, -OH, -NH2, -OC 1-6 Alkyl, -OC 1-6 or R 14a and R 14b Together they form C 3-6 carbocyclic or 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, -OH, -NH2, C 1-6 Alkyl, -C 1-6 Haloalkyl, -OC 1-6 Alkyl, -OC 1-6 Substitution with haloalkyl, =O and -CN substituents; R 15 is independently selected at each occurrence from hydrogen, halogen, =O, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 carbocyclic ring and 3 to 6 membered heterocyclic ring; or two R 15 Together they form C 3-6 Carbon ring; R 16 At each occurrence selected from hydrogen and C 1-6 alkyl; R 17 Independently selected at each occurrence from: hydrogen; C 1-6 Alkyl, optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 21 、-SR 21 、-N(R 21 )2. -C(O)R 21 、-C(O)OR 21 、-OC(O)R 21 、-OC(O)N(R 21 )2、-C(O)N(R 21 )2、-N(R 21 )C(O)R 21 、-NO2、=O、=S、=NR 21 and -CN; and C 3-10 carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 21 、-SR 21 、-N(R 21 )2. -C(O)R 21 、-C(O)OR 21 、-OC(O)R 21 、-OC(O)N(R 21 )2、-C(O)N(R 21 )2、-N(R 21 )C(O)R 21 、-N(R 21 )C(O)OR 21 、-N(R 21 )C(O)N(R 21 )2、-N(R 21 )C(S)N(R 21 )2、-N(R 21 )S(O)2(R 21 )、-S(O)R 21 、-S(O)2R 21 、-S(O)2N(R 21 )2, -NO2, =O, =S, =NR 17 、-CN、C 3-6 Carbocyclic rings and 3 to 6 membered heterocyclic rings; and R 18 and R 21 are independently selected at each occurrence from hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl and C 1-6 Aminoalkyl.

44. The compound or salt of claim 43, wherein A is:

45. The compound or salt of claim 44, wherein A is selected from:

46. ​​The compound or salt of claim 45, wherein A is:

47. The compound or salt of claim 45, wherein A is:

48. The compound or salt of claim 43, wherein A is 49. The compound or salt of claim 48, wherein A is: And n is 0 or 1.

50. A compound or salt according to any one of claims 43 to 49, wherein Y is a bond.

51. A compound or salt according to any one of claims 43 to 50, wherein R 4a and R 4b are each independently selected from hydrogen, halogen, C 1-3 Alkyl and C 1-3 Halogenated alkyl.

52. The compound or salt according to claim 51, wherein R 4a and R 4b Each is hydrogen or halogen.

53. A compound or salt according to any one of claims 43 to 52, wherein R 5 For hydrogen.

54. A compound or salt according to any one of claims 43 to 53, wherein R 3 is hydrogen, methyl or ethyl.

55. The compound or salt of claim 54, wherein R 3 For hydrogen.

56. A compound or salt according to any one of claims 43 to 55, wherein Z is selected from: a bond, -C(O)-, -C(R 15 )2-、-C(O)C(R 15 )2-、-C(O)[C(R 15 )2] p S-, -C(=N-CN)- and -S(O)2-.

57. The compound or salt of claim 56, wherein Z is -C(O)-.

58. A compound or salt according to any one of claims 43 to 57, wherein B is selected from: phenyl, naphthyl, C 3-10 Cycloalkyl, 5- to 6-membered monocyclic heterocycle, and 7- to 10-membered bicyclic heterocycle, any of which is optionally substituted.

59. The compound or salt of claim 58, wherein B is selected from the group consisting of phenyl, naphthyl, cyclopropyl, cyclohexyl, bicyclo[2.2.2]octane, adamantane, thiazole, pyrrole, pyrazole, pyridine, pyrimidine, pyrazine, indole, indazole, benzimidazole, indoline, azaindole, azaindoline, 1,3-dihydrobenzo[c]isothiazole, tetrahydropyran, azetidine, pyrrolidine, piperidine, quinuclidine, azepane, and 8-azabicyclo[3.2.1]octane, any of which is optionally substituted.

60. The compound or salt of claim 59, wherein B is selected from the group consisting of phenyl, cyclohexyl, pyrazole, pyridine, indole, indazole, benzimidazole, indoline, 1,3-dihydrobenzo[c]isothiazole, pyrrolidine, piperidine, pyrrolidine and piperidine, any of which is optionally substituted.

61. A compound or salt according to any one of claims 43 to 60, wherein B is substituted with 1, 2 or 3 substituents.

62. The compound or salt of claim 61, wherein B is substituted with 2 or 3 substituents.

63. A compound or salt according to any one of claims 43 to 62, wherein any substituent on B is independently selected at each occurrence from: halogen, -OR 17 , -SR 17 , -N(R 17 )2, -C(O)R 17 , -C(O)OR 17 , -OC(O)R 17 , -OC(O)N(R 17 )2, -C(O)N(R 17 )2, -N(R 17 )C(O)R 17 , -N(R 17 )C(O)OR 17 , -N(R 17 )C(O)N(R 17 )2, -N(R 17 )C(S)N(R 17 )2, -N(R 17 )S(O)2(R 17 , -S(O)R 17 , -S(O)2R 17 , -S(O)2N(R 17 )2 and -CN; C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from: halogen, -OR 17 , -SR 17 , -N(R 17 )2, -C(O)R 17 , -N(R 17 )C(O)R 17 , -N(R 17 )C(O)OR 17 , -N(R 17 )S(O)2(R 17 ), -S(O)2N(R 17 )2, =O, -CN; and C 3-10 carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OR 17 、-SR 17 、-N(R 17 )2. -C(O)R 17 、-C(O)OR 17 、-C(O)N(R 17 )2、-N(R 17 )S(O)2(R 17 )、-S(O)2R 17 , =O, =S and -CN; and C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OR 17 , -SR 17 , -N(R 17 )2, -C(O)R 17 , -C(O)OR 17 , -C(O)N(R 17 )2, -(R 17 )S(O)2(R 17 ), -S(O)R 17 , -S(O)2R 17 ), =O, =S, -CN; and C 1-6 Alkyl, optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 17 、-SR 17 、-N(R 17 )2, =O, =S and -CN.

64. The compound or salt of claim 63, wherein any substituent on B is independently selected at each occurrence from: chlorine, -OR 17 , -N(R 17 )2, -C(O)R 17 , -C(O)N(R 17 )2, -N(R 17 )S(O)2(R 17 ), -S(O)2R 17 W-CN; C 1-6 Alkyl, which is optionally substituted with one or more substituents independently selected from halogen and 3 to 10 membered heterocyclic rings, the 3 to 10 membered heterocyclic rings being optionally substituted with one or more substituents independently selected from halogen, C 1-6 Alkyl and C 1-6 Substitution of haloalkyl groups; and C 3-10 carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from: halogen, C 1-6 Alkyl and C 1-6 The substituents of the haloalkyl group are substituted.

65. The compound or salt of claim 64, wherein any substituent on B is independently selected at each occurrence from: Halogen, -N(R 17 )2、-N(R 17 )S(O)2(R 17 ) and -CN; C 1-6 Alkyl, which is optionally substituted with one or more substituents independently selected from halogen and 3 to 10 membered heterocyclic rings, which are optionally substituted with one or more substituents independently selected from halogen and C 1-6 Substitution of the alkyl group by a substituent; and 3 to 10 membered heterocyclic ring, which is optionally substituted by one or more independently selected from C 1-6 Alkyl and C 1-6 The substituents of the haloalkyl group are substituted.

66. A compound or salt according to any one of claims 43 to 65, wherein R 17 is independently selected at each occurrence from: hydrogen; C 1-6 Alkyl, optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 21 、-SR 21 、-N(R 21 )2 and -CN; and C 3-10 carbocyclic and 3 to 10 membered heterocyclic rings, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -OC(O)N(R 21 )2 and C 3-6 Carbon ring.

67. A compound or salt according to any one of claims 43 to 66, wherein R 21 is independently selected at each occurrence from hydrogen and C 1-6 alkyl.

68. The compound or salt according to claim 63, wherein any substituent on B is independently selected at each occurrence from: halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, OC 1-6 Alkyl, -OC 1-6 Haloalkyl, =O, -CN, acetyl, difluoroacetyl, 69. A compound or salt according to any one of claims 43 to 57, wherein B is selected from:

70. The compound or salt of any one of claims 43 to 57, wherein B is selected from:

71. A compound or salt according to any one of claims 43 to 57, wherein B is selected from:

72. A compound or salt according to any one of claims 43 to 70, wherein C is selected from phenyl, a 5-6 membered monocyclic heterocycle and a 7-10 membered bicyclic heterocycle, each of which is optionally substituted.

73. The compound or salt of claim 71, wherein C is selected from phenyl, pyridine, pyridin-2-one, pyrimidinone, pyrimidinedione, pyrazine, pyridazin-3-one, isoquinoline, naphthyridine, phthalazine, naphthyridine-2-one, 5,6,7,8-tetrahydronaphthyridin-2-one, triazolo[1,5-a]pyrazine, imidazo[1,2-a]pyrazine, pyrazolo[1,5-a]pyrazine, pyrido[4,3-d]pyrimidine-2,4-dione, pyrido[3,4-d]pyrimidine-2,4-dione, quinazoline-2,4-dione, quinolin-2-one, 3,4-dihydroquinolin-2-one, isoindololin-1-one and 1,3-dihydrobenzo[d]imidazol-2-one, each of which is optionally substituted.

74. A compound or salt according to any one of claims 1 to 73, wherein one or more optional substituents on C are independently selected at each occurrence from: Halogen, -OR 18 、-SR 18 、-N(R 18 )2. -C(O)R 18 、-C(O)OR 18 、-C(O)N(R 18 )2. -S(O)R 18 、-S(O)2R 18 , -NO2, =O, =S and -CN; C 1-6 Alkyl and C 2-6 alkenyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR 18 、-SR 18 、-N(R 18 )2. -C(O)R 18 、-C(O)OR 18 、-OC(O)R 18 、-OC(O)N(R 18 )2、-C(O)N(R 18 )2、-N(R 18 )C(O)R 18 、-N(R 18 )C(O)OR 18 、-N(R 18 )C(O)N(R 18 )2、-N(R 18 )C(S)N(R 18 )2、-N(R 18 )S(O)2(R 18 )、-S(O)2N(R 18 )2, -NO2, =O, =S, -CN and a 3 to 6 membered heterocyclic ring, the 3 to 6 membered heterocyclic ring being optionally substituted by one or more substituents independently selected from the following: halogen, C 1-4 Alkyl and C 1-4 haloalkyl; and C 3-6 carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl and C 1-6 The substituents of the haloalkyl group are substituted.

75. The compound or salt of claim 74, wherein the optional substituents on C are independently selected at each occurrence from: Halogen, -OR 18 、-N(R 18 )2, =O and -CN; C 1-6 Alkyl and C 2-6 alkenyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR 18 、-N(R 18 )2, =O, -CN and a 3 to 6-membered heterocyclic ring, the 3 to 6-membered heterocyclic ring being optionally substituted by one or more substituents independently selected from the following: halogen, C 1-4 Alkyl and C 1-4 haloalkyl; and C 3-6 carbocyclic and 3 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more independently selected from halogen, C 1-6 Alkyl and C 1-6 The substituents of the haloalkyl group are substituted.

76. A compound or salt according to any one of claims 43 to 75, wherein R 18 is independently selected at each occurrence from hydrogen and C 1-6 alkyl.

77. according to any one of claims 43 to 74 compounds or salts, wherein the optional substituents on C are independently selected at each occurrence from: halogen, =O, -N(CH3)2, C 1-6 Alkyl, C 2-6 Alkenyl, C 1-6 Haloalkyl, -OC 1-6 Alkyl, -OC 1-6 Halogenated alkyl, 78. A compound or salt according to any one of claims 43 to 70, wherein C is selected from:

79. A compound or salt according to any one of claims 43 to 70, wherein C is selected from:

80. A compound or salt according to any one of claims 43 to 71, wherein C is selected from:

81. A compound or salt according to claim 43, wherein the compound or salt of Formula I or Formula (Ia) is selected from Table 1, Table 2, Table 3, Table 4, Table 14, Table 15, Table 16, Table 17, Table 18, Table 19, Table 20, Table 21, Table 22, Table 23, Table 24, Table 25, Table 26, Table 27 or Table 28.

82. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound or salt according to any one of claims 1 to 81.

83. A method of modulating α4β7 integrin in a subject in need thereof, comprising administering to the subject a compound or salt according to any one of claims 1 to 81 or a pharmaceutical composition according to claim 82.

84. A method of treating an inflammatory disease or condition comprising administering to a subject in need thereof a compound or salt according to any one of claims 1 to 81 or a pharmaceutical composition according to claim 82.

85. The method of claim 84, wherein the inflammatory disease or disorder is selected from the group consisting of: inflammatory bowel disease, ulcerative colitis, Crohn's disease, graft-versus-host disease, type 1 diabetes, immune-mediated colitis, checkpoint inhibitor-induced colitis, and primary sclerosing cholangitis.

Images